

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
16 October 2003 (16.10.2003)

PCT

(10) International Publication Number
WO 03/084984 A1(51) International Patent Classification⁷: C07K 5/078,
A61K 31/4025, A61P 25/28, 29/00, 35/04

(21) International Application Number: PCT/EP03/03635

(22) International Filing Date: 8 April 2003 (08.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2002 00805 8 April 2002 (08.04.2002) ES(71) Applicant (for all designated States except US): J. URI-
ACH & CIA. S.A. [ES/ES]; Av. Camí Reial, 51-57,
E-08184 Palau-Solita i Plegamans (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CARCELLER
GONZALEZ, Elena [ES/ES]; C/Joan Miró, 2, E-08190
San Cugat del Valles, Barcelona (ES). SALAS SOLANA,
Jorge [ES/ES]; C/Juli Gonzalez 2, 3^o, 1a, E-08400
Granollers (ES). ALVAREZ FARRERONS, Cristina
[ES/ES]; C/Dos de Mayo 310, 6^o, 2a, E-08025 Barcelona
(ES). ANDREU AZANZA, Juan, Andrés [ES/ES];
C/Roc Boronat 67, 1^o, 1a, E-08005 Barcelona (ES).(74) Agents: ZUMSTEIN, F. et al.; Bräuhäusstr. 4, 80331
Munich (DE).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report


(48) Date of publication of this corrected version:

11 December 2003

(15) Information about Correction:

see PCT Gazette No. 50/2003 of 11 December 2003, Sec-
tion IIFor two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY

(57) Abstract: The present invention
relates to new compounds of Formula
(I) and the salts, solvates and prodrugs
thereof, wherein the meanings for the
various substituents are as disclosed in
the description. These compounds are
useful as integrin α_4 antagonists.

(I)

03/084984 A1

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 October 2003 (16.10.2003)

PCT

(10) International Publication Number
WO 03/084984 A1


- (51) International Patent Classification⁷: **C07K 5/078**, (74) Agents: **ZUMSTEIN, F. et al.**; Bräuhausstr. 4, 80331 Munich (DE).
A61K 31/4025, A61P 25/28, 29/00, 35/04
- (21) International Application Number: **PCT/EP03/03635**
- (22) International Filing Date: **8 April 2003 (08.04.2003)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
2002 00805 **8 April 2002 (08.04.2002)** **ES**
- (71) Applicant (for all designated States except US): **J. URI-ACH & CIA. S.A.** [ES/ES]; Av. Camí Reial, 51-57, E-8184 Palau-Solita i Plegamans (ES).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CARCELLER GONZALEZ, Elena** [ES/ES]; C/Joan Miró, 2, E-08190 San Cugat del Valles, Barcelona (ES). **SALAS SOLANA, Jorge** [ES/ES]; C/Juli Gonzalez 2, 3^o, 1a, E-08400 Granollers (ES). **ALVAREZ FARRERONS, Cristina** [ES/ES]; C/Dos de Mayo 310, 6^o, 2a, E-08025 Barcelona (ES). **ANDREU AZANZA, Juan, Andrés** [ES/ES]; C/Roc Boronat 67, 1^o, 1a, E-08005 Barcelona (ES).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY**



(57) Abstract: The present invention relates to new compounds of Formula (I) and the salts, solvates and prodrugs thereof, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as integrin α_4 antagonists.

HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY

Field of the invention.

The present invention relates to a new series of compounds with α_4 integrin antagonist activity, as well as to a process for their preparation, to the pharmaceutical compositions that contain these compounds and to their use in medicine.

Background of the invention.

Cell adhesion is a process by which cells bind either to other cells or to extracellular matrix through an extracellular ligand. The cell-extracellular ligand binding triggers in its turn several processes related to signal transduction, cell cycle and apoptosis, which are involved in processes of great physiological relevance. Thus, cell adhesion takes part in processes such as embryological development, angiogenesis or platelet aggregation and is also involved in pathological processes, such as inflammation and metastasis.

Cell-cell and cell-extracellular matrix interactions are mediated by different molecule families such as the integrins. Integrins are heterodimeric receptors that are anchored in the cell membrane and that consist of an α subunit and a β subunit. Up to now, 16 α subunits (α_{1-10} , α -L, α -M, α -X, α -IIb, α -V and α -E) and 8 β subunits (β_{1-8}), which give rise to 24 combinations of integrins, have been identified. The α_4 subunit combines only with the β_1 and β_7 subunits, giving rise to the $\alpha_4\beta_1$ (also called *Very Late Antigen 4*, VLA-4, or CD49d/CD29) and $\alpha_4\beta_7$ (or Lymphocyte Peyer's patch cell Adhesion Molecule, LPAM-1) integrins.


The integrin $\alpha_4\beta_1$ is widely expressed on mononuclear leukocytes, mast cells, macrophages, basophils and eosinophils, and on neutrophils as well but with a low level of functionality. The integrin $\alpha_4\beta_7$ is only expressed on some types of lymphocytes. The integrin $\alpha_4\beta_1$ binds to VCAM-1 (Vascular Cell Adhesion Molecule-1), which is a membrane protein of endothelial cells induced by pro-inflammatory cytokines, through the sequence Gln-Ile-Asp-Ser. It also binds to the sequence Leu-Asp-Val of the CS-1 domain of fibronectin, an extracellular matrix molecule. The integrin $\alpha_4\beta_7$ also binds to the constitutive immunoglobulin MadCAM (Mucosal addressing Cell Adhesion Molecule) and is responsible for the attraction of lymphocytes to the intestinal and mesenteric lymph nodes.

Integrins α_4 , by means of their binding to the above-mentioned ligands, are

involved in numerous cell adhesion pathological processes such as asthma, multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease, among others. Compounds which antagonize the action of these integrins are therefore expected to be useful for the treatment or prevention of said diseases. The present invention describes new compounds with α_4 integrin antagonist activity.

Description of the invention.

An aspect of the present invention relates to the new compounds of general formula I:



I

wherein:

R¹ represents -SO₂R², -COR² or -CH₂R³;

R² represents C₁₋₈ alkyl, C₂₋₈ alkenyl or C₂₋₈ alkynyl, which can be optionally substituted with one or more groups R^a, or R² represents Cy, CyC₁₋₄ alkyl, CyC₂₋₄ alkenyl or CyC₂₋₄ alkynyl, where the groups Cy can be optionally substituted with one or more groups R^b;

R³ represents hydrogen, C₁₋₈ alkyl, C₂₋₈ alkenyl or C₂₋₈ alkynyl, where the groups C₁₋₈ alkyl, C₂₋₈ alkenyl and C₂₋₈ alkynyl can be optionally substituted with one or more groups R^c, or R³ represents Cy or CyC₁₋₄ alkyl, where the groups Cy can be optionally substituted with one or more groups selected from R^c and R^d;

each R⁴ independently represents hydrogen, C₁₋₈ alkyl, Cy or CyC₁₋₄ alkyl, where the C₁₋₈ alkyl group can be optionally substituted with one or more groups R^c and where the groups Cy can be optionally substituted with one or more groups selected from R^c and R^d;

W represents -CR⁴R⁴- when R¹ is -SO₂R² or -COR², or W represents -CO- when R¹ is -CH₂R³;

Z represents -CO- or -CS-;

E represents $-\text{COOR}^6$, $-\text{CONR}^7\text{R}^8$ or 5-tetrazolyl;

X represents $-\text{CH}_2-$, $-\text{NR}^5-$ or $-\text{O}-$;

each R^5 independently represents hydrogen or C_{1-4} alkyl;

R^6 represents hydrogen, C_{1-8} alkyl, C_{3-7} cycloalkyl or aryl, where the C_{1-8} alkyl group can be optionally substituted with a group selected from C_{3-7} cycloalkyl, aryl, $-\text{OR}^9$, $-\text{OCOR}^d$, $-\text{OCOOR}^d$, $-\text{COOR}^9$ and $-\text{NHCOR}^9$ and the aryl groups can be optionally substituted with one or more groups R^b ;

R^7 represents hydrogen, C_{1-8} alkyl, C_{3-7} cycloalkyl, aryl or $-\text{SO}_2\text{R}^d$, where the C_{1-8} alkyl group can be optionally substituted with a group selected from C_{3-7} cycloalkyl, aryl, $-\text{SO}_2\text{R}^d$, $-\text{COOR}^9$ and $-\text{COR}^d$;

R^8 represents hydrogen or C_{1-8} alkyl;

or R^7 and R^8 together with the nitrogen atom to which they are bound can form a cycle Het^1 ;

A represents C_{3-7} cycloalkyl or Het^1 , which can be optionally substituted with one or more groups selected from oxo, C_{1-8} alkyl and C_{1-8} haloalkyl;

L represents $-(\text{CR}^9\text{R}^9)_n-$;

each R^9 independently represents hydrogen or C_{1-4} alkyl;

B represents:

i) C_{3-7} cycloalkyl, Het^1 or Het^2 , which can be optionally substituted with one or more groups selected from oxo, R^b and Cy optionally substituted with one or more groups R^b ; or

ii) a group selected from $-\text{COR}^e$, $-\text{NR}^f\text{R}^f$, $-\text{OR}^f$, $-\text{SR}^f$, $-\text{S(O)}_p\text{R}^e$, $-\text{CONR}^f\text{R}^f$, $-\text{NR}^f\text{COR}^f$, $-\text{NR}^f\text{CONR}^f\text{R}^f$, $-\text{NR}^f\text{CSNR}^f\text{R}^f$, $-\text{NR}^f\text{COOR}^e$, $-\text{OCOR}^e$, $-\text{OCONR}^f\text{R}^f$, $-\text{NR}^f\text{SO}_2\text{R}^e$ and $-\text{SO}_2\text{NR}^f\text{R}^f$;

m represents 0 or 1;

n represents 1, 2, 3 or 4;

p represents 1 or 2;

each R^a independently represents halogen, $-\text{COR}^d$, $-\text{OR}^9$, $-\text{NR}^9\text{R}^9$, $-\text{COOR}^9$, $-\text{OCOR}^d$, $-\text{CONR}^9\text{R}^9$, $-\text{NR}^9\text{COR}^9$, $-\text{OCONR}^9\text{R}^9$ or $-\text{NR}^9\text{COOR}^d$;

each R^b independently represents a group R^a , $-\text{NO}_2$, $-\text{SR}^9$, $-\text{S(O)}_p\text{R}^d$ or C_{1-8} alkyl optionally substituted with one or more groups R^c ;

each R^c independently represents halogen, $-\text{OR}^h$ or $-\text{NR}^h\text{R}^h$;

each R^d independently represents C_{1-8} alkyl, C_{3-7} cycloalkyl or aryl, which can be optionally substituted with one or more groups R^c ;

each R^e independently represents C₁₋₈ alkyl, C₂₋₈ alkenyl or C₂₋₈ alkynyl, which can be optionally substituted with one or more groups R^a, or R^e represents Cy or CyC₁₋₄ alkyl, where the groups Cy can be optionally substituted with one or more groups selected from oxo, Cy* and R^b, and where the groups Cy* can be
5 optionally substituted with one or more groups selected from oxo and R^b;

each R^f independently represents hydrogen or any of the meanings described for R^e;

or two groups R^f placed on the same nitrogen atom can be attached to each other to form together with said nitrogen atom a cycle Het¹ which can be
10 optionally substituted with one or more groups selected from oxo, Cy and R^b, where the groups Cy can be optionally substituted with one or more groups selected from oxo and R^b;

each R^g independently represents hydrogen or any of the meanings described for R^d;

15 or two groups R^g placed on the same nitrogen atom can be attached to each other to form together with said nitrogen atom a cycle Het¹ which can be optionally substituted with one or more groups selected from oxo, Cy and R^b, where the groups Cy can be optionally substituted with one or more groups selected from oxo and R^b;

20 each R^h independently represents hydrogen, C₁₋₈ alkyl, C₃₋₇ cycloalkyl or aryl, where the groups C₁₋₈ alkyl, C₃₋₇ cycloalkyl and aryl can be optionally substituted with one or more halogen atoms;

Cy and Cy* independently represent aryl, C₃₋₇ cycloalkyl, Het¹ or Het²;

aryl in the above definitions represents phenyl or naphthyl;

25 Het¹ in the above definitions represents a saturated or unsaturated non-aromatic 5- to 7-membered monocyclic ring containing from one to four heteroatoms selected from N, O and S, which can be optionally fused to a phenyl, naphthyl or Het² ring, and which is chemically stable and obtainable through chemical synthesis; and

30 Het² in the above definitions represents an aromatic 5- to 7-membered monocyclic or 9- to 11-membered bicyclic ring, which contains from one to four heteroatoms selected from N, O and S, and which is chemically stable and obtainable through chemical synthesis.

The present invention also relates to the addition salts of the compounds of

the invention, as well as to their solvates and prodrugs.

Some compounds of formula I can have chiral centres, which can give rise to various stereoisomers. The present invention relates to each one of the individual stereoisomers as well as to their mixtures. Moreover, some of the compounds of the present invention can show cis/trans isomery. The present invention relates to each one of the geometric isomers as well as to their mixtures.

Another aspect of the present invention relates to the pharmaceutical compositions which comprise an effective amount of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof and one or more pharmaceutically acceptable excipients.

Another aspect of the present invention relates to the use of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament for the treatment or prevention of diseases mediated by integrins α_4 . In a preferred embodiment, said α_4 integrin-mediated disease is selected from the group consisting of: inflammatory diseases, immune diseases, autoimmune diseases, degenerative disorders, tumor metastasis and ischemia-reperfusion disorders.

Another aspect of the present invention relates to the use of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament for the treatment or prevention of inflammatory, immune and/or autoimmune diseases. In a preferred embodiment, said inflammatory, immune and/or autoimmune disease is selected from: diseases with an allergic component, such as for example asthma, allergic rhinitis, allergic dermatitis and allergic conjunctivitis; inflammatory diseases with an autoimmune component, such as for example rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, psoriasis and diabetes; inflammatory bowel disease, including Crohn's disease and ulcerative colitis; inflammatory processes having an alloimmune origin caused by transplants or rejections; inflammatory processes that develop as a consequence of blood vessel revascularization treatments, such as percutaneous transluminal coronary angioplasty; encephalomyelitis; hepatitis; bronchitis; vasculitis; and atherosclerosis.

Another aspect of the present invention relates to the use of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the

manufacture of a medicament for the treatment or prevention of degenerative disorders, such as Alzheimer's disease and arthrosis.

Another aspect of the present invention relates to the use of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament for the treatment or prevention of tumor metastasis.

Another aspect of the present invention relates to the use of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament for the treatment or prevention of ischemia-reperfusion disorders, including acute coronary diseases and stroke.

Another aspect of the present invention relates to a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the treatment or prevention of diseases mediated by integrins α_4 . In a preferred embodiment, said α_4 integrin-mediated disease is selected from the group consisting of: inflammatory diseases, immune diseases, autoimmune diseases, degenerative disorders, tumor metastasis and ischemia-reperfusion disorders.

Another aspect of the present invention relates to a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the treatment or prevention of inflammatory, immune and/or autoimmune diseases. In a preferred embodiment, said inflammatory, immune and/or autoimmune disease is selected from: diseases with an allergic component, such as for example asthma, allergic rhinitis, allergic dermatitis and allergic conjunctivitis; inflammatory diseases with an autoimmune component, such as for example rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, psoriasis and diabetes; inflammatory bowel disease, including Crohn's disease and ulcerative colitis; inflammatory processes having an alloimmune origin caused by transplants or rejections; inflammatory processes that develop as a consequence of blood vessel revascularization treatments, such as percutaneous transluminal coronary angioplasty; encephalomyelitis; hepatitis; bronchitis; vasculitis; and atherosclerosis.

Another aspect of the present invention relates to a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the treatment or prevention of degenerative disorders, such as Alzheimer's disease and arthrosis.

Another aspect of the present invention relates to a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the treatment or prevention of tumor metastasis.

Another aspect of the present invention relates to a compound of formula I
5 or a pharmaceutically acceptable salt, solvate or prodrug thereof for the treatment or prevention of ischemia-reperfusion disorders, including acute coronary diseases and stroke.

Another aspect of the present invention relates to the use of a compound
10 of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the treatment or prevention of diseases mediated by integrins α_4 . In a preferred embodiment, said α_4 integrin-mediated disease is selected from the group consisting of: inflammatory diseases, immune diseases, autoimmune diseases, degenerative disorders, tumor metastasis and ischemia-reperfusion disorders.

Another aspect of the present invention relates to the use of a compound
15 of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the treatment or prevention of inflammatory, immune and/or autoimmune diseases. In a preferred embodiment, said inflammatory, immune and/or autoimmune disease is selected from: diseases with an allergic component, such as for example asthma, allergic rhinitis, allergic dermatitis and allergic
20 conjunctivitis; inflammatory diseases with an autoimmune component, such as for example rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, psoriasis and diabetes; inflammatory bowel disease, including Crohn's disease and ulcerative colitis; inflammatory processes having an alloimmune origin caused by transplants or rejections; inflammatory processes that develop as a consequence of blood
25 vessel revascularization treatments, such as percutaneous transluminal coronary angioplasty; encephalomyelitis; hepatitis; bronchitis; vasculitis; and atherosclerosis.

Another aspect of the present invention relates to the use of a compound of
30 formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the treatment or prevention of degenerative disorders, such as Alzheimer's disease and arthrosis.

Another aspect of the present invention relates to the use of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the treatment or prevention of tumor metastasis.

Another aspect of the present invention relates to the use of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof for the treatment or prevention of ischemia-reperfusion disorders, including acute coronary diseases and stroke.

Another aspect of the present invention relates to a method of treating or preventing diseases mediated by integrins α_4 in a mammal in need thereof, especially a human being, which comprises administering to said mammal a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof. In a preferred embodiment, said α_4 integrin-mediated disease is selected from the group consisting of: inflammatory diseases, immune diseases, autoimmune diseases, degenerative disorders, tumor metastasis and ischemia-reperfusion disorders.

Another aspect of the present invention relates to a method of treating or preventing inflammatory, immune and/or autoimmune diseases in a mammal in need thereof, especially a human being, which comprises administering to said mammal a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof. In a preferred embodiment, said inflammatory, immune and/or autoimmune disease is selected from: diseases with an allergic component, such as for example asthma, allergic rhinitis, allergic dermatitis and allergic conjunctivitis; inflammatory diseases with an autoimmune component, such as for example rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, psoriasis and diabetes; inflammatory bowel disease, including Crohn's disease and ulcerative colitis; inflammatory processes having an alloimmune origin caused by transplants or rejections; inflammatory processes that develop as a consequence of blood vessel revascularization treatments, such as percutaneous transluminal coronary angioplasty; encephalomyelitis; hepatitis; bronchitis; vasculitis; and atherosclerosis.

Another aspect of the present invention relates to a method of treating or preventing degenerative disorders, such as Alzheimer's disease and arthrosis, in a mammal in need thereof, especially a human being, which comprises


administering to said mammal a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof.

Another aspect of the present invention relates to a method of treating or preventing tumor metastasis in a mammal in need thereof, especially a human being, which comprises administering to said mammal a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof.

Another aspect of the present invention relates to a method of treating or preventing ischemia-reperfusion disorders, including acute coronary diseases and stroke, in a mammal in need thereof, especially a human being, which comprises administering to said mammal a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof.


Another aspect of the present invention relates to a process for preparing the compounds of formula I, which comprises:

(a) when in a compound of formula I X represents $-NR^5-$, reacting an amine of formula II with an acid of formula III





wherein R^1 , R^4 , R^5 , W, Z, E, A, L, B and m have the meaning described above; or

(b) when in a compound of formula I X represents $-O-$, reacting an alcohol of formula IV with an acid of formula III





wherein R^1 , R^4 , R^5 , W, Z, E, A, L, B and m have the meaning described above; or



(c) when in a compound of formula I X represents $-CH_2-$ and cycle A is bound to the carbonyl group through a nitrogen atom, reacting an acid of formula V with an amine of formula VI

**V****VI**


wherein R^1 , R^4 , R^5 , W , Z , E , A , L , B and m have the meaning described above; or
 (d) when in a compound of formula I X represents $-NR^5-$ and cycle A is bound to
 the carbonyl group through a nitrogen atom, reacting an amine of formula II
 5 previously activated with an activating agent suitable for the preparation of ureas
 with an amine of formula VI

**II****VI**

wherein R^1 , R^4 , R^5 , W , Z , E , A , L , B and m have the meaning described above, or
 reacting an amine of formula VI previously activated with an activating agent
 10 suitable for the preparation of ureas with an amine of formula II, or alternatively
 reacting a compound of formula V' previously activated with an azide suitable for
 a Curtius rearrangement with an amine of formula VI

**V'****VI**

wherein R^1 , R^4 , R^5 , W , Z , E , A , L , B and m have the meaning described above; or
 15 (e) when in a compound of formula I X represents $-O-$ and cycle A is bound to the
 carbonyl group through a nitrogen atom, reacting an alcohol of formula IV
 previously activated with an activating agent suitable for the preparation of
 carbamates with an amine of formula VI




IV




VI

wherein R^1 , R^4 , R^5 , W , Z , E , A , L , B and m have the meaning described above; or
 (f) when in a compound of formula I Z represents $-CO-$, reacting an acid of formula VII with an amine of formula XVII




VII



XVII

5

wherein R^1 , R^4 , R^5 , W , E , X , A , L , B and m have the meaning described above; or
 (g) when in a compound of formula I W represents $-CR^4R^4-$ and R^1 represents $-SO_2R^2$, reacting a compound of formula XVIII with a sulfonyl chloride of formula IX



XVIII




IX

10

wherein R^2 , R^4 , R^5 , Z , E , X , A , L , B and m have the meaning described above; or
 (h) when in a compound of formula I W represents $-CR^4R^4-$ and R^1 represents $-COR^2$, reacting a compound of formula XVIII with an acid of formula X


12



XVIII

X

wherein R^2 , R^4 , R^5 , Z , E , X , A , L , B and m have the meaning described above; or
 (i) when in a compound of formula I W represents $-\text{CO}-$ and R^1 represents $-\text{CH}_2\text{R}^3$, reacting a compound of formula XIX with a compound of formula XI



XIX


XI

5

wherein R^2 , R^4 , R^5 , Z , E , X , A , L , B and m have the meaning described above and D represents a good leaving group; or

(j) when in a compound of formula I cycle A is bound to the $-\text{L}-\text{B}$ moiety through a ring nitrogen atom, alkylating the secondary amine of a compound of formula XX

10 with a compound of formula XIV



XX

XIV

wherein R^1 , R^4 , R^5 , W , Z , E , X , A , L , B and m have the meaning described above and D represents a good leaving group; or

(k) transforming, in one or a plurality of steps, a compound of formula I into

15 another compound of formula I; and

(l) if desired, after the above steps, reacting a compound of formula I with an acid or a base to give the corresponding addition salt.

In the above definitions, the term C₁₋₄ or C₁₋₈ alkyl, as a group or part of a group, means a linear or branched alkyl group that contains from 1 to 4 or from 1 to 8 carbon atoms, respectively. Examples include among others the groups methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl and octyl.

A C₂₋₄ or C₂₋₈ alkenyl group, as a group or part of a group, means a linear or branched alkyl chain that contains from 2 to 4 or from 2 to 8 carbon atoms, respectively, and that in addition contains one or more double bonds. Examples include among others the groups ethenyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 6-heptenyl or 7-octenyl.

A C₂₋₄ or C₂₋₈ alkynyl group, as a group or part of a group, means a linear or branched alkyl chain which contains from 2 to 4 or from 2 to 8 carbon atoms, respectively, and that in addition contains one or more triple bonds. Examples include the groups ethynyl, 1-propynyl, 2-propynyl, 1-butylnyl, 2-butylnyl, 3-butylnyl, 2-pentylnyl, 3-pentylnyl, 4-pentylnyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 6-heptylnyl or 7-octynyl.

A halogen radical or its abbreviation halo means fluoro, chloro, bromo or iodo.

An oxo group means a carbonyl group (-CO-).

A C₁₋₈ haloalkyl group means a group resulting from the substitution of one or more hydrogen atoms of a C₁₋₈ alkyl group with one or more halogen atoms (that is, fluoro, chloro, bromo or iodo), which can be the same or different. Examples include trifluoromethyl, fluoromethyl, 1-chloroethyl, 2-chloroethyl, 1-fluoroethyl, 2-fluoroethyl, 2-bromoethyl, 2-iodoethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3-fluoropropyl, 3-chloropropyl, 2,2,3,3-tetrafluoropropyl, 2,2,3,3,3-pentafluoropropyl, heptafluoropropyl, 4-fluorobutyl, nonafluorobutyl, 5-fluoropentyl, 6-fluorohexyl, 7-fluoroheptyl and 8-fluorooctyl.

The term Cy or Cy*, as a group or part of a group, means aryl, C₃₋₇ cycloalkyl, Het¹ or Het², which can be optionally substituted as mentioned above in the definition of general formula I and where said substituents, if present, can

be on any available position of the Cy or Cy* groups.

The term aryl means phenyl or naphthyl.

A group C₃₋₇ cycloalkyl represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

5 The term Het¹ means a saturated or insaturated non-aromatic 5- to 7-membered monocyclic ring containing from one to four heteroatoms selected from N, O and S, and which is chemically stable and obtainable through chemical synthesis. Said cycle can be bound to the rest of the molecule through a carbon or nitrogen atom and can be optionally fused to a phenyl, naphthyl or Het² ring.
10 Examples of heterocycles Het¹ include among others, piperidine, piperazine, pyrrolidine, pyrazolidine, imidazolidine, morpholine, dioxane, thiazolidine, isothiazolidine, oxazolidine, isoxazolidine and homopiperazine.

 The term Het² means an aromatic 5- to 7-membered monocyclic or 9- to 11-membered bicyclic ring, which contains from one to four heteroatoms selected
15 from N, O and S, and which is chemically stable and obtainable through chemical synthesis. Examples of monocyclic aromatic heterocycles include thiophene, furan, pyrrole, thiazole, isothiazole, oxazole, isoxazole, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,2,4-oxadiazole, 1,2,4-thiadiazole, pyridine, pyrazine, pyrimidine and pyridazine. Examples of bicyclic
20 heteroaryl groups include among others benzimidazole, benzofuran, indole, isoindole, benzothiophene, benzothiazole, quinoline, isoquinoline, phthalazine, quinazoline, quinoxaline, cinnoline, naphthyridine, indazole, imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, pyrazolopyrazine, pyrazolopyridine and pyrazolopyrimidine. The examples of bicyclic heteroaryls
25 mentioned above whose name can have more than one possible interpretation are to be understood as including all the possible fusion combinations between the monocycles that constitute them.

 A CyC₁₋₄ alkyl group means a group resulting from the substitution of a hydrogen atom of a C₁₋₄ alkyl group with a Cy defined above, that is with an aryl,
30 C₃₋₇ cycloalkyl, Het¹ or Het² group. Examples include among others benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 4-phenylbutyl, cyclohexylmethyl, 1-cyclohexylethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 1-(4-pyridyl)ethyl, 2-(4-pyridyl)ethyl, 3-(4-pyridyl)propyl, 4-(4-pyridyl)butyl, 1-piperidylmethyl, 2-

piperidylmethyl, 3-piperidylmethyl, 4-piperidylmethyl, 2-(4-piperidyl)ethyl, 3-(4-piperidyl)propyl, 4-(4-piperidyl)butyl, 1-piperazinylmethyl, 2-piperazinylmethyl, 1-(1-piperazinyl)ethyl, 2-(1-piperazinyl)ethyl, 3-(1-piperazinyl)propyl and 4-(1-piperazinyl)butyl.

5 A CyC_{2-4} alkenyl group means a group resulting from the substitution of a hydrogen atom of a C_{2-4} alkenyl group with a Cy, that is with an aryl, C_{3-7} cycloalkyl, Het¹ or Het² group. Examples include among others 1-phenylethenyl, 2-phenylethenyl, 3-phenyl-1-propenyl, 3-phenyl-2-propenyl, 4-phenyl-1-butenyl, 4-phenyl-1,3-butadienyl, 2-cyclohexylethenyl, 3-cyclohexyl-2-propenyl, 4-
10 cyclohexyl-2-butenyl, 2-(2-pyridyl)ethenyl, 2-(3-pyridyl)ethenyl, 2-(4-pyridyl)ethenyl, 3-(4-pyridyl)-2-propenyl, 4-(4-pyridyl)-3-butenyl, 2-(1-piperazinyl)ethenyl, 3-(1-piperazinyl)-2-propenyl, 4-(1-piperazinyl)-2-butenyl, 2-(1-piperidyl)ethenyl, 2-(4-piperidyl)ethenyl, 3-(1-piperidyl)-2-propenyl and 4-(1-piperidyl)-3-butenyl.

15 A CyC_{2-4} alkynyl group means a group resulting from the substitution of a hydrogen atom of a C_{2-4} alkynyl group with a Cy, that is with an aryl, C_{3-7} cycloalkyl, Het¹ or Het² group. Examples include among others phenylethynyl, 3-phenyl-2-propynyl, 4-phenyl-3-butyne, cyclohexylethynyl, 3-cyclohexyl-2-propynyl, 4-cyclohexyl-2-butyne, 2-pyridylethynyl, 3-pyridylethynyl, 4-pyridylethynyl, 3-(2-
20 pyridyl)-2-propynyl, 3-(3-pyridyl)-2-propynyl, 3-(4-pyridyl)-2-propynyl, 4-(4-pyridyl)-3-butyne, 1-piperazinylethynyl, 3-(1-piperazinyl)-2-propynyl, 4-(1-piperazinyl)-3-butyne, 1-piperidylethynyl, 4-piperidylethynyl, 3-(4-piperidyl)-2-propynyl and 4-(4-piperidyl)-3-butyne.

25 The sentence "substituted with one or more" means the possibility of a group being substituted with one or more, preferably with 1, 2, 3 or 4 substituents, as long as said group has 1, 2, 3 or 4 positions capable of being substituted.

 Although the present invention includes all the compounds mentioned above, those compounds of formula I wherein R^1 represents $-SO_2R^2$ are preferred.

30 Those compounds of formula I wherein R^2 represents aryl optionally substituted with one or more groups R^b are also preferred.

 Those compounds of formula I wherein all the groups R^4 represent hydrogen are also preferred.

 Those compounds of formula I wherein R^5 represents hydrogen are also

preferred.

Those compounds of formula I wherein W represents $-CR^4R^4-$, preferably $-CH_2-$, are also preferred.

Those compounds of formula I wherein Z represents $-CO-$ are also preferred.

Those compounds of formula I wherein E represents $-COOR^6$, preferably $-COOH$, are also preferred.

Those compounds of formula I wherein m represents 1 are also preferred.

Another preferred group of compounds of formula I are those compounds wherein X represents $-NH-$.

Another preferred group of compounds of formula I are those compounds wherein X represents $-CH_2-$.

Another preferred group of compounds of formula I are those compounds wherein X represents $-O-$.

Those compounds of formula I wherein A represents piperidine or piperazine are also preferred.

Those compounds of formula I wherein L represents $-(CH_2)_n-$, preferably methylene or ethylene, are also preferred.

Those compounds of formula I wherein B represents Het^1 or Het^2 optionally substituted with one or more groups selected from oxo, R^b and Cy optionally substituted with one or more groups R^b are also preferred. More preferably, B represents imidazopyridine optionally substituted with one or more groups selected from oxo, R^b and Cy optionally substituted with one or more groups R^b .

Those compounds of formula I wherein B represents $-NR^fR^f$, $-OR^f$, $-NR^fCOR^f$, $-NR^fCONR^fR^f$, $-NR^fCSNR^fR^f$, $-NR^fCOOR^e$ or $-OCONR^fR^f$ are also preferred. More preferably, B represents $-OCONR^fR^f$, and still more preferably B represents $-OCONR^fR^f$ wherein both R^f groups are attached to each other to form together with the nitrogen atom a cycle Het^1 which can be optionally substituted with one or more groups selected from oxo, Cy and R^b , wherein the groups Cy can be optionally substituted with one or more groups selected from oxo and R^b .

Accordingly, a preferred embodiment of the present invention are the compounds of formula I wherein:

R^1 represents $-SO_2R^2$;

W represents $-CR^4R^4-$;

Z represents $-CO-$;

E represents $-COOR^6$;

m represents 1;

and R^2 , R^4 , R^5 , R^6 , X, A, L and B have the meaning described above.

Another preferred embodiment of the present invention are the compounds of formula I wherein:

R^1 represents $-SO_2R^2$;

R^2 represents aryl optionally substituted with one or more groups R^b ;

each R^4 represents hydrogen;

R^5 represents hydrogen;

W represents $-CH_2-$;

Z represents $-CO-$;

E represents $-COOR^6$;

m represents 1;

and R^6 , R^b , X, A, L and B have the meaning above described.

Another preferred embodiment of the present invention are the compounds of formula I wherein:

R^1 represents $-SO_2R^2$;

R^2 represents aryl optionally substituted with one or more groups R^b ;

each R^4 represents hydrogen;

R^5 represents hydrogen;

W represents $-CH_2-$;

Z represents $-CO-$;

E represents $-COOR^6$;

m represents 1;

A represents piperidine or piperazine;

and R^6 , R^b , X, L and B have the meaning described above.

Another preferred embodiment of the present invention are the compounds of formula I wherein:

R^1 represents $-SO_2R^2$;

R^2 represents aryl optionally substituted with one or more groups R^b ;

each R^4 represents hydrogen;

R^5 represents hydrogen;

W represents $-\text{CH}_2-$;

Z represents $-\text{CO}-$;

E represents $-\text{COOR}^6$;

m represents 1;

5 A represents piperidine or piperazine;

L represents $-(\text{CH}_2)_n-$;

and R^6 , R^b , X, B and n have the meaning described above.

Another preferred embodiment of the present invention are the compounds
of formula I wherein:

10 R^1 represents $-\text{SO}_2\text{R}^2$;

R^2 represents aryl optionally substituted with one or more groups R^b ;

each R^4 represents hydrogen;

R^5 represents hydrogen;

W represents $-\text{CH}_2-$;

15 Z represents $-\text{CO}-$;

E represents $-\text{COOR}^6$;

m represents 1;

A represents piperidine or piperazine;

L represents $-(\text{CH}_2)_n-$;

20 B represents Het^1 or Het^2 , optionally substituted with one or more groups
selected from oxo, R^b and Cy optionally substituted with one or more groups R^b ;

and R^6 , R^b , X, n, Cy, Het^1 and Het^2 have the meaning described above.

Another preferred embodiment of the present invention are the compounds
of formula I wherein:

25 R^1 represents $-\text{SO}_2\text{R}^2$;

R^2 represents aryl optionally substituted with one or more groups R^b ;

each R^4 represents hydrogen;

R^5 represents hydrogen;

W represents $-\text{CH}_2-$;

30 Z represents $-\text{CO}-$;

E represents $-\text{COOR}^6$;

m represents 1;

A represents piperidine or piperazine;

L represents $-(\text{CH}_2)_n-$;

B represents $-NR^fR^f$, $-OR^f$, $-NR^fCOR^f$, $-NR^fCONR^fR^f$, $-NR^fCSNR^fR^f$, $-NR^fCOOR^e$ or $-OCONR^fR^f$;

and R^6 , R^b , R^f , R^e , X and n have the meaning described above.

Another preferred embodiment of the present invention are the compounds

of formula I wherein:

R^1 represents $-SO_2R^2$;

R^2 represents aryl optionally substituted with one or more groups R^b ;

each R^4 represents hydrogen;

R^5 represents hydrogen;

W represents $-CH_2-$;

Z represents $-CO-$;

E represents $-COOH$;

m represents 1;

X represents $-NH-$;

A represents piperidine or piperazine;

L represents $-(CH_2)_n-$;

B represents Het^1 or Het^2 , optionally substituted with one or more groups selected from oxo, R^b and Cy optionally substituted with one or more groups R^b ;

and R^b , Cy, n, Het^1 and Het^2 have the meaning described above.

Another preferred embodiment of the present invention are the compounds of formula I wherein:

R^1 represents $-SO_2R^2$;

R^2 represents aryl optionally substituted with one or more groups R^b ;

each R^4 represents hydrogen;

R^5 represents hydrogen;

W represents $-CH_2-$;

Z represents $-CO-$;

E represents $-COOH$;

m represents 1;

X represents $-NH-$;

A represents piperidine or piperazine;

L represents $-(CH_2)_n-$;

B represents $-NR^fR^f$, $-OR^f$, $-NR^fCOR^f$, $-NR^fCONR^fR^f$, $-NR^fCSNR^fR^f$, $-NR^fCOOR^e$ or $-OCONR^fR^f$;

and R^b , R^f , R^e and n have the meaning described above.

Another preferred embodiment of the present invention are the compounds of formula I wherein:

R^1 represents $-\text{SO}_2\text{R}^2$;

R^2 represents aryl optionally substituted with one or more groups R^b ;

each R^4 represents hydrogen;

R^5 represents hydrogen;

W represents $-\text{CH}_2-$;

Z represents $-\text{CO}-$;

E represents $-\text{COOH}$;

m represents 1;

X represents $-\text{CH}_2-$ or $-\text{O}-$;

A represents piperidine or piperazine;

L represents $-(\text{CH}_2)_n-$;

B represents Het^1 or Het^2 optionally substituted with one or more groups selected from oxo, R^b and Cy optionally substituted with one or more groups R^b ; and R^b , Cy , n , Het^1 and Het^2 have the meaning described above.

Another preferred embodiment of the present invention are the compounds of formula I wherein:

R^1 represents $-\text{SO}_2\text{R}^2$;

R^2 represents aryl optionally substituted with one or more groups R^b ;

each R^4 represents hydrogen;

R^5 represents hydrogen;

W represents $-\text{CH}_2-$;

Z represents $-\text{CO}-$;

E represents $-\text{COOH}$;

m represents 1;

X represents $-\text{CH}_2-$ or $-\text{O}-$;

A represents piperidine or piperazine;

L represents $-(\text{CH}_2)_n-$;

B represents $-\text{NR}^f\text{R}^f$, $-\text{OR}^f$, $-\text{NR}^f\text{COR}^f$, $-\text{NR}^f\text{CONR}^f\text{R}^f$, $-\text{NR}^f\text{CSNR}^f\text{R}^f$, $-\text{NR}^f\text{COOR}^e$ or $-\text{OCONR}^f\text{R}^f$;

and R^b , R^f , R^e and n have the meaning described above.

Another preferred embodiment of the present invention are the compounds

of formula I wherein:

R¹ represents -SO₂R²;

R² represents aryl optionally substituted with one or more groups R^b;

each R⁴ represents hydrogen;

5 R⁵ represents hydrogen;

W represents -CH₂-;

Z represents -CO-;

E represents -COOH;

m represents 1;

10 X represents -NH-;

A represents piperidine or piperazine;

L represents -(CH₂)_n-;

15 B represents imidazopyridine optionally substituted with one or more groups selected from oxo, R^b and Cy optionally substituted with one or more groups R^b;

and R^b, Cy and n have the meaning described above.

Another preferred embodiment of the present invention are the compounds of formula I wherein:

R¹ represents -SO₂R²;

20 R² represents aryl optionally substituted with one or more groups R^b;

each R⁴ represents hydrogen;

R⁵ represents hydrogen;

W represents -CH₂-;

Z represents -CO-;

25 E represents -COOH;

m represents 1;

X represents -NH-;

A represents piperidine or piperazine;

L represents -(CH₂)_n-;

30 B represents -OCONR^fR^f;

and R^b, R^f and n have the meaning described above.

Another preferred embodiment of the present invention are the compounds of formula I wherein:

R¹ represents -SO₂R²;

R² represents aryl optionally substituted with one or more groups R^b;

each R⁴ represents hydrogen;

R⁵ represents hydrogen;

W represents -CH₂-;

5 Z represents -CO-;

E represents -COOH;

m represents 1;

X represents -CH₂- or -O-;

A represents piperidine or piperazine;

10 L represents -(CH₂)_n-;

B represents imidazopyridine optionally substituted with one or more groups selected from oxo, R^b and Cy optionally substituted with one or more groups R^b;

and R^b, Cy and n have the meaning described above.

15 Another preferred embodiment of the present invention are the compounds of formula I wherein:

R¹ represents -SO₂R²;

R² represents aryl optionally substituted with one or more groups R^b;

each R⁴ represents hydrogen;

20 R⁵ represents hydrogen;

W represents -CH₂-;

Z represents -CO-;

E represents -COOH;

m represents 1;

25 X represents -CH₂- or -O-;

A represents piperidine or piperazine;

L represents -(CH₂)_n-;

B represents -OCONR^fR^f;

and R^b, R^f and n have the meaning described above.

30 Another preferred embodiment of the present invention are the compounds of formula I wherein:

R¹ represents -SO₂R²;

R² represents aryl optionally substituted with one or more groups R^b;

each R⁴ represents hydrogen;

R⁵ represents hydrogen;

W represents -CH₂-;

Z represents -CO-;

E represents -COOH;

5 m represents 1;

X represents -NH-;

A represents piperidine or piperazine;

L represents -(CH₂)_n-;

10 B represents -OCONR^fR^f, wherein both groups R^f are attached to each other to form together with the nitrogen atom a cycle Het¹, which can be optionally substituted with one or more groups selected from oxo, Cy and R^b, wherein the groups Cy can be optionally substituted with one or more groups selected from oxo and R^b;

and R^b, Cy, n and Het¹ have the meaning described above.

15 Another preferred embodiment of the present invention are the compounds of formula I wherein:

R¹ represents -SO₂R²;

R² represents aryl optionally substituted with one or more groups R^b;

each R⁴ represents hydrogen;

20 R⁵ represents hydrogen;

W represents -CH₂-;

Z represents -CO-;

E represents -COOH;

m represents 1;

25 X represents -CH₂- or -O-;

A represents piperidine or piperazine;

L represents -(CH₂)_n-;

30 B represents -OCONR^fR^f, wherein both groups R^f are attached to each other to form together with the nitrogen atom a cycle Het¹, which can be optionally substituted with one or more groups selected from oxo, Cy and R^b, wherein the groups Cy can be optionally substituted with one or more groups selected from oxo and R^b;

and R^b, Cy, n and Het¹ have the meaning described above.

The compounds of the present invention can contain one or more acid

protons and one or more basic nitrogens and, consequently, can form salts with organic and inorganic bases and acids, which are also included in the present invention. There is no limitation on the nature of said salts, provided that, when used for therapeutic purposes, they are pharmaceutically acceptable. Examples of

5 said salts include: salts with inorganic cations such as sodium, potassium, calcium, magnesium, lithium, aluminum, zinc, etc; salts formed with pharmaceutically acceptable amines such as ammonia, alkylamines, hydroxyalkylamines, lysine, arginine, *N*-methylglucamine, procaine and the like; salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic

10 acid, nitric acid, perchloric acid, sulfuric acid or phosphoric acid; and salts with organic acids, such as methanesulfonic acid, trifluoromethanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, *p*-toluenesulfonic acid, fumaric acid, oxalic acid, acetic acid or maleic acid, among others. The salts can be prepared by treatment of a compound of formula I with a sufficient amount of the desired

15 acid or base to give the salt in a conventional manner. The compounds of formula I and their salts differ in certain physical properties, such as solubility, but they are equivalent for the purposes of the invention.

Some compounds of the present invention can exist in solvated form, including hydrated forms. In general, the solvated forms, with pharmaceutically

20 acceptable solvents such as water, ethanol and the like, are equivalent to the unsolvated form for the purposes of the invention.

The compounds of the present invention can exist as various diastereoisomers and/or various optical isomers. Diastereoisomers can be separated by conventional techniques such as chromatography or fractional

25 crystallization. The optical isomers can be resolved using conventional techniques of optical resolution, to give the optically pure isomers. This resolution can be performed upon any chiral synthetic intermediate or upon the products of general formula I. The optically pure isomers can also be individually obtained using enantioespecific synthesis. The present invention covers both the individual

30 isomers and the mixtures (for example racemic mixtures), whether obtained by synthesis or by physically mixing them up.


Furthermore, some of the compounds of the present invention can exhibit *cis/trans* isomery. The present invention includes each one of the geometric isomers as well as the mixtures thereof.

The compounds of the present invention can be prepared following the processes that are explained in detail below. As it will be obvious to a person skilled in the art, the precise method used for the preparation of a given compound can vary depending on its chemical structure. Furthermore, in most processes that are explained below it may be necessary or advisable to protect the labile or reactive groups using conventional protecting groups. Both the nature of said protecting groups and the processes for their introduction and removal are well known and belong to the state of the art (see for example Greene T.W. and Wuts P.G.M, "Protective Groups in Organic Synthesis", John Wiley & Sons, 3rd edition, 1999). By way of illustration, the groups *tert*-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz) or fluorenylmethoxycarbonyl (Fmoc) can be used as protecting groups for an amino function, or the triphenylmethyl group can be used as a protecting group for the acidic nitrogen of a tetrazole. Carboxyl groups can be protected, for example, as C₁₋₄ alkyl esters, such as methyl, ethyl or *tert*-butyl, or arylC₁₋₄ alkyl esters, such as benzyl. When a protecting group is present, a later deprotection step will be necessary, which is performed under standard conditions, such as those described in the reference above mentioned.

Given that the compounds of formula I contain several functional groups in their structure, their process of preparation will comprise the formation of said functional groups by the subsequent union of different building blocks. As it will be obvious to those skilled in the art, the order in which these reactions are carried out does not matter as long as the reactive or labile groups are protected, when necessary, with protecting groups.


A preferred method of synthesis for obtaining the compounds of formula I involves the formation, in a last step, of the -XC(O)A- group, wherein X and A have the meaning described above. This group can be prepared either by forming the bond between X and CO, or between CO and A, or by forming both bonds at the same time, depending on the meaning of X and A.

Thus, for example, the compounds of formula I wherein X is -NR⁵- (Ia)



Ia

wherein R^1 , R^4 , R^5 , W, Z, E, A, L, B and m have the meaning described above,
can be obtained by formation of the amide group reacting an amine of formula II
5 with an acid of formula III



II

III


wherein R^1 , R^4 , R^5 , W, Z, E, A, L, B and m have the meaning described above.

To prepare said amide, any conventional reaction of formation of amides
can be used. For example, the carboxylic acid III can be reacted with the amine of
10 formula II in the presence of a suitable condensing agent such as a carbodiimide
(for example dicyclohexylcarbodiimide, *N*-(3-dimethylaminopropyl)-*N'*-
ethylcarbodiimide, 1,3-diisopropylcarbodiimide, *O*-(benzotriazol-1-yl)-*N,N,N',N'*-
tetramethyluronium hexafluorophosphate (HBTU) or (benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP)), alone or
15 associated with 1-hydroxybenzotriazole, in a suitable solvent. Examples of
suitable solvents include substituted amides, such as dimethylformamide; ethers,
such as dioxane and tetrahydrofuran; and halogenated hydrocarbons, such as
dichloromethane and chloroform. When the starting amine or the carbodiimide are
used as an addition salt, for example the hydrochloride, the reaction is performed
20 in the presence of a base, such as triethylamine, *N,N*-diisopropylethylamine or *N*-
methylmorpholine.

Alternatively, the amide bond can be prepared by reacting the amine with a
reactive derivative of the acid of formula III, such as its acid chloride, its *N*-
hydroxysuccinimide ester, its anhydride or a mixed anhydride. In this case, the


reaction is carried out in the presence of a proton scavenger base, for example pyridine, triethylamine or *N,N*-diisopropylethylamine, in a suitable solvent, or, when appropriate, the same proton scavenger amine can be used as solvent. Examples of suitable solvents include halogenated hydrocarbons, such as dichloromethane and chloroform; ethers, such as diethyl ether, tetrahydrofuran and dioxane; and aromatic hydrocarbons such as benzene and toluene.

The compounds of formula I wherein X is -O- (**lb**)



lb

- 10 wherein R^1 , R^4 , R^5 , W, Z, E, A, L, B and m have the meaning described above, can be obtained by formation of the ester bond reacting an alcohol of formula IV with an acid of formula III



IV


III

wherein R^1 , R^4 , R^5 , W, Z, E, A, L, B and m have the meaning described above.


- 15 Any conventional method of preparation of esters can be used here, for example, a reactive derivative of the carboxylic acid III can be reacted with the alcohol of formula IV in the presence of a base and in a suitable solvent. Thus, for example, the reaction can be carried out using *N,N'*-dicyclohexylcarbodiimide as activating agent, in the presence of 4-dimethylaminopyridine and in a solvent such as diethyl ether. Other suitable reaction conditions include the use of bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl) and triethylamine in dichloromethane or
- 20 the use of 2,4,6-trichlorobenzoyl chloride and triethylamine in tetrahydrofuran.

The compounds of formula I wherein X is -CH₂- and cycle A is bound to the carbonyl group through a nitrogen atom (**lc**)

28

**Ic**


wherein R^1 , R^4 , R^5 , W , Z , E , A , L , B and m have the meaning described above, can be obtained by reacting an acid of formula **V** with an amine of formula **VI**

**V****VI**

5

wherein R^1 , R^4 , R^5 , W , Z , E , A , L , B and m have the meaning described above, using the methods described above for the formation of amide bonds.

The compounds wherein X is $-NR^5-$ or $-O-$ and cycle A is bound to the carbonyl group through a nitrogen atom (**Id** and **Ie**, respectively)

**Id****Ie**

10

wherein R^1 , R^4 , R^5 , W , Z , E , A , L , B and m have the meaning described above, can be obtained by forming the urea (compound **Id**) or carbamate (compound **Ie**) groups starting from the compounds of formulae **II** and **VI** in the first case and from the compounds of formulae **IV** and **VI** in the second one.

15


Said functions are prepared using a two-step procedure: in a first step, one of the amines **II** or **VI** in the case of the urea, or the alcohol of formula **IV** in the case of the carbamate, is reacted with an activating agent suitable for the

preparation of ureas or carbamates such as triphosgene, phosgene or 1,1'-carbonyldiimidazole, in the presence of a base such as diisopropylethylamine, triethylamine or *N*-methymorpholine, in a suitable solvent such as acetonitrile or a halogenated hydrocarbon such as chloroform or dichloromethane. The resulting compound is reacted in a second step with the second amine in the case of the urea and with the amine of formula VI in the case of the carbamate, in the presence of any of the bases cited above if the amine is present as hydrochloride, and in a suitable solvent, for example the solvent used in the first step. The reaction can be carried out at a temperature comprised between room temperature and the boiling point of the solvent.

The activation of the primary amine of formula II or of the alcohol of formula IV in the first step can also be carried out by reacting said compounds with agents such as phenyl chloroformate or nitrophenyl chloroformate, under the same conditions described above for the other activating agents.

The ureas of formula Id can also be obtained by reaction of an amine of formula II with di-*tert*-butyl dicarbonate as activating agent, in the presence of a catalytic amount of 4-dimethylaminopyridine (DMAP) and then reacting the resulting intermediate with the amine of formula VI. Both steps are carried out in a suitable solvent such as dichloromethane, and it is not necessary to isolate the obtained intermediate.

Alternatively, the ureas of formula Id can also be obtained in two steps from a compound of formula V'




V'


wherein R¹, R⁴, R⁵, W, Z, E and m have the meaning described above. In a first step, a Curtius rearrangement is carried out, that is, the compound of formula V' is treated with a suitable azide for carrying out said rearrangement such as for example sodium azide combined with thionyl chloride, or diphenylphosphorylazide, in the presence of a base such as triethylamine, diisopropylethylamine or *N*-methymorpholine. The reaction is preferably carried

out in an apolar solvent such as benzene, stirring first at room temperature and then at a temperature comprised between room temperature and reflux. The resulting compound is reacted in a second step with an amine of formula VI, in an inert solvent such as for example a halogenated hydrocarbon such as dichloromethane or chloroform, or a substituted amide such as dimethylformamide, optionally in the presence of a base such as diisopropylethylamine, triethylamine or pyridine. The reaction can be carried out at a temperature comprised between room temperature and reflux, optionally irradiating with microwaves, when necessary.

The intermediates of formulae II, IV, V and V' used in the reactions described above can be obtained, when Z is a carbonyl group (compounds of formulae II*, IV*, V* and V'), by reacting the acid of formula VII with the amines of formulae IIa, IVa, Va or V'a as shown in the following scheme



31




scheme 1


wherein R¹, R⁴, R⁵, W, E and m have the meaning described above. Said reactions are carried out according to the methods described above for the preparation of amide bonds, previously protecting, if necessary, the labile or reactive groups with conventional protecting groups. The compounds of formulae II, IV, V and V' wherein Z represents -CS- can be obtained from the compounds II*, IV*, V* and V** respectively, by transforming the amide group into a thioamide, if no other amide group is present in the molecule. Said transformation can be carried out using any of the methods widely described in the literature, for example, by treatment with phosphorous pentasulfide or Lawesson's reagent in a suitable solvent such as tetrahydrofuran or toluene, or with oxalyl chloride and trimethylsilyl sulfide (TMS₂S), triphosgene/TMS₂S or POCl₃/TMS₂S in dichloromethane.

The precursors of formula VII can be commercially available or can be obtained from commercially available compounds by reactions widely known by any person skilled in the art.

Thus, for example, the compounds of formula VII wherein R¹ represents -SO₂R₂ (VIIa)



wherein R², R⁴ and m have the meaning described above, can be obtained by formation of the sulfonamide from an amine of formula VIIIa and a sulfonyl chloride of formula IX




VIIIa

IX

wherein R^2 , R^4 and m have the meaning described above. The reaction can be carried out in basic medium, using a base such as sodium carbonate, sodium hydroxide or triethylamine, and in a suitable solvent such as an ether, for example dioxane, or a halogenated hydrocarbon, for example chloroform or dichloromethane.


The compounds of formula VII wherein R^1 represents $-\text{COR}^2$ (VIIb)



VIIb


wherein R^2 , R^4 and m have the meaning described above, can be obtained by formation of the amide group according to the methods described above, starting from an amine of formula VIIIa having the carboxy group unprotected or protected as an ester, and an acid of formula $R^2\text{COOH}$ (X) or an activated form thereof.

Finally, the compounds of formula VII wherein R^1 represents $-\text{CH}_2\text{R}^3$ (VIIc)



VIIc


wherein R^3 , R^4 and m have the meaning described above, can be obtained by alkylation of the amide of formula VIIb



VIIlb


wherein R^4 and m have the meaning described above, with a compound of formula R^3-CH_2-D (XI), wherein R^3 has the meaning described above and D is a good leaving group, for example an alkylsulfonate or arylsulfonate such as mesylate or tosylate, or a halogen such as Cl, Br or I. This reaction is carried out under the standard conditions for the alkylation of amides, that is in the presence of a strong base such as sodium hydride in a suitable solvent and at a temperature comprised between room temperature and the boiling point of the solvent. Examples of solvents include halogenated hydrocarbons such as dichloromethane or chloroform, substituted amides such as for example dimethylformamide and alcohols such as ethanol.

The intermediates of formulae III and VI used in the reactions described above




wherein A, L and B have the meaning described above, can be obtained by reactions widely known by any person skilled in the art, using one or another depending on the specific structure sought.

Thus, for example, the compounds of formulae III and VI wherein cycle A is bound to the -L-B moiety through a ring nitrogen atom (compounds of formulae IIIa and VIa, respectively)




wherein A, L and B have the meaning described above, can be obtained by alkylation of the amine of cycle A, by reacting the compounds of formulae XII and XIII, respectively,




wherein A has the meaning described above and GP is a suitable protecting

group, with a compound of formula D-L-B (**XIV**) wherein D, L and B have the meaning described above, and subsequent removal of the protecting group. The reaction of **XII** or **XIII** with **XIV** is carried out under the standard conditions for the alkylation of amines, that is in the presence of a base such as triethylamine, sodium carbonate, potassium carbonate or sodium hydride in a suitable solvent such as a halogenated hydrocarbon (for example dichloromethane or chloroform), a substituted amide (for example dimethylformamide) or an alcohol (for example ethanol or butanol), and at a temperature comprised between room temperature and the boiling point of the solvent.

- 10 The compounds of formulae **III** and **VI** can also be obtained by forming the bond between the groups L and B. When B is a cycle Het¹ or Het² bound to the rest of the molecule through a ring nitrogen atom (**IIIb** and **VIb**)




- 15 wherein A and L have the meaning described above, the compounds of formulae **IIIb** and **VIb** can be obtained by alkylation of the nitrogen of the amine of cycle B (**XV**) with a compound of formula **XIIa** or **XIIIa** respectively,




- 20 wherein A, L, B, D and GP have the meaning described above, under the conditions described above for the alkylation of amines, and by subsequent removal of the protecting group.

Alternatively, the compounds of formulae **IIIb** and **VIb** can also be obtained by construction of the cycle B starting from a primary amine of formula **XIb** or **XIIIb**



- 25 wherein A, L and GP have the meaning described above, by reaction them with a suitable bifunctional compound, and subsequent removal of the protecting group


GP. By way of illustration, some suitable reactions of construction of the cycle B are shown below.



scheme 2

5

wherein the compound **XVI** represents in combined form the compounds **XIIb** and **XIIIb**, A and L have the meaning described above, q represents 0, 1 or 2 and R represents GP-CO- or



10


When B represents one of the functions ii), that is $-COR^e$, $-NR^fR^f$, $-OR^f$, $-SR^f$, $-S(O)_pR^e$, $-CONR^fR^f$, $-NR^fCOR^f$, $-NR^fCONR^fR^f$, $-NR^fCSNR^fR^f$, $-NR^fCOOR^e$, $-OCOR^e$, $-OCONR^fR^f$, $-NR^fSO_2R^e$ or $-SO_2NR^fR^f$, the compounds of formulae **III** and **VI** can be obtained by forming said functions starting from suitable precursors, using standard reactions in organic chemistry such as those explained below. Though not being mentioned each time, whenever in said reactions a protecting group GP is present in the starting products, a final deprotection step will be needed to provide the compounds of formulae **III** and **VI**.

15

Thus, for example, the compounds of formulae **III** and **VI** wherein B is $-NHCOR^e$ and $-NHSO_2R^e$ can be obtained from the compounds of formulae **XIIb**


and **XIIIb** by forming the amide and sulfonamide groups, reacting them with an acid R^eCOOH or a sulfonyl chloride R^eSO_2Cl , respectively, under the conditions described above for the preparation of amides and sulfonamides. The compounds of formulae **III** and **VI** wherein B represents an urea, thiourea or carbamate function can also be obtained from a compound of formula **XVI**. Thus, the compounds of formulae **III** and **VI** wherein B is $-NHCONR^fR^f$ can be obtained, for example, by using the method for preparing ureas described above; the compounds of formulae **III** and **VI** wherein B is $-NHCSNR^fR^f$ can be obtained following the same method but using thiophosgene instead of triphosgene as coupling agent. The compounds of formulae **III** and **VI** wherein B represents an urea or thiourea of formula $-NHCONHR^e$ or $-NHCSNHR^e$ can be obtained by reaction of an amine of formula **XVI** with an isocyanate of formula R^eNCO or a thioisocyanate of formula R^eNCS , respectively. This reaction is carried out by reacting the amine **XVI** with the desired isocyanate or thioisocyanate in an inert solvent such as for example toluene, a substituted amide such as dimethylformamide or an ether such as tetrahydrofuran. The compounds of formula **III** and **VI** wherein B is a carbamate of formula $-NHCOOR^e$ can be obtained by reaction of an amine **XVI** with a chloroformate of formula $ClCOOR^e$, carrying out the reaction in the presence of a base such as a tertiary amine (triethylamine, diisopropylethylamine or *N*-methylmorpholine) and in a suitable solvent such as for example a halogenated hydrocarbon such as chloroform or dichloromethane. Finally, a compound of formula **XVI** can also be transformed into a secondary or tertiary amine (that is, a compound of formula **III** or **VI** wherein the group B is $-NR^fR^e$) by alkylation with one or two compounds of formula $D-R^e$, wherein D represents a good leaving group, using the methods described above or alternatively by reductive amination of a suitable aldehyde or ketone. This reaction is in general carried out by reacting the amine with an aldehyde or ketone in the presence of a suitable reducing agent such as a metallic hydride, for example sodium cyanoborohydride or sodium triacetoxyborohydride, and in a suitable solvent such as methanol, tetrahydrofuran, acetonitrile or mixtures thereof, among others.

The compounds of formulae **III** and **VI** wherein B is $-OCOR^e$, $-OCONR^fR^f$, or $-OR^f$ can be obtained from a compound of formula **XVIa**

**XVIa**

wherein R, A and L have the meaning described above. Thus, starting from said compound **XVIa**, the compounds **III** and **VI** that contain ester and carbamate groups can be easily obtained by using the methods described above for the preparation of said functions. The compounds of formulae **III** and **VI** wherein B is an ether of formula $-\text{OR}^e$ can be obtained for example by using the Mitsunobu reaction, reacting a compound of formula **XVIa** with another alcohol of formula R^eOH in the presence of triphenylphosphine and diethyl azodicarboxylate (DEAD), in a suitable solvent such as tetrahydrofuran. The formation of the ether can also be carried out by reacting the alcohol of formula **XVIa** with a suitable base such as potassium carbonate in a solvent such as acetone or 2-butanone and treating the obtained salt with a compound of formula $\text{R}^e\text{-D}$, wherein D represents a good leaving group. The compounds of formulae **III** and **VI** wherein B is $-\text{OR}^f$ and R^f is hydrogen are obtained from an alcohol of formula **XVIa** by deprotection.


The compounds of formulae **III** and **VI** wherein B is $-\text{SR}^f$ or $-\text{S(O)}_p\text{R}^e$ can be in general obtained from a compound of formula **XVIb**

**XVIb**

wherein R, A and L have the meaning described above. Thus, for example, the compounds of formulae **III** and **VI** wherein B is a sulfide of formula $-\text{SR}^e$ can be obtained by reacting the thiol **XVIb** with an alkylating agent $\text{R}^e\text{-D}$, wherein D is preferably a tosylate, in the presence of a base such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and in a suitable solvent such as *N,N*-dimethylformamide and subsequent removal of the protecting group. The compounds of formulae **III** and **VI** wherein B is $-\text{SR}^f$ and R^f is hydrogen are directly obtained from the thiol of formula **XVIb** by deprotection. The compounds of formulae **III** and **VI** wherein B is $-\text{S(O)}_p\text{R}^e$ can be obtained by oxidation of the previously obtained sulfide (**III** or **VI** wherein B is $-\text{SR}^e$) using a suitable oxidizing agent. Suitable reagents for the oxidation of a sulfide to a sulfoxide ($-\text{SOR}^e$) include among others hydrogen peroxide, meta-chloroperoxybenzoic acid and sodium

periodate. The oxidation reaction is carried out reacting the corresponding sulfide with one equivalent of the oxidizing agent in a suitable solvent such as for example dichloromethane. Likewise, the compounds **III** and **VI** wherein B is $-\text{SO}_2\text{R}^e$ can be obtained either from the corresponding sulfide by reaction with at least two equivalents of a suitable oxidizing agent, such as hydrogen peroxide, sodium tungstate, meta-chloroperoxybenzoic acid or potassium permanganate, or from the corresponding sulfoxide by reaction with at least one equivalent of the oxidizing agent.

The compounds of formulae **III** and **VI** wherein B is a sulfonamide ($-\text{SO}_2\text{NR}^f\text{R}^f$), can be obtained, for example, by a sequence that comprises the conversion of a compound of formula **XIIa** or **XIIIa**, respectively,



wherein A, L, D and GP have the meaning described above, into the corresponding thioacetate ($-\text{SAC}$), the subsequent transformation of said thioacetate into the corresponding sulfonyl chloride by treatment with chlorine and the reaction of said sulfonyl chloride with an amine HNR^fR^f , following a sequence analogous to that described by R. J. Watson *et al.* in *Tetrahedron Letters*, **2002**, 43, 683-685, followed by the removal of the protecting group GP.


The precursors of formulae **XII**, **XIII**, **XIIa**, **XIIIa**, **XIIb**, **XIIIb**, **XVIa** and **XVIb**, which contain functional groups suitably protected, can be obtained by protection of commercially available compounds or compounds obtained from commercially available compounds by standard processes.

The precursors of formulae **Ila**, **Iva**, **Va**, **V'a**, **VIIla**, **VIIlb**, **IX**, **X**, **XI**, **XIV**, **XV**, R^eCOOH , $\text{R}^e\text{SO}_2\text{Cl}$, R^eNCO , R^eNCS , ClCOOR^e , R^eOH , HNR^fR^f and D-R^e can be commercially available or can be obtained from commercially available compounds using processes widely known by those skilled in the art.

By way of illustration, the compounds of formulae **Ila**, **Iva**, **Va** and **V'a** wherein E is an ester or an amide can be commercially available or can be obtained from the commercially available amino acid (2,3-diaminopropionic acid, serine, glutamic and aspartic acid, respectively) by transforming the carboxylic acid present in all of them into an ester or amide group following the methods


described above. The compounds of formulae **Ila**, **IVa**, **Va** and **V'a** wherein E is a 5-tetrazolyl group can be obtained in 2 steps from the primary amide of the corresponding aminoacid. Said amide is first transformed into the nitrile by treatment with an efficient dehydrating agent such as phosphorous pentoxide, phosphoryl chloride, thionyl chloride or acetic anhydride in a suitable solvent and the cyano group obtained is subsequently converted into a tetrazole by treatment with one equivalent of an azide such as tributyltin azide (previously formed or formed *in situ* from sodium azide and tributyltin chloride) in an apolar solvent such as xylene or toluene at a temperature comprised between room temperature and the boiling point of the solvent.

Moreover, the compounds of formula **VIIIb** can be commercially available or can be obtained by dehydrating a compound of formula **VIII***





wherein m and R^4 have the meaning described above, that is, by dehydrating aspartic and glutamic acids, when all the groups R^4 represent hydrogen and m represents 0 and 1, respectively, or by dehydrating substituted derivatives thereof, when one or more groups R^4 is different from hydrogen.

The compounds of formula **I** wherein Z represents CO (**If**)





wherein R^1 , R^4 , R^5 , W , E , X , A , L , B and m have the meaning described above, can also be obtained by forming the amido bond present in the molecule as the last step of the synthesis, starting from the intermediates of formula **VII** and **XVII**


**VII****XVII**

wherein R^1 , R^4 , R^5 , W , E , X , A , L , B and m have the meaning described above, using any of the methods described above for the formation of said amido bond.

The compounds of formula I wherein W represents $-CR^4R^4-$ and R^1 represents $-SO_2R^2$ or $-COR^2$ (compounds of formulae **Ig** and **Ih**, respectively)


**Ig****Ih**

wherein R^2 , R^4 , R^5 , Z , E , X , A , L , B and m have the meaning described above, can be obtained by forming, in a last step, the bond between the group R^1 and the compound of formula **XVIII**

**XVIII**


wherein R^4 , R^5 , Z , E , X , A , L , B and m have the meaning described above. Thus, depending on the meaning of the group R^1 , the compound of formula **XVIII** can be reacted with a sulfonyl chloride of formula **IX**, or with an acid of formula **X** or an activated form thereof, to obtain a sulfonamide or amide, respectively. These reactions can be carried out under the conditions described above for the preparation of the precursors of formulae **VIIa** and **VIIb**, respectively.

The compounds of formula I wherein W represents -CO- and R¹ represents -CH₂R³ (II)



II


wherein R³, R⁴, R⁵, Z, E, X, A, L, B and m have the meaning described above, can be obtained by alkylation of a compound of formula XIX



XIX

wherein R⁴, R⁵, Z, E, X, A, L, B and m have the meaning described above, with a compound of formula XI, under the standard conditions for the alkylation of amides described above in connection with compounds of formula VIIc.

The compounds of formula I wherein cycle A is bound to the -L-B moiety through a ring nitrogen atom (Ij)




Ij

wherein R¹, R⁴, R⁵, W, Z, E, X, A, L, B and m have the meaning described above, can be obtained by alkylation of the amine of cycle A of a compound of formula XX

XX


42

**XX**

wherein R^1 , R^4 , R^5 , W , Z , E , X , A and m have the meaning described above, with a compound of formula **XIV**, under the standard alkylation conditions described above.


5 The intermediates of formulae **XVII**, **XVIII**, **XIX** and **XX** can be obtained, as described for the compounds of formula **I**, by formation of the various functional groups present in said compounds, by the subsequent combination of different building blocks and/or the transformation of functional groups already present in said building blocks. All these reactions, as well as the reactions for preparing
 10 non-commercially available precursors, can be carried out by using the chemistry described throughout the present invention and by using standard reactions in organic chemistry. As in the case of the compounds of formula **I**, the order in which the reactions are carried out does not matter as long as the reactive or labile groups are protected, whenever necessary, with suitable protecting groups.

15 By way of illustration, the intermediates of formula **XVII** can be obtained by forming, in a last step, the $-XC(O)A-$ group. The intermediates of formula **XVII** wherein X is $-CH_2-$ and cycle A is bound to the carbonyl group through a ring carbon atom (**XVIIa**)

**XVIIa**

20 wherein R^5 , A , L , E and B have the meaning described above, may be obtained by following a method analogous to that described by Ying-zi Xu *et al.* in *J. Org. Chem.*, **1999**, 64, 4069-4078, by reaction of the compounds of formulae **XXI** and

XXII as shown in the following scheme



5 wherein A, L and B have the meaning described above, alk represents C₁₋₈ alkyl and M represents Li, Br-Mg-, Cl-Mg- or I-Mg-, and subsequent transformation of the compound obtained into a compound of formula **XVIIa** using standard reactions in organic chemistry. As it will be obvious to those skilled in the art, the compounds of formula **XXI** can be obtained by intramolecular cyclation of the
 10 corresponding glutamic acid derivative; the compounds of formula **XXII** can be obtained using standard methods for preparing organolithium or organomagnesium compounds, starting from the corresponding halide.


The compounds of the present invention can also be obtained by interconversion from another compound of formula I, in one or a plurality of steps,
 15 using standard reactions, widely used in organic chemistry.

For example, a group E can be converted into another group E, by transforming a carboxylic acid into an ester or amide as described above. Furthermore, the carboxylic acid can be obtained from the corresponding ester or amide by hydrolysis. The hydrolysis of an ester group to give a carboxy group can
 20 be carried out in the presence of a base such as potassium hydroxide or lithium hydroxide in a suitable solvent such as for example ethanol, tetrahydrofuran, ethanol-water mixtures and tetrahydrofuran-water mixtures or in an apolar solvent such as benzene in the presence of a crown ether, for example 18-C-6. The hydrolysis of the amide can be carried out for example by using a strong acid such
 25 as hydrochloric, hydrobromic, sulfuric or phosphoric acid either in a polar solvent such as water or ethanol-water mixtures, or in a basic medium by using a strong base such as sodium hydroxide or potassium hydroxide in ethylene glycol. Alternatively, a primary amide can be transformed into a tetrazolyl group as described above.

30 A group B can also be interconverted into another group B, giving thus rise


to further compounds of formula I.

Thus, for example, the compounds of formula I wherein B represents a cycle Het¹ or Het² bound to the rest of the molecule through a ring nitrogen atom (Ik),



Ik

wherein R¹, R⁴, R⁵, W, Z, E, X, A, L, B and m have the meaning described above, can be obtained by construction of the cycle B upon a compound of formula Im




Im

wherein R¹, R⁴, R⁵, W, Z, E, X, A, L and m have the meaning described above, by reaction with a suitable bifunctional compound such as those shown in scheme 2 above.

Moreover, the compounds of formula I wherein B represents a function of formula -NHCOR^e, -NHCO^e, -NHCONR^fR^f, -NHCSNR^fR^f, -NHCONHR^e, -NHCSNHR^e, -NHCOOR^e or -NR^eR^e can all be obtained from a primary amine of formula Im, by treatment with suitable reagents. Said reagents, as well as the reaction conditions, are the same as those described above for the preparation of compounds of formulae III and VI wherein B has the same meaning. Thus, the compounds wherein B represents -NHCOR^e can be obtained by reaction of an amine of formula Im with an acid R^eCOOH or an activated form thereof; the compounds wherein B is -NHCO^e, by reaction of the amine Im with a sulfonyl chloride of formula R^eSO₂Cl; the compounds wherein B is -NHCONR^fR^f or

-NHCSNR^fR^f, by reaction of an amine **Im** with an amine of formula HNR^fR^f, where one of the two amines is activated with an activating agent suitable for the formation of ureas or thioureas; the compounds wherein B is -NHCONHR^e or -NHCSNHR^e, by reaction of an amine **Im** with an isocyanate of formula R^eNCO or with a thioisocyanate of formula R^eNCS, respectively; the compounds wherein B is -NHCOOR^e, by reaction of an amine **Im** with a chloroformate of formula ClCOOR^e; and the compounds wherein B is -NR^fR^e, by alkylation of an amine of formula **Im** with one or two compounds of formula D-R^e wherein D represents a good leaving group, or by reductive amination of a suitable aldehyde or ketone.

The compounds of formula **I** wherein B represents a function of formula -OCOR^e, -OCONR^fR^f or -OR^f can all be obtained from an alcohol of formula **In**




In

wherein R¹, R⁴, R⁵, W, Z, E, X, A, L and m have the meaning described above, by treatment with suitable reagents for the preparation of the desired function. Thus, when B represents -OCOR^e, an alcohol of formula **In** can be reacted with a reactive derivative of a carboxylic acid of formula R^eCOOH, under the conditions described above for the formation of ester groups. For the preparation of compounds of formula **I** wherein B represents -OCONR^fR^f, an alcohol of formula **In** can be reacted with an amine of formula HNR^fR^f following any of the methods described above for the preparation of carbamates. The compounds wherein B represents an ether -OR^e can be obtained by reaction of an alcohol of formula **In** with an alcohol of formula R^eOH, or with an alkylating agent of formula D-R^e, wherein D has the meaning described above, according to the methods described above for the preparation of compounds of formulae **III** and **VI** wherein B is an ether -OR^e.

Likewise, the compounds of formula **In** can also give rise to further compounds of formula **Ik** by conversion into an intermediate of formula **XXIII**


46

**XXIII**

wherein R^1 , R^4 , R^5 , W , Z , E , X , A , L , D and m have the meaning described above, and subsequent reaction of **XXIII** with an amine of formula **XV**, under the standard conditions for the alkylation of amines described above. The transformation of **In** into **XXIII** is performed by using standard reactions for transforming alcohols into leaving groups such as halides or alkyl or arylsulfonates.

Moreover, the intermediate of formula **XXIII** can be transformed into a compound of formula **I** wherein B represents $-\text{SO}_2\text{NR}^f\text{R}^f$ by following a sequence analogous to that described by R. J. Watson *et al.* in *Tetrahedron Letters*, 2002, 43, 683-685.

The compounds of formula **I** wherein B is $-\text{SR}^f$ or $-\text{S}(\text{O})_p\text{R}^e$ can all be obtained from a compound of formula **Io**

**Io**

wherein R^1 , R^4 , R^5 , W , Z , E , X , A , L and m have the meaning described above.

Following the method described above for the preparation of compounds of formulae **III** and **VI** wherein B represents the same functions, a compound of formula **Io** can be transformed into a compound of formula **I** wherein B is $-\text{SR}^e$, by reaction of compound **Io** with an alkylating agent; the resulting sulfide ($-\text{SR}^e$) can then be oxidized to give compounds of formula **I** wherein B represents $-\text{SOR}^e$ or $-\text{SO}_2\text{R}^e$.

Other transformations of groups that may be present in the compounds of

formula I and that give rise to other compounds of formula I include, among others: the conversion of an amide into a thioamide, for example under the conditions described above; the conversion of a nitro group into an amino group, for example by hydrogenation in the presence of a suitable catalyst such as Pd/C or by treatment with a suitable reducing agent such as SnCl₂; and the conversion of a primary or secondary hydroxyl group into an amino, thioether or halogen group in a two-step procedure. First, the hydroxyl is converted into a good leaving group by treatment, for example, with a sulfonyl halide such as tosyl chloride in pyridine. The resulting tosylate can be easily converted into the corresponding azide by treatment with sodium azide, in a suitable solvent such as *N,N*-dimethylformamide-water mixtures, which can then be hydrogenated in the presence of a suitable catalyst such as Pd/C to give the corresponding amine. Likewise, said tosylate can be treated with a thiol in the presence of a base such as DBU, in a suitable solvent such as *N,N*-dimethylformamide to give the corresponding thioether. Moreover, the resulting tosylate can be treated for example with sodium iodide in acetone, lithium chloride in *N,N*-dimethylformamide or ethanol, or sodium bromide in *N,N*-dimethylformamide or dimethylsulfoxide, to give the corresponding halide.

The salts of the compounds of formula I can be prepared by conventional methods by treatment for example with an acid such as hydrochloric acid, sulfuric acid, nitric acid, oxalic acid or methanesulfonic acid, or by treatment with a base such as sodium hydroxide or potassium hydroxide.

As mentioned above, the compounds of the present invention act as antagonists of integrins α_4 , which are involved in numerous cell adhesion pathological processes. Therefore, the compounds of the present invention are useful for the treatment or prevention of diseases mediated by integrins α_4 . In a preferred embodiment, the compounds of the present invention are useful for the treatment or prevention of inflammatory, immune and/or autoimmune diseases selected from: diseases with an allergic component, such as for example asthma, allergic rhinitis, allergic dermatitis and allergic conjunctivitis; inflammatory diseases with an autoimmune component, such as for example rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, psoriasis, and diabetes; inflammatory bowel disease, including Crohn's disease and ulcerative colitis; inflammatory processes having an alloimmune origin caused by transplants or rejections;

inflammatory processes that develop as a consequence of blood vessel revascularization treatments, such as percutaneous transluminal coronary angioplasty; as well as other inflammatory diseases such as encephalomyelitis, hepatitis, bronchitis, vasculitis and atherosclerosis.

5 The compounds of the present invention can also be useful for the treatment of other disorders mediated by integrins α_4 . For example, the compounds of formula I can inhibit cell proliferation and might therefore be useful for the treatment or prevention of tumor metastasis. Other uses of the compounds of formula I include the treatment or prevention of degenerative diseases, such as
10 for example Alzheimer's disease and arthrosis, and the treatment or prevention of ischemia-reperfusion disorders, including among others acute coronary diseases and stroke.

According to the activity of the products herein described, the present invention also relates to compositions which contain a compound of the present
15 invention, together with an excipient or other auxiliary agents if necessary. The compounds of the present invention can be administered in the form of any pharmaceutical formulation, the nature of which, as it is well known, will depend upon the nature of the active compound and its route of administration. Any route of administration may be used, for example oral, parenteral, nasal, ocular, rectal
20 and topical administration.

According to the present invention, solid compositions for oral administration include tablets, granulates and capsules. In any case the manufacturing method is based on a simple mixture, dry granulation or wet granulation of the active compound with excipients. These excipients can be, for
25 example, diluents such as lactose, microcrystalline cellulose, mannitol or calcium hydrogenphosphate; binding agents such as for example starch, gelatin or polyvinylpyrrolidone; disintegrants such as sodium carboxymethyl starch or sodium croscarmellose; and lubricating agents such as for example magnesium stearate, stearic acid or talc. Tablets can be additionally coated with suitable
30 excipients by using known techniques with the purpose of delaying their disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period, or simply to improve their organoleptic properties or their stability. The active compound can also be incorporated by coating onto inert *pellets* using natural or synthetic film-coating agents. Soft

gelatin capsules are also possible, in which the active compound is mixed with water or an oily medium, for example coconut oil, liquid paraffin or olive oil.

Powders and granulates for the preparation of oral suspensions by the addition of water can be obtained by mixing the active compound with dispersing or wetting agents; suspending agents and preservatives. Other excipients can also be added, for example sweetening, flavouring and colouring agents.

Liquid forms for oral administration include emulsions, solutions, suspensions, syrups and elixirs containing commonly-used inert diluents, such as distilled water, ethanol, sorbitol, glycerol, polyethylene glycols and propylene glycol. Said compositions can also contain coadjuvants such as wetting, suspending, sweetening, flavouring, preserving agents and buffers.

Injectable preparations, according to the present invention, for parenteral administration, comprise sterile solutions, suspensions or emulsions, in an aqueous or non-aqueous solvent such as propylene glycol, polyethylene glycol or vegetable oils. These compositions can also contain coadjuvants, such as wetting, preserving, emulsifying and dispersing agents. They may be sterilized by any known method or prepared as sterile solid compositions which will be dissolved in water or any other sterile injectable medium immediately before use. It is also possible to start from sterile materials and keep them under these conditions throughout all the manufacturing process.

The compounds of the present invention can also be formulated as a solid form, dissolved or dispersed in a suitable vehicle, for inhalation in single or multidose container. Preparations to be administered as an aerosol (dispersion of solid or liquid particles in a gas) use suitable devices such as nebulisers, pressured metered-dose inhalers or dry-powder inhalers. Depending on this, the compound will be formulated with excipients such as propellants responsible for developing the proper pressure within the container to force the content out through the opening of the valve, solvents, emulsifying agents, viscosity-increasing agents, preservatives, stabilizing agents and lubricants to avoid the blockade of the valve.

For the rectal administration, the active compound can be preferably formulated as a suppository on an oily base, such as for example vegetable oils or solid semisynthetic glycerides, or on a hydrophilic base such as polyethylene glycols.

The compound can also be formulated for its topical application for the treatment of pathologies occurring in zones or organs accessible through this route, such as eyes, skin and the intestinal tract. Formulations include creams, lotions, gels, powders, solutions and patches wherein the compound is dispersed or dissolved in suitable excipients.

The activity of the compounds of the present invention can be determined using the following test:

Inhibition of $\alpha_4\beta_1$ -dependent cell adhesion

Inhibition of $\alpha_4\beta_1$ -dependent cell adhesion was assayed by evaluating the interaction between the peptide CS-1 (H-CLHGPEILDVPST-CONH₂) and Jurkat cells (T lymphocyte cell line expressing activated integrin $\alpha_4\beta_1$ but not integrin $\alpha_4\beta_7$) after preincubation of said cells with the compounds of formula I to be tested. The peptide CS-1 was synthesized by conventional solid phase chemistry and purified by HPLC. Its identity was determined by elemental analysis and mass spectroscopy.

1.- Preparation of CS-1-coated plates

96-black well plates (Costar 3925) were used. 200 μ L of 2% bovine serum albumin solution (BSA, Sigma A-4503) was added per well and the plate was incubated for 2 hours at 37 °C. The solution was discarded and the plate was washed twice with 200 μ L of phosphate buffered saline solution (PBS, Gibco 14190-094) per well. Then, 200 μ L of 10 μ g/mL N-succinimidyl 3-(2-pyridyldithio)propionate solution (SPDP, Sigma P-3415) was added per well, and the plate was incubated at 37 °C for 30 minutes. The remaining solution was discarded and the plate was twice washed with 200 μ L per well of PBS. Next, 200 μ L of 25 μ g/mL CS-1 peptide solution (equivalent to 5 μ g/well) was added per well and the plate was incubated at 37 °C for 2 hours and then overnight at 4 °C.

2.- Jurkat cell line: culture and fluorescent labelling

Jurkat cells were kept in culture at a density comprised between 2×10^5 and $1,5 \times 10^6$ cells/mL in 1640 RPMI medium (Gibco 21875-034) enriched with 10% fetal calf serum (FCS, Gibco 10270-106).

50×10^6 cells were extracted, centrifuged (1200 rpm, 10 min, room temperature) and the medium was discarded. Cells were resuspended in 5 mL of

RPMI, and 10 μ L of a 1 mM solution of the fluorophore calceine.AM (Molecular Probes, C-3100) was added. The suspension was incubated for 30 min at 37 °C in the darkness, with occasional shaking. 40 mL of RPMI was added to stop the labelling and the suspension was centrifuged (1200 rpm, 10 min, room temperature). The medium was discarded, and the labelled cells were washed with 40 mL of RPMI in order to remove the unincorporated fluorescent probe. Finally, cells were resuspended in RPMI enriched with 10% FCS to obtain a 8×10^6 cells/mL suspension.

3.- Adhesion experiment

The plate previously prepared was twice washed with 200 μ L per well of PBS and blocked with 200 μ L of 1% BSA for at least 1 hour at room temperature.

The products to be tested were dissolved in dimethylsulfoxide at a concentration of 10 mM and dilutions thereof were prepared in RPMI medium enriched with 10% FCS. The products were preincubated with the Jurkat cells at 37 °C for 30 minutes, at a product concentration comprised between 1 nM and 10 μ M, at a cell density of 4×10^6 cells/mL and at a maximal dimethylsulfoxide concentration of 0,1%.

100 μ L of the resulting cell-product suspension was added per well (cellular density 4×10^5 cells/well). The product was omitted in the control wells and cells or CS-1 were omitted in the blanks. The plate was incubated for 60 min at room temperature in the darkness, was twice washed with 200 μ L per well of RPMI and then 100 μ L of PBS was added. The plate was read with a fluorescence reader at an excitation wavelength of 485 nm and at an emission wavelength of 530 nm.

Maximal adhesion (100%) was determined as the average of the fluorescence intensities (FI) of the control wells, and the minimal adhesion as the average FI of the blanks. The adhesion inhibition percentage was determined using the following formula:

$$\text{Inhibition} = 100 - \frac{FI_{\text{product}} - FI_{\text{blank}}}{FI_{\text{control}} - FI_{\text{blank}}} \times 100$$

The results are expressed as the IC_{50} values (concentration producing 50% inhibition). IC_{50} values were calculated by testing at least 6 product concentrations

and by adjusting the inhibition percentages to a dose-response curve of variable slope.

The results obtained with representative compounds of the present invention, are shown in the following table.

5

Compound (example n°)	IC ₅₀ (nM)
54	22
55	58
56	23
58	166
59	13.3
60	11.6
61	2.3
62	188
63	198
64	193
65	45
66	3.5
67	33.0
70	17
71	37
72	15
73	57
74	48
75	101
76	67
77	247
79	7.6
80	0.5
81	33
82	89
83	65
84	6.0

85	12.0
86	18
87	14.1
88	83.9
89	7.7
91	64.6
93	26.7
94	14.1
95	4.9
96	74.8
97	122
98	17.7
99	13.1
102	305
105	120
116	9.8
117	135.4
119	49.8
123	4.6

The following examples illustrate, but do not limit, the scope of the present invention. The following abbreviations have been used in the examples:

EtOAc: ethyl acetate

5 DCC: dicyclohexylcarbodiimide

DEAD: diethyl azodicarboxylate

DIEA: diisopropylethylamine

DMF: dimethylformamide

EDC: *N*-[3-(dimethylamino)propyl]-*N'*-ethylcarbodiimide

10 HOBT: 1-hydroxybenzotriazole

HBTU: *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate

MeOH: methanol

NHS: *N*-hydroxysuccinimide

NMM: *N*-methylmorpholine

15 NMP: 1-methyl-2-pyrrolidinone

TEA: triethylamine

THF: tetrahydrofuran

REFERENCE EXAMPLE 1

5 4-Aminomethyl-1-*tert*-butoxycarbonylpiperidine

To a solution of 4-(aminomethyl)piperidine (100 g, 0.88 mol) in CHCl_3 (550 mL), cooled to 0 °C and under argon atmosphere, di-*tert*-butyl dicarbonate (98 g, 0.45 mol) dissolved in CHCl_3 (350 mL) was added. The resulting mixture was stirred at room temperature for 48 h. Next, it was washed with H_2O and the
10 aqueous phase was reextracted with CHCl_3 . The combined organic phases were dried over sodium sulfate and the solvents were removed to afford 84.5 g of the title compound (88% yield).

^1H NMR (80MHz, CDCl_3) δ (TMS): 4.11 (broad d, $J = 13.4$ Hz, 2 H), 2.69 (m, 4 H), 1.45 (s, 9 H), 1.8 - 0.8 (complex signal, 7 H).

15 REFERENCE EXAMPLE 2

(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl mesylate

a) 4-Piperidylmethanol

To a mixture of LiAlH_4 (8.82 g, 0.232 mol) and THF (125 mL), cooled to 0 °C, a solution of ethyl isonipecotatate (18 mL, 0.117 mol) in THF (325 mL) was
20 added dropwise and under argon atmosphere, and the mixture was stirred overnight at room temperature. A mixture of H_2O (12.03 mL) and THF (25 mL), followed by a mixture of 15% NaOH (10.03 mL) and H_2O (32.4 mL) was slowly added at 0 °C. The resulting mixture was filtered while washing with THF and the solvent was evaporated. The residue was partitioned between H_2O and CHCl_3 ,
25 the phases were separated, the aqueous phase was extracted with CHCl_3 and the combined organic extracts were dried over Na_2SO_4 and concentrated. 8.2 g of the desired product was obtained (61% yield).

b) (1-*tert*-Butoxycarbonylpiperidin-4-yl)methanol

To a solution of 4-piperidylmethanol (obtained in the preceding section)
30 (15.3 g, 133 mmol) in DMF (160 mL) cooled to 0 °C and under argon atmosphere, di-*tert*-butyl dicarbonate (29 g, 133 mmol) dissolved in DMF (80 mL) was added, and the solution was stirred overnight at room temperature. It was concentrated to dryness and the residue was dissolved in a mixture of THF (100 mL), MeOH (100

mL), and NaOH 1N (100 mL) and stirred at room temperature for 18 h. The organic phase was evaporated and the aqueous phase was extracted three times with CHCl₃. The combined organic phases were dried over sodium sulfate and concentrated to dryness. 23.0 g of the desired product was obtained (80% yield).

5 **c) Title compound**

To a solution of the product obtained in the preceding section (6.8 g, 31 mmol) and DIEA (5.75 mL, 33 mmol) in CH₂Cl₂ (50 mL), cooled to 0 °C and under argon atmosphere, mesyl chloride (2.4 mL, 31 mmol) was added dropwise. The reaction mixture was stirred overnight at room temperature. Then, it was treated
10 with H₂O, the phases were separated and the aqueous phase was reextracted with CH₂Cl₂. The combined organic phases were dried over sodium sulfate and concentrated, to afford the title compound in quantitative yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 4.12 (broad d, J = 11.8 Hz, 2 H), 4.04 (d, J = 6.5 Hz, 2 H), 2.98 (s, 3 H), 2.69 (broad t, J = 12.4 Hz, 2 H), 1.89 (m, 1 H), 1.72
15 (broad d, J = 12.9 Hz, 2 H), 1.43 (s, 9 H), 1.25 (m, 2 H).

REFERENCE EXAMPLE 3

(4-Piperidylmethyl)pyrrolidin-2-one hydrochloride

a) 1-*tert*-Butoxycarbonyl-4-(3-chloropropylcarbonylaminomethyl)piperidine

To a solution of 4-aminomethyl-1-*tert*-butoxycarbonylpiperidine (obtained in
20 reference example 1) (7 g, 33 mmol) and TEA (5.46 mL, 39 mmol) in CHCl₃ (250 mL), cooled to 0 °C, a solution of 4-chlorobutyryl chloride (3.66 mL, 33 mmol) in CHCl₃ (10 mL) was added dropwise and under argon atmosphere. The reaction mixture was stirred overnight at room temperature and concentrated. The residue was treated with 0.2 M NaHCO₃ and CHCl₃. The phases were separated, the
25 aqueous phase was reextracted with CHCl₃ and the combined organic phases were dried over sodium sulfate and concentrated. The desired compound was obtained in quantitative yield.

b) 1-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]pyrrolidin-2-one

To a solution of the compound obtained in the preceding section (10,5 g,
30 33 mmol) in DMF (160 mL), cooled to 0 °C and under argon atmosphere, potassium *tert*-butoxide (3.8 g, 34 mmol) was slowly added, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated to dryness and treated with phosphate buffer and CHCl₃. The phases were

separated, the aqueous phase was reextracted with CHCl_3 and the combined organic phases were dried over sodium sulfate and concentrated. A crude product was obtained, which was purified by chromatography on silica gel, using $\text{CH}_2\text{Cl}_2/\text{MeOH}$ mixtures of increasing polarity as eluent. 4.3 g of the desired compound was obtained (33% yield).

c) Title compound

The compound obtained in the preceding section (4.3 g, 11 mmol) and a 4 M dioxane/ $\text{HCl}_{(\text{g})}$ mixture (30 mL) were mixed in a flask under argon atmosphere. The mixture was stirred overnight at room temperature and concentrated to dryness by adding CH_2Cl_2 at the end of the evaporation process. 2.4 g of the title compound was obtained (quantitative yield).

^1H NMR (300 MHz, $\text{CD}_3\text{OD} + \text{CDCl}_3$) δ (TMS): 4.50 (s, 2 H), 3.40 (m, 2 H), 3.30 (m, 2 H), 3.17 (m, 2 H), 2.85 (m, 2 H), 2.42 (m, 2 H), 2.05 (m, 2 H), 1.85 (m, 1 H), 1.90 (m, 2 H), 1.49 (m, 2 H).

REFERENCE EXAMPLE 4

2-(4-Piperidylmethyl)isoindolin-1-one hydrochloride

a) 2-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]isoindolin-1-one

To a solution of 4-aminomethyl-1-*tert*-butoxycarbonylpiperidine (obtained in reference example 1) (6 g, 28 mmol) and 2-formylbenzoic acid (4.8 g, 32 mmol) in MeOH (53 mL) and H_2O (5.3 mL), sodium cyanoborohydride (2.64 g, 42 mmol) was slowly added, and the reaction mixture was stirred at reflux overnight. 10% NaOH (6.3 mL) was added and MeOH was evaporated. The mixture was extracted with EtOAc and the combined organic phases were dried over sodium sulfate and concentrated. The resulting crude product was purified by chromatography on silica gel, using EtOAc as eluent. 2.15 g of the desired compound was obtained (23% yield).

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using 2-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]isoindolin-1-one (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

^1H NMR (300 MHz, CD_3OD) δ (TMS): 7.76 (m, 1 H), 7.58 (m, 2 H), 7.49 (m, 1 H), 4.84 (s, 2 H), 4.55 (s, 2 H), 3.58 (d, $J = 7.2$ Hz, 2 H), 3.40 (d, $J = 12.7$ Hz, 2 H),

2.98 (broad t, J = 12.3 Hz, 2 H), 2.16 (m, 1 H), 1.92 (broad d, J = 14.2 Hz, 2 H), 1.48 (m, 2 H).

REFERENCE EXAMPLE 5

1-(4-Piperidylmethyl)-2,5-pyrrolidin-2,5-dione hydrochloride

5 a) 1-[(*tert*-Butoxycarbonylpiperidin-4-yl)methyl]pyrrolidin-2,5-dione

To a solution of 4-aminomethyl-1-*tert*-butoxycarbonylpiperidine (obtained in reference example 1) (5 g, 23 mmol) in CH₂Cl₂ (50 mL), succinic anhydride (4.7 g, 46 mmol) was slowly added under argon atmosphere, and the resulting mixture was stirred at room temperature for 3 h. Next, the reaction mixture was cooled to
10 0 °C, 1,1'-carbonyldiimidazole was slowly added and the mixture was stirred overnight at room temperature. The solvent was evaporated and the residue obtained was treated with H₂O and EtOAc. It was filtered, the phases were separated and the organic phase was washed with 40% NaHSO₄ solution, dried over sodium sulfate and concentrated, to afford 5.9 g of the desired compound
15 (87% yield).

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using 1-[(*tert*-butoxycarbonylpiperidin-4-yl)methyl]pyrrolidin-2,5-dione (obtained in the preceding section) as starting product, the title compound
20 of the example was obtained in 76% yield.

¹H NMR (300 MHz, CD₃OD + CDCl₃) δ (TMS): 3.88 (s, 2 H), 3.41 (d, J = 6.8 Hz, 2 H), 3.33 (broad d, J = 12.8 Hz, 2 H), 2.82 (m, 2 H), 2.71 (s, 4 H), 1.90 (m, 3 H), 1.51 (m, 2 H).

REFERENCE EXAMPLE 6

25 3-[(4-Piperidyl)methyl]oxazolidin-2-one hydrochloride

a) 1-*tert*-Butoxycarbonyl-4-(2-chloroethoxycarbonylaminomethyl)piperidine

Following a similar procedure to that described in section a of reference example 3, but using 2-chloroethyl chloroformate instead of 4-chlorobutyl chloride, the desired compound was obtained in 78% yield.

30 b) 3-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]oxazolidin-2-one

To a solution of 1-*tert*-butoxycarbonyl-4-(2-chloroethoxycarbonylamino-methyl)piperidine (obtained in the preceding section) (4 g, 12 mmol) in DMF (60 mL), 50% sodium hydride (0.6 g, 12 mmol) was slowly added under argon

atmosphere, and the reaction mixture was stirred overnight at 40 °C. Some drops of H₂O were added and the mixture was evaporated to dryness. The residue was partitioned between phosphate buffer (pH = 7.8) and CH₂Cl₂, the phases were separated, the aqueous phase was reextracted with CH₂Cl₂ and the combined
5 organic phases were dried over sodium sulfate and concentrated. The resulting crude product was purified by chromatography on silica gel, using hexane/EtOAc mixtures of increasing polarity as eluent. 2.1 g of the desired compound was obtained (59% yield).

c) Title compound

10 Following a similar procedure to that described in section c of reference example 3, but using 3-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]oxazolidin-2-one (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 4.34 (m, 2 H), 4.77 (s, 2 H), 3.92 (m, 2 H),
15 3.44 (m, 2 H), 3.17 (m, 1 H), 3.02 (m, 3 H), 2.04 (m, 2 H), 1.50 (m, 2 H).

REFERENCE EXAMPLE 7

2-Phenyl-1-[(4-piperidyl)methyl]imidazole

a) 1-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]-2-phenylimidazole

Following a similar procedure to that described in section b of reference
20 example 6, but using THF as solvent and (1-*tert*-butoxycarbonylpiperidin-4-yl)methyl mesylate (obtained in reference example 2) and 2-phenylimidazole as reagents instead of 1-*tert*-butoxycarbonyl-4-(2-chloroethoxycarbonylaminomethyl)piperidine, and carrying out the reaction at reflux, the desired compound was obtained in 61% yield.

b) Title compound

25 The compound obtained in the preceding section (1.1 g, 3 mmol) and a 4 M dioxane/HCl_(g) mixture (10 mL) were mixed in a flask under argon atmosphere. The mixture was stirred overnight at room temperature and concentrated to dryness. The residue obtained was partitioned between 1 N NaOH solution and
30 CHCl₃. The phases were separated and the organic phase was dried over sodium sulfate and concentrated to dryness, to afford 0.62 g of the title compound of the example (87% yield).

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.40-7.90 (complex signal, 5 H), 7.10 (d, J = 1 Hz, 1 H), 6.96 (d, J = 1 Hz, 1 H), 3.87 (d, J = 7.4 Hz, 2 H), 3.57 (m, 1 H), 3.01 (m, 2 H), 2.51 (m, 2 H), 1.74 (m, 1 H), 1.46 (m, 2 H), 1.11 (m, 2 H).

REFERENCE EXAMPLE 8

5 **2-Methyl-1-(4-piperidylmethyl)imidazo[4,5-c]pyridine**

a) 4-[[[(1-*tert*-Butoxycarbonyl)piperidin-4-yl)methyl]amino]-3-nitropyridine

Following a similar procedure to that described in section a of reference example 3, but using 4-chloro-3-nitropyridine instead of 4-chlorobutyryl chloride, the desired compound was obtained in 48% yield.

10 **b) 3-Amino-4-[[[(1-*tert*-butoxycarbonyl)piperidin-4-yl)methyl]amino]pyridine**

A solution of the product obtained in the preceding section (26.2 g, 77 mmol) in MeOH (500 mL) was hydrogenated under atmospheric pressure in the presence of 10% Pd/C (3.83 g) for 18 h. The catalyst was filtered off and the solvent removed, to afford 22.9 g of a crude product that was directly used in the

15 following step.

c) 1-[[[(1-*tert*-Butoxycarbonyl)piperidin-4-yl)methyl]-2-methylimidazo[4,5-c]pyridine

To a solution of 3-amino-4-[[[(1-*tert*-butoxycarbonyl)piperidin-4-yl)methyl]amino]pyridine (obtained in the preceding section) (22.9 g, 70 mmol) in

20 EtOH (350 mL), ethyl acetimidate hydrochloride (9.2 g, 74 mmol) was added under argon atmosphere, and the mixture was heated at reflux for 4 h. Next, a second equivalent of ethyl acetimidate hydrochloride (9.2 g, 74 mmol) was added and the mixture was further heated at reflux for 18 h and a third equivalent of ethyl acetimidate hydrochloride (9.2 g, 74 mmol) was added and the mixture was

25 further heated for 4 h. The resulting solution was concentrated *in vacuo* and was partitioned between CHCl₃ and 0.5 N NaOH solution. The organic phase was dried over sodium sulfate and the solvents were removed to afford 30 g of a crude product, which was purified by chromatography on silica gel (CHCl₃:MeOH 10%), to yield 23.4 g of a yellow solid (95% yield):

30 **d) Title compound**

Following a similar procedure to that described in section b of reference example 7, but using 1-[[[(1-*tert*-butoxycarbonyl)piperidin-4-yl)methyl]-2-

methylimidazo[4,5-*c*]pyridine (obtained in the preceding section) as starting product, 15.8 g of the title compound of the example was obtained (98% yield).

¹H NMR (80MHz, CDCl₃) δ (TMS): 8.96 (s, 1 H), 8.35 (d, J = 5.5 Hz, 1 H), 7.20 (d, J = 5.5 Hz, 1 H), 3.95 (d, J = 7.3 Hz, 2 H), 3.06 (broad d, J = 12.0 Hz, 2 H), 2.61 (s, 3 H), 2.51 (broad t, J = 12.7 Hz, 2 H), 2.2 - 1.0 (complex signal, 6 H).

REFERENCE EXAMPLE 9

2-Ethyl-5,7-dimethyl-3-(4-piperidylmethyl)imidazo[4,5-*b*]pyridine dihydrochloride

a) 3-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]-2-ethyl-5,7-dimethylimidazo[4,5-*b*]pyridine

Following a similar procedure to that described in section b of reference example 6, but using (1-*tert*-butoxycarbonylpiperidin-4-yl)methyl mesylate (obtained in reference example 2) and 2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine (obtained as described in EP 400974) as reagents, instead of 1-*tert*-butoxycarbonyl-4-(2-chloroethoxycarbonylaminomethyl)piperidine, and carrying out the reaction at room temperature the desired compound was obtained in 61% yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using 3-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]-2-ethyl-5,7-dimethylimidazo[4,5-*b*]pyridine (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.36 (s, 1 H), 4.47 (d, J = 7.4 Hz, 2 H), 4.78 (s, 3 H), 3.67 (m, 2 H), 3.36 (m, 2 H), 2.98 (m, 2 H), 2.66 (s, 3 H), 2.65 (s, 3 H), 2.44 (m, 1 H), 1.92 (m, 2 H), 1.71 (m, 2 H), 1.56 (t, J = 7.5 Hz, 3 H).

REFERENCE EXAMPLE 10

1-(2-Ethoxyethyl)-2-[(1-piperazinyl)methyl]benzimidazole

a) 2-[(4-Formylpiperazin-1-yl)methyl]benzimidazole

To a solution of 1-formylpiperazine (23.1 mL, 0.225 mol) in ethanol (70 mL), heated at 60 °C under argon atmosphere, a solution of 2-chloromethylbenzimidazole (15 g, 0.090 mol) in ethanol (100 mL) and DMF (25 mL) was added. The mixture was stirred at 60 °C for 2 h, the solvent was evaporated and the resulting residue was treated with 4 N NaOH solution (40 mL).

It was extracted with CHCl_3 , the combined organic phases were dried over sodium sulfate and concentrated to dryness, to give 30 g of a crude product, which was directly used in the following step.

b) 1-(2-Ethoxyethyl)-2-[(4-formylpiperazin-1-yl)methyl]benzimidazole

Following a similar procedure to that described in section b of reference example 6, but using the crude product obtained in the preceding section and 2-bromoethyl ethyl ether as reagents, instead of 1-*tert*-butoxycarbonyl-4-(2-chloroethoxycarbonylaminomethyl)piperidine, and carrying out the reaction at 60 °C, the desired compound was obtained in 32% yield.

c) Title compound

A solution of 1-(2-ethoxyethyl)-2-[(4-formylpiperazin-1-yl)methyl]benzimidazole (obtained in the preceding section) (2 g, 6 mmol) in MeOH (30 mL) and 10% HCl (17 mL) was heated at reflux for 1 hour. MeOH was evaporated and the residue was treated with 1 N NaOH solution and was extracted with CHCl_3 . The organic phase was dried over sodium sulfate and concentrated to dryness to afford a crude product which was purified by chromatography on silica gel using $\text{CHCl}_3/\text{MeOH}/\text{NH}_3$ mixtures of increasing polarity as eluent. 0.94 g of the title compound of the example was obtained (50% yield).

^1H NMR (300 MHz, CDCl_3) δ (TMS): 7.70 (m, 1 H), 7.37 (m, 1 H), 7.25 (m, 2 H), 4.52 (m, 2 H), 3.84 (s, 2 H), 3.74 (m, 2 H), 3.40 (q, $J = 7$ Hz, 2 H), 2.85 (m, 4 H), 2.48 (m, 4 H), 1.69 (broad s, 1 H), 1.12 (t, $J = 7$ Hz, 3 H).

REFERENCE EXAMPLE 11

1-(2-Pyridylmethyl)piperazine

a) 2-Chloromethylpyridine hydrochloride

To a solution of 2-pyridylmethanol (141.88 mL, 1.47 mol) in anhydrous CH_2Cl_2 (800 mL) cooled to 0 °C and under argon atmosphere, SOCl_2 (104.4 mL, 1.43 mol) was added dropwise. The reaction mixture was heated at reflux for 2 hours, allowed to cool to room temperature and was concentrated to dryness. The crude product obtained was directly used in the following step.

b) Title compound

To a solution of piperazine (124 g, 1.44 mol) in H_2O (500 mL) cooled to 0 °C, was added first 37% HCl (129 mL, 1.57 mol) and then a solution of 2-

chloromethylpyridine hydrochloride (obtained in the preceding section) (0.735 mols) in H₂O (400 mL) dropwise. The resulting mixture was stirred at room temperature for 48 hours and was extracted with EtOAc. The resulting aqueous phase was extracted several times with the same solvent at different pH: progressively basifying by addition of solid NaOH, it was firstly extracted at pH 7, then at a slightly basic pH and finally at basic pH. The organic phase resulting from this last extraction was dried over sodium sulfate and concentrated to dryness to afford 204 g of the title compound of the example (80% yield).

¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.47 (m, 1 H), 7.80 (m, 1 H), 7.53 (m, 1 H), 7.32 (m, 1 H), 4.85 (broad s, 1 H), 3.67 (s, 2 H), 3.00 (m, 4 H), 2.58 (m, 4 H).

REFERENCE EXAMPLE 12

1-(2-Thienylmethyl)piperazine

A suspension of 2-thienylmethanamine (5.0 g, 44 mmol), bis-(2-chloroethyl)amine hydrochloride (7.8 g, 44 mmol) and K₂CO₃ (3.1 g, 22 mmol) in 1-butanol (30 mL) was heated at reflux overnight and under argon atmosphere. A second equivalent of K₂CO₃ (3.1 g, 22 mmol) was added and the suspension was further heated at reflux overnight. The resulting mixture was concentrated to dryness and the residue was partitioned between CHCl₃ and 0.5 N NaOH solution. The phases were separated, the organic phase was dried over sodium sulfate and the solvent was evaporated. The resulting crude product was purified by chromatography on silica gel using CHCl₃/MeOH/NH₃ mixtures of increasing polarity as eluent. 0.28 g of the title compound of the example was obtained (3% yield).

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.28 (m, 1 H), 6.96 (m, 2 H), 4.83 (s, 1 H), 3.73 (s, 2 H), 2.83 (m, 4 H), 2.41 (m, 4 H).

REFERENCE EXAMPLE 13

1-(2-Aminoethyl)-4-*tert*-butoxycarbonylpiperazine

a) 1-(2-Benzylidenaminoethyl)piperazine

A mixture of 1-(2-aminoethyl)piperazine (10.2 mL, 78.9 mmol), benzaldehyde (8.1 mL, 78.9 mmol) and toluene (100 mL) under argon atmosphere was heated at reflux in a Dean-Stark overnight. The resulting mixture was allowed to cool to room temperature and was directly used in the following step.

b) Title compound

To the mixture obtained in the preceding section, cooled to 0 °C, di-*tert*-butyl dicarbonate (17.2 g, 78.9 mmol) was slowly added, and the resulting mixture was stirred overnight at room temperature. It was concentrated to dryness and the residue was treated with 1 N KHSO₄ solution. It was washed three times with EtOAc and basified while cooling with 2 N NaOH solution. CHCl₃ was added, the phases were separated, and the combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated to dryness. The title compound was obtained in 77% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 3.43 (m, 4 H), 2.78 (m, 2 H), 2.39 (m, 6 H), 1.56 (broad s, 2 H), 1.44 (s, 9 H).

REFERENCE EXAMPLE 14**4-[(3-Methylbutanoylamino)methyl]piperidine hydrochloride****a) 1-*tert*-Butoxycarbonyl-4-[(3-methylbutanoylamino)methyl]piperidine**

Following a similar procedure to that described in section a of reference example 3, but using isopentanoyl chloride instead of 4-chlorobutanoyl chloride, the desired compound was obtained in 46% yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using 1-*tert*-butoxycarbonyl-4-[(isobutylcarbonylamino)methyl]piperidine (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 4.88 (s, 3 H), 3.33 (m, 2 H), 3.14 (d, J = 5.9 Hz, 2 H), 2.96 (broad t, J = 12.2 Hz, 2 H), 2.08 (m, 2 H), 2.05 (m, 1 H), 1.90 (m, 3 H), 1.40 (m, 2 H), 0.94 (d, J = 6.1 Hz, 6 H).

REFERENCE EXAMPLE 15***N-tert*-Butyl-*N'*-(4-piperidylmethyl)urea hydrochloride****a) *N-tert*-Butyl-*N'*-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]urea**

To a solution of 4-aminomethyl-1-*tert*-butoxycarbonylpiperidine (obtained in reference example 1) (5 g, 23 mmol) in DMF (20 mL), *tert*-butyl isocyanate (2.63 mL, 23 mmol) was added dropwise and under argon atmosphere. The reaction

mixture was stirred overnight at room temperature and was concentrated to dryness to afford the desired compound in quantitative yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using *N*-*tert*-butyl-*N'*-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]urea (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 4.92 (s, 4 H), 3.37 (m, 2 H), 2.97 (m, 4 H), 1.95 (m, 2 H), 1.80 (m, 1 H), 1.43 (m, 2 H), 1.31 (s, 9 H).

REFERENCE EXAMPLE 16

Isobutyl (4-piperidylmethyl)carbamate hydrochloride

a) Isobutyl [(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]carbamate

Following a similar procedure to that described in section a of reference example 3, but using isobutyl chloroformate instead of 4-chlorobutyryl chloride, the desired compound was obtained in 69% yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using isobutyl [(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]carbamate (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 9.67 (broad s, 1 H), 9.65 (broad s, 1 H), 4.84 (m, 1 H), 3.84 (m, 2 H), 3.51 (broad d, J = 12.1 Hz, 2 H), 3.27 (m, 1 H), 3.10 (m, 2 H), 2.83 (m, 2 H), 1.97 (m, 2 H), 1.84 (m, 1 H), 1.62 (m, 2 H), 0.91 (d, J = 6.8 Hz, 6 H).

REFERENCE EXAMPLE 17

***N*-(4-Piperidylmethyl)isopropanesulfonamide hydrochloride**

a) *N*-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]isopropanesulfonamide

Following a similar procedure to that described in section a of reference example 3, but using isopropylsulfonyl chloride instead of 4-chlorobutyryl chloride, the desired compound was obtained in 9% yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using *N*-[(1-*tert*-butoxycarbonylpiperidin-4-

yl)methyl]isopropanesulfonamide (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 5.04 (s, 3 H), 3.52 (m, 2 H), 3.17 (m, 5 H), 2.18 (m, 2 H), 2.01 (m, 1 H), 1.60 (m, 2 H), 1.49 (d, J = 7.7 Hz, 6 H).

REFERENCE EXAMPLE 18

N-Isopropyl-*N'*-(4-piperidylmethyl)thiourea hydrochloride

a) *N*-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]-*N'*-isopropylthiourea

To a solution of 4-aminomethyl-1-*tert*-butoxycarbonylpiperidine (obtained in reference example 1) (3 g, 14 mmol) in THF (20 mL), cooled to 0 °C and under argon atmosphere, isopropyl isothiocyanate (1.5 mL, 14 mmol) was added dropwise. The reaction mixture was stirred overnight at room temperature and was treated with 0.2 M NaHCO₃. The phases were separated, the aqueous phase was reextracted with CHCl₃ and the combined organic phases were dried over sodium sulfate and concentrated. The desired compound was obtained in 48% yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using *N*-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]-*N'*-isopropylthiourea (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 4.84 (s, 4 H), 4.30 (m, 1 H), 3.45 (m, 4 H), 2.96 (broad t, J = 12.7 Hz, 2 H), 1.95 (m, 3 H), 1.43 (m, 2 H), 1.17 (d, J = 6.5 Hz, 6 H).

REFERENCE EXAMPLE 19

4-(1-Pyrrolylmethyl)piperidine

a) 1-*tert*-Butoxycarbonyl-4-(1-pyrrolylmethyl)piperidine

To a solution of 4-aminomethyl-1-*tert*-butoxycarbonylpiperidine (obtained in reference example 1) (5 g, 23.3 mol) in acetic acid (123.7 mL), 2,5-dimethoxytetrahydrofuran (3.0 mL, 23.3 mol) was slowly added under argon atmosphere. The reaction mixture was heated at reflux for 1 h, concentrated to dryness and the resulting crude product was purified by chromatography on silica gel using EtOAc/hexane mixtures of increasing polarity as eluent. The desired compound was obtained in 37% yield.

b) Title compound

Following a similar procedure to that described in section b of reference example 7, but using 1-*tert*-butoxycarbonyl-4-(1-pyrrolylmethyl)piperidine (obtained in the preceding section) as starting product and purifying the crude product obtained by chromatography on silica gel using CHCl₃/MeOH mixtures of increasing polarity as eluent, the title compound of the example was obtained in 14% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 6.62 (m, 2 H), 6.13 (m, 2 H), 3.72 (d, J = 7.2 Hz, 2 H), 3.05 (m, 2 H), 2.55 (m, 2 H), 1.79 (m, 1 H), 1.60 (m, 3 H), 1.20 (m, 2 H).

REFERENCE EXAMPLE 20**4-[(2,5-Dimethylpyrrol-1-yl)methyl]piperidine hydrochloride****a) 1-*tert*-Butoxycarbonyl-4-[(2,5-dimethylpyrrol-1-yl)methyl]piperidine**

Following a similar procedure to that described in section a of reference example 19, but using acetonylacetone instead of 2,5-dimethoxytetrahydrofuran, the desired compound was obtained in 34% yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using 1-*tert*-butoxycarbonyl-4-[(2,5-dimethylpyrrol-1-yl)methyl]piperidine (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 5.58 (d, J = 3.5 Hz, 2 H), 4.85 (s, 2 H), 3.72 (d, J = 7.5 Hz, 2 H), 3.39 (m, 2 H), 2.93 (m, 2 H), 2.19 (s, 6 H), 2.03 (m, 1 H), 1.81 (m, 2 H), 1.20 (m, 2 H).

REFERENCE EXAMPLE 21**4-(Dimethylaminomethyl)piperidine dihydrochloride****a) 1-*tert*-Butoxycarbonyl-4-(dimethylaminomethyl)piperidine**

To a solution of 4-aminomethyl-1-*tert*-butoxycarbonylpiperidine (obtained in reference example 1) (5 g, 23.3 mmol) in acetonitrile, 37% aqueous formaldehyde (17.5 mL, 233.3 mmol) and sodium cyanoborohydride (4.4 g, 70.0 mmol) were added, and the reaction mixture was stirred at room temperature for 15 min. It was brought to pH 7 by the addition of glacial acetic acid (2.3 mL) and was stirred for 45 min. It was concentrated to dryness and the residue was treated with 2 N NaOH and was extracted with CHCl₃. The combined organic extracts were dried

over anhydrous Na₂SO₄ and concentrated, to afford a crude product which was purified by chromatography on silica gel using CHCl₃/MeOH mixtures of increasing polarity as eluent. 851 mg of the desired product was obtained (9% yield).

5 **b) Title compound**

Following a similar procedure to that described in section c of reference example 3, but using 1-*tert*-butoxycarbonyl-4-(dimethylaminomethyl)piperidine (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

10 ¹H NMR (300 MHz, CD₃OD+CDCl₃) δ (TMS): 4.17 (s, 3 H), 3.36 (m, 2 H), 2.98 (m, 4 H), 2.83 (s, 6 H), 2.17 (m, 1 H), 2.02 (m, 2 H), 1.63 (m, 2 H).

REFERENCE EXAMPLE 22

1-[2-(Dimethylamino)ethyl]piperazine hydrochloride

a) 4-*tert*-Butoxycarbonyl-1-[2-(dimethylamino)ethyl]piperazine

15 Following a similar procedure to that described in section a of reference example 21 but starting from 1-(2-aminoethyl)-4-*tert*-butoxycarbonylpiperazine (obtained in reference example 13) instead of 4-aminomethyl-1-*tert*-butoxycarbonylpiperidine, the desired compound was obtained in 45% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 3.42 (m, 4 H), 2.45 (m, 8 H), 2.24 (s, 6 H),
20 1.44 (s, 9 H).

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using 4-*tert*-butoxycarbonyl-1-[2-(dimethylamino)ethyl]piperazine (obtained in the preceding section) as starting product, the title compound of the
25 example was obtained in quantitative yield.

REFERENCE EXAMPLE 23

2-Ethyl-1-(4-piperidylmethyl)imidazo[4,5-*c*]pyridine dihydrochloride

a) 1-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]-2-ethylimidazo[4,5-*c*]pyridine

30 To a solution of 3-amino-4-[[1-(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]amino]pyridine (obtained in section b of reference example 8) (2 g, 5.94 mmol) in DMF (16 mL), catalytic *para*-toluenesulfonic acid was first added, and then triethyl orthopropionate (7.3 g, 41.5 mmol) was added dropwise. The reaction

mixture was heated at 120 °C for 1 h, DMF was evaporated and the residue was partitioned between CHCl₃ and 0.1 M NaOH. The combined organic phases were washed with H₂O, dried over Na₂SO₄ and concentrated to dryness. The crude product obtained was purified by chromatography on silica gel using CHCl₃/MeOH (9:1) as eluent, to afford the desired compound in 7% yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using 1-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]-2-ethylimidazo[4,5-*c*]pyridine (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD+ CDCl₃) δ (TMS): 9.00 (s, 1 H), 8.47 (m, 2 H), 4.40 (s, 3 H), 4.36 (m, 2 H), 3.37 (m, 2 H), 3.07 (q, J = 7.4 Hz, 2H), 2.90 (m, 2 H), 2.26 (m, 1 H), 1.91 (m, 2 H), 1.66 (m, 2 H), 1.51 (t, J = 7.4 Hz, 3 H).

REFERENCE EXAMPLE 24

3*H*-1-(4-Piperidylmethyl)imidazo[4,5-*c*]pyridin-2-one dihydrochloride

a) 3*H*-1-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]imidazo[4,5-*c*]pyridin-2-one

Following a similar procedure to that described in section a of reference example 5, but using only 3-amino-4-[[[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]amino]pyridine (obtained in section b of reference example 8) and 1,1'-carbonyldiimidazole as reagents, the desired compound was obtained in 6% yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using 3*H*-1-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]imidazo[4,5-*c*]pyridin-2-one (obtained in the preceding section) as starting product, the title compound of the example was obtained in 68% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.46 (m, 2 H), 7.83 (m, 1 H), 4.82 (s, 4 H), 3.99 (d, J = 7.2 Hz, 2 H), 3.41 (broad d, J = 12.9 Hz, 2 H), 2.97 (m, 2 H), 2.26 (m, 1 H), 1.95 (m, 2 H), 1.60 (m, 2 H).

REFERENCE EXAMPLE 25

4-[2-(1-Pyrrolidinylcarbonyloxy)ethyl]piperidine hydrochloride

a) 2-(1-*tert*-Butoxycarbonylpiperidin-4-yl)ethanol

Following a similar procedure to that described in section b of reference example 2, but starting from 2-(4-piperidyl)ethanol instead of 4-piperidylmethanol, the desired compound was obtained in 88% yield.

b) 1-*tert*-Butoxycarbonyl-4-[2-(phenoxycarbonyloxy)ethyl]piperidine

5 Following a similar procedure to that described in section a of reference example 3, but using the compound obtained in the preceding section instead of 4-aminomethyl-1-*tert*-butoxycarbonylpiperidine and using phenyl chloroformate instead of 4-chlorobutyryl chloride, the desired compound was obtained in 93% yield.

10 **c) 1-*tert*-Butoxycarbonyl-4-[2-(1-pyrrolidinylcarbonyloxy)ethyl]piperidine**

To a solution of the compound obtained in the preceding section (1.5 g, 4.29 mmol) in pyridine (10 mL), pyrrolidine (0.36 mL, 4.29 mmol) was added under argon atmosphere, and the resulting mixture was heated at 80 °C overnight. It was concentrated to dryness and the residue obtained was partitioned between
15 H₂O and CHCl₃. The phases were separated and the combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated. A crude product was obtained, which was purified by chromatography on silica gel using EtOAc/hexane (1:1) as eluent. 0.49 g of the desired compound was obtained (35% yield).

d) Title compound

20 Following a similar procedure to that described in section c of reference example 3, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 9.62 (broad s, 1 H), 9.30 (broad s, 1 H), 4.13 (t, J = 5.2 Hz, 2 H), 3.47 (m, 2 H), 3.36 (m, 4 H), 2.87 (m, 2 H), 1.93 (m, 5 H), 1.60
25 (m, 6 H).

REFERENCE EXAMPLE 26

2-[(4-Piperidylmethyl)amino]-4-(trifluoromethyl)pyrimidine dihydrochloride

a) 2-[[1-(*tert*-Butoxycarbonylpiperidin-4-yl)methyl]amino]-4-(trifluoromethyl)-pyrimidine

30 Following a similar procedure to that described in section a of reference example 3, but using 2-chloro-4-(trifluoromethyl)pyrimidine instead of 4-chlorobutyryl chloride and using acetonitrile as solvent, the desired compound was obtained in 82% yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using 2-[[*(1-tert*-butoxycarbonylpiperidin-4-yl)methyl]amino]-4-(trifluoromethyl)pyrimidine (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.51 (d, J = 4.9 Hz, 1 H), 6.92 (d, J = 8.9 Hz, 1 H), 4.83 (s, 4 H), 3.65 (m, 1 H), 3.56 (m, 1 H), 3.39 (m, 2 H), 2.97 (m, 2 H), 2.01 (m, 3 H), 1.48 (m, 2 H).

REFERENCE EXAMPLE 27**1-Methyl-4-[(4-piperidyl)methyl]piperazine trihydrochloride****a) 4-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]-1-methylpiperazine**

To a solution of (1-*tert*-butoxycarbonylpiperidin-4-yl)methyl mesylate (obtained in reference example 2, 1.0 g, 3.48 mmol) in NMP, 1-methylpiperazine (0.75 mL, 6.8 mmol) was added under argon atmosphere, and the resulting mixture was heated at 85 °C for 48 h. It was concentrated to dryness and the residue obtained was partitioned between 0.2 M NaHCO₃ and CHCl₃. The phases were separated and the organic phase was dried over anhydrous Na₂SO₄ and concentrated. The crude product obtained was purified by chromatography on silica gel using CHCl₃/MeOH 2% as eluent. 0.61 g of the desired compound was obtained (62% yield).

b) Compound titular

Following a similar procedure to that described in section c of reference example 3, but using 4-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]-1-methylpiperazine (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 4.84 (s, 4 H), 3.66 (m, 2 H), 3.42 (m, 2 H), 3.31 (m, 8 H), 3.03 (m, 2 H), 2.99 (s, 3 H), 2.15 (m, 3 H), 1.51 (m, 2 H).

REFERENCE EXAMPLE 28**2-Ethyl-5,7-dimethyl-3-[2-(4-piperidyl)ethyl]imidazo[4,5-*b*]pyridine dihydrochloride****a) 2-(1-*tert*-Butoxycarbonylpiperidin-4-yl)ethyl mesylate**

Following a similar procedure to that described in section c of reference example 2, but starting from 2-(1-*tert*-butoxycarbonylpiperidin-4-yl)ethanol

(obtained in section a of reference example 25) and using TEA instead of DIEA and CHCl_3 instead of CH_2Cl_2 , the desired compound was obtained in quantitative yield.

b) 3-[2-(1-*tert*-Butoxycarbonylpiperidin-4-yl)ethyl]-2-ethyl-5,7-dimethylimidazo[4,5-*b*]pyridine

Following a similar procedure to that described in section b of reference example 6, but using 2-(1-*tert*-butoxycarbonylpiperidin-4-yl)ethyl mesylate (obtained in the preceding section) and 3*H*-2-ethyl-5,7-dimethylimidazo[4,5-*b*]pyridine (obtained as described in EP 400974) as reagents, instead of 1-*tert*-butoxycarbonyl-4-(2-chloroethoxycarbonylaminomethyl)piperidine, and carrying out the reaction at room temperature, the desired compound was obtained in 37% yield.

c) Title compound

Following a similar procedure to that described in section c of reference example 3, but using 3-[2-(1-*tert*-butoxycarbonylpiperidin-4-yl)ethyl]-2-ethyl-5,7-dimethylimidazo[4,5-*b*]pyridine (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

^1H NMR (300 MHz, CD_3OD) δ (TMS): 7.56 (s, 1 H), 5.06 (s, 3 H), 4.75 (m, 2 H), 3.62 (m, 2 H), 3.30 (m, 2 H), 3.18 (m, 2 H), 2.85 (s, 6 H), 2.36 (m, 2 H), 2.12 (m, 2 H), 2.01 (m, 1 H), 1.77 (m, 5 H).

REFERENCE EXAMPLE 29

***N*-[2-(4-Piperidyl)ethyl]morpholine dihydrochloride**

a) *N*-[2-(1-*tert*-Butoxycarbonylpiperidin-4-yl)ethyl]morpholine

To a mixture of morpholine (0.56 mL, 6.5 mmol), Na_2CO_3 (0.68 g, 6.5 mmol), KI (36 mg) and 2-butanone (50 mL), 2-(1-*tert*-butoxycarbonylpiperidin-4-yl)ethyl mesylate (obtained in section a of reference example 28) (1 g, 3.25 mmol) was slowly added under argon atmosphere, and the resulting mixture was stirred at reflux overnight. It was filtered and concentrated, to afford a residue which was partitioned between 0.2 M NaHCO_3 and CHCl_3 . The organic phase was dried over anhydrous Na_2SO_4 and concentrated. The crude product obtained was purified by chromatography on silica gel using $\text{CHCl}_3/\text{MeOH}$ 2% as eluent. 0.65 g of the desired compound was obtained (67% yield).

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using *N*-[2-(1-*tert*-butoxycarbonylpiperidin-4-yl)ethyl]morpholine (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

- 5 ¹H NMR (300 MHz, CD₃OD) δ (TMS): 4.83 (s, 3 H), 4.03 (m, 2 H), 3.85 (m, 2 H), 3.50 (m, 2 H), 3.39 (m, 2 H), 3.25 (m, 4 H), 2.99 (m, 2 H), 1.98 (broad d, J = 14.3 Hz, 2 H), 1.80 (m, 3 H), 1.49 (m, 2 H).

REFERENCE EXAMPLE 30

2-Dimethylamino-*N*-(4-piperidylmethyl)acetamide dihydrochloride

10 a) *N*-[(Dimethylamino)acetoxy]succinimide

To a solution of *N,N*-dimethylglycine hydrochloride (1.95 g, 14 mmol), TEA (3.2 mL, 23 mmol) and NHS (1.61 g, 14 mmol) in CHCl₃ (125 mL), cooled to 0 °C and under argon atmosphere, DCC (2.9 g, 14 mmol) was added, and the resulting mixture was stirred overnight at room temperature. The formed solid was filtered
15 off and the solution was concentrated to dryness. A crude product was obtained which was directly used in the following step.

b) *N*-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]-2-dimethylaminoacetamide

Following a similar procedure to that described in section a of reference
20 example 3 but using the crude product obtained in the preceding section instead of 4-chlorobutyl chloride, a crude product was obtained, which was purified by chromatography on silica gel using CHCl₃/MeOH (98:2) as eluent. 2.5 g of the desired compound was obtained.

c) Title compound

25 Following a similar procedure to that described in section c of reference example 3, but using *N*-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]-2-dimethylaminoacetamide (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

- 30 ¹H NMR (300 MHz, CD₃OD) δ (TMS): 4.85 (s, 4 H), 4.00 (s, 2 H), 3.41 (broad d, J = 12.8 Hz, 2 H), 3.22 (d, J = 6.5 Hz, 2 H), 2.97 (m, 2 H), 2.94 (s, 6 H), 1.98 (m, 3 H), 1.47 (m, 2 H).

REFERENCE EXAMPLE 31

**2-Isopropylamino-1-(4-piperidylmethyl)imidazo[4,5-c]pyridine
trihydrochloride**

a) 1-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]-2-isopropylaminoimidazo[4,5-c]pyridine

5 A mixture of 3-amino-4-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]amino]pyridine (obtained in section b of reference example 8) (5 g, 14.8 mmol) and isopropyl isothiocyanate (1.8 mL, 16.8 mmol) in pyridine (76 mL) was stirred under argon atmosphere at 80 °C for 30 min. EDC·HCl (3.7 g, 19.3 mmol) was added and the resulting mixture was stirred at 90 °C for 2.5 h. It was cooled
10 to room temperature, the solvent was evaporated and the residue was redissolved in EtOAc and H₂O. The phases were separated, the aqueous phase was washed with EtOAc, basified and extracted with EtOAc. The extracted organic phase was dried over sodium sulfate and concentrated to dryness, to afford a crude product which was purified by chromatography on silica gel, using CHCl₃/MeOH mixtures
15 of increasing polarity as eluent. 0.33 g of the desired product was obtained (6% yield).

¹H NMR (300 MHz, CDCl₃) δ (TMS): 8.73 (s, 1 H), 8.24 (d, J = 5.3 Hz, 1 H), 6.98 (d, J = 5.3 Hz, 1 H), 4.30 (m, 3 H), 3.72 (d, J = 7.3 Hz, 2 H), 3.05 (m, 1 H), 2.60 (m, 2 H), 1.95 (m, 1 H), 1.61 (m, 2 H), 1.45 (s, 9 H), 1.22 (m, 2 H), 1.11 (m, 6 H).

20 **b) Title compound**

Following a similar procedure to that described in section c of reference example 3, but using 1-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]-2-isopropylaminoimidazo[4,5-c]pyridine (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative
25 yield.

REFERENCE EXAMPLE 32

4-(Diethylaminomethyl)piperidine dihydrochloride

a) 1-(*tert*-Butoxycarbonyl)-4-(diethylaminomethyl)piperidine

Following a similar procedure to that described in section a of reference
30 example 21 but using acetaldehyde instead of formaldehyde, the desired compound was obtained in 17% yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using 1-(*tert*-butoxycarbonyl)-4-(diethylaminomethyl)piperidine (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

- 5 ¹H NMR (300 MHz, CDCl₃+CD₃OD) δ (TMS): 4.29 (s, 3H), 3.36 (m, 2H), 3.22 (m, 4H), 3.11 (m, 4H), 2.22 (m, 1H), 2.12 (m, 2H), 1.64 (m, 2H), 1.37 (m, 6H).

REFERENCE EXAMPLE 33

4-(2-Diethylaminoethyl)piperidine dihydrochloride

a) 1-(*tert*-Butoxycarbonyl)-4-(2-diethylaminoethyl)piperidine

- 10 A mixture of 2-(1-*tert*-butoxycarbonylpiperidin-4-yl)ethyl mesylate (obtained in section a of reference example 28) (0.7 g, 2.4 mmol) and diethylamine (6 mL, 85 mmol) was heated at reflux overnight and under argon atmosphere. It was concentrated to dryness and the residue was redissolved in H₂O and CHCl₃, the phases were separated and the organic phase was dried over sodium sulfate and
15 concentrated to dryness. 0.54 g of the desired product was obtained (79% yield).

b) Title compound

- Following a similar procedure to that described in section c of reference example 3, but using 1-(*tert*-butoxycarbonyl)-4-(2-diethylaminoethyl)piperidine (obtained in the preceding section) as starting product, the title compound of the
20 example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 4.79 (s, 3 H), 3.38 (broad d, J = 10.5 Hz, 2 H), 3.30 (m, 2 H), 3.25 (m, 4 H), 3.00 (m, 2 H), 1.99 (broad d, J = 13.7 Hz, 2 H), 1.74 (m, 3 H), 1.54 (m, 2 H), 1.33 (t, J = 7.1 Hz, 6 H).

REFERENCE EXAMPLE 34

- 25 **4-[2-(1-Pyrrolidinyl)ethyl]piperidine dihydrochloride**

a) 1-(*tert*-Butoxycarbonyl)-4-[2-(1-pyrrolidinyl)ethyl]piperidine

Following a similar procedure to that described in section a of reference example 33, but using pyrrolidine instead of diethylamine, the desired compound was obtained in 77% yield.

- 30 **b) Title compound**

Following a similar procedure to that described in section c of reference example 3, but using 1-(*tert*-butoxycarbonyl)-4-[2-(1-pyrrolidinyl)ethyl]piperidine

(obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 4.79 (s, 3 H), 3.41 (broad d, J = 12.8 Hz, 2 H), 3.29 (m, 4 H), 3.10 (m, 2 H), 3.00 (m, 2 H), 2.16 (m, 4 H), 1.99 (m, 2 H), 1.77 (m, 3 H), 1.49 (m, 2 H).

REFERENCE EXAMPLE 35

4-[2-[(4-Methylpiperazin-1-yl)carbonyloxy]ethyl]piperidine dihydrochloride

a) 1-(*tert*-Butoxycarbonyl)-4-[2-[(4-methylpiperazin-1-yl)carbonyloxy]ethyl]piperidine

Following a similar procedure to that described in section c of reference example 25, but using 1-methylpiperazine instead of pyrrolidine, the desired compound was obtained in 38% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 4.13 (m, 2 H), 4.09 (m, 2 H), 3.49 (m, 4 H), 2.69 (m, 2 H), 2.35 (m, 4 H), 2.31 (s, 3 H), 1.67 (m, 2 H), 1.58 (m, 3 H), 1.45 (s, 9 H), 1.12 (m, 2 H)

b) Desired compound

Following a similar procedure to that described in section c of reference example 3, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in quantitative yield.

REFERENCE EXAMPLE 36

4-[2-[(2-Methoxyethyl)aminocarbonyloxy]ethyl]piperidine hydrochloride

a) 1-(*tert*-Butoxycarbonyl)-4-[2-[(2-methoxyethyl)aminocarbonyloxy]ethyl]piperidine

Following a similar procedure to that described in section c of reference example 25, but using 2-methoxyethylamine instead of pyrrolidine, the desired compound was obtained in 50% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 4.98 (m, 1 H), 4.11 (m, 4 H), 3.40 (m, 2 H), 3.35 (s, 3 H), 2.68 (m, 2 H), 1.66 (m, 2 H), 1.55 (m, 4 H), 1.45 (s, 9 H), 1.13 (m, 3 H).

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in quantitative yield.

REFERENCE EXAMPLE 37

4-(1-Pyrrolidinylcarbonylaminomethyl)piperidine hydrochloride**a) 1-(*tert*-Butoxycarbonyl)-4-(phenoxycarbonylaminomethyl)piperidine**

Following a similar procedure to that described in section a of reference example 3, but using phenyl chloroformate instead of 4-chlorobutyl chloride, the desired compound was obtained in 42% yield.

b) 1-(*tert*-Butoxycarbonyl)-4-(1-pyrrolidinylcarbonylaminomethyl)piperidine

A mixture of 1-(*tert*-butoxycarbonyl)-4-(phenoxycarbonylaminomethyl)-piperidine (obtained in the preceding section) (1 g, 2.99 mmol) and pyrrolidine (3 mL) was heated overnight at 80 °C. It was concentrated to dryness and the residue was treated with CHCl₃ and basified by the addition of 0.5 N NaOH solution. The mixture was treated with 0.2 M NaHCO₃ and CHCl₃, the phases were separated and the organic phase was dried over sodium sulfate and concentrated. The crude product obtained was purified by chromatography on silica gel using EtOAc/MeOH mixtures of increasing polarity as eluent, to afford 780 mg of the desired compound (84% yield).

c) Title compound

Following a similar procedure to that described in section c of reference example 3, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, DMSO-d₆) δ (TMS): 8.78 (s, 1 H), 8.49 (s, 1 H), 6.15 (s, 1 H), 3.41 (m, 2 H), 3.14 (m, 4 H), 2.90 (d, J = 6.2 Hz, 2 H), 2.74 (m, 2 H), 1.77 (m, 6 H), 1.64 (m, 1 H), 1.30 (m, 2 H).

REFERENCE EXAMPLE 38

4-(4-Morpholinylcarbonylaminomethyl)piperidine hydrochloride**a) 1-(*tert*-Butoxycarbonyl)-4-(4-morpholinylcarbonylaminomethyl)piperidine**

Following a similar procedure to that described in section b of reference example 37, but using morpholine instead of pyrrolidine, the desired compound was obtained in 97% yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, DMSO-d₆) δ (TMS): 8.84 (s, 1 H), 8.58 (s, 1 H), 6.64 (s, 1 H), 3.40 (m, 6 H), 3.22 (m, 4 H), 2.91 (d, J = 5.3 Hz, 2 H), 2.78 (m, 2 H), 1.69 (m, 3 H), 1.28 (m, 2 H).

REFERENCE EXAMPLE 39

4-(1-Piperidylmethyl)piperidine dihydrochloride

a) 1-(*tert*-Butoxycarbonyl)-4-(1-piperidylmethyl)piperidine

Following a similar procedure to that described in section a of reference example 29, but using piperidine instead of morpholine and (1-*tert*-butoxycarbonylpiperidin-4-yl)methyl mesylate (obtained in reference example 2) instead of 2-(1-*tert*-butoxycarbonylpiperidin-4-yl)ethyl mesylate, the desired compound was obtained in quantitative yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using 1-(*tert*-butoxycarbonyl)-4-(1-piperidylmethyl)piperidine (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, DMSO-d₆) δ (TMS): 10.23 (s, 1 H), 9.00 (s, 1 H), 8.89 (s, 1 H), 3.45 (m, 2 H), 3.25 (m, 2 H), 2.90 (m, 2 H), 2.85 (m, 4 H), 2.11 (m, 1 H), 1.93 (m, 4 H), 1.7 (m, 4 H), 1.45 (m, 2 H).

REFERENCE EXAMPLE 40

N-Ethyl-2,2,2-trifluoro-*N*-(4-piperidylmethyl)acetamide hydrochloride

a) *N*-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]-2,2,2-trifluoroacetamide

To a solution of ethyl trifluoroacetate (3.33 mL, 28 mmol) in tetrahydrofuran (3 mL) under argon atmosphere, 4-aminomethyl-1-*tert*-butoxycarbonylpiperidine (obtained in reference example 1) (6 g, 28 mmol) was added, and the resulting mixture was stirred overnight at room temperature. It was concentrated to dryness and 7.1 g of a crude product was obtained, which was directly used in the following reaction.

b) *N*-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]-*N*-ethyl-2,2,2-trifluoroacetamide

Following a similar procedure to that described in section b of reference example 6, but using ethyl iodide and *N*-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]-2,2,2-trifluoroacetamide (obtained in the preceding section) as

reagents, instead of 1-*tert*-butoxycarbonyl-4-(2-chloroethoxycarbonylaminomethyl)piperidine, the desired compound was obtained in 37% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 4.10 (q, J = 6.8 Hz, 2 H), 4.02 (m, 2 H), 3.26 (m, 2 H), 2.65 (broad t, J = 12.2 Hz, 2 H), 1.98 (m, 1 H), 1.43 (m, 2 H), 1.42 (s, 9 H), 1.18 (t, J = 6.8 Hz, 3 H), 1.16 (m, 2 H).

c) Title compound

Following a similar procedure to that described in section c of reference example 3, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in quantitative yield.

REFERENCE EXAMPLE 41

4-[(4-Methylpiperazin-1-yl)carbonylaminomethyl]piperidine dihydrochloride

a) 1-(*tert*-Butoxycarbonyl)-4-[(4-methylpiperazin-1-yl)carbonylaminomethyl]-piperidine

Following a similar procedure to that described in section b of reference example 37, but using 1-methylpiperazine instead of pyrrolidine, the desired compound was obtained in 53% yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, DMSO-d₆) δ (TMS): 10.92 (s, 1 H), 8.84 (s, 1 H), 8.63 (s, 1 H), 6.90 (s, 1 H), 4.03 (broad d, J = 14.3 Hz, 2 H), 3.39 (m, 4 H), 3.18 (m, 4 H), 2.85 (m, 4 H), 2.71 (s, 3 H), 1.69 (m, 3 H), 1.26 (m, 2 H).

REFERENCE EXAMPLE 42

4-(4-Pyridylaminomethyl)piperidine dihydrochloride

a) 1-(*tert*-Butoxycarbonyl)-4-(4-pyridylaminomethyl)piperidine

To a solution of 4-chloropyridine (2 g, 13.3 mmol) and TEA (5.6 mL, 40.2 mmol) in xylene (25 mL), a solution of 4-aminomethyl-1-*tert*-butoxycarbonylpiperidine (obtained in reference example 1) (2.86 g, 13.3 mmol) in xylene (5 mL) was added dropwise under argon atmosphere, and the resulting mixture was heated at reflux for 3 days. The solvent was removed and the residue was treated with CHCl₃ and 0.5 N NaOH solution. The phases were separated

and the combined organic phases were dried over sodium sulfate and concentrated to dryness. The crude product obtained was purified by chromatography on silica gel using a CHCl₃/MeOH/NH₃ 100:10:1 mixture as eluent. 200 mg of the desired compound was obtained.

- 5 ¹H NMR (300 MHz, CDCl₃) δ (TMS): 8.18 (d, J = 6 Hz, 2 H), 7.30 (m, 1 H), 6.41 (d, J = 6 Hz, 2 H), 4.16 (m, 2 H), 3.06 (m, 2 H), 2.69 (broad t, J = 12.6 Hz, 2 H), 1.74 (m, 3 H), 1.46 (s, 9 H), 0.85 (m, 2 H).

b) Title compound

- 10 Following a similar procedure to that described in section c of reference example 3, but using 1-(*tert*-butoxycarbonyl)-4-(4-pyridylaminomethyl)piperidine (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

REFERENCE EXAMPLE 43

Isobutyl *N*-ethyl-*N*-(4-piperidylmethyl)carbamate hydrochloride

- 15 **a) 1-(*tert*-Butoxycarbonyl)-4-(ethylaminomethyl)piperidine**

- To a solution of *N*-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]-*N*-ethyl-2,2,2-trifluoroacetamide (obtained in section b of reference example 40) (700 mg, 2.0 mmol) in EtOH (10 mL), 1 N NaOH solution (10 mL) was added, and the resulting mixture was stirred overnight at room temperature. EtOH was removed
20 and the resulting suspension was extracted 3 times with CHCl₃. The combined organic phases were dried over sodium sulfate and concentrated to dryness, to afford a crude product which was directly used in the following step.

b) Isobutyl *N*-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]-*N*-ethylcarbamate

- 25 Following a similar procedure to that described in section a of reference example 3, but using 1-(*tert*-butoxycarbonyl)-4-(ethylaminomethyl)piperidine (obtained in the preceding section) and isobutyl chloroformate as reagents and treating the residue with 2.5% NaHSO₄ solution instead of 0.2 M NaHCO₃ solution, the desired compound was obtained in 82% yield.

c) Title compound

- 30 Following a similar procedure to that described in section c of reference example 3, but using isobutyl *N*-[(1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]-*N*-ethylcarbamate (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 9.65 (broad s, 1 H), 9.35 (broad s, 1 H), 3.85 (d, J = 6.5 Hz, 2 H), 3.50 (m, 2 H), 3.26 (m, 2 H), 3.13 (d, J = 6.3 Hz, 2 H), 2.85 (m, 2 H), 1.92 (m, 4 H), 1.25 (m, 2 H) 1.12 (m, 3 H), 0.93 (d, J = 6.6 Hz, 6 H).

REFERENCE EXAMPLE 44

5 **4-Piperidylmethyl *N,N*-diethylcarbamate hydrochloride**

a) 1-*tert*-Butoxycarbonyl-4-(phenoxycarbonyloxymethyl)piperidine

Following a similar procedure to that described in section a of reference example 3, but using (1-*tert*-butoxycarbonylpiperidin-4-yl)methanol (obtained in section b of reference example 2) instead of 4-aminomethyl-1-*tert*-
10 butoxycarbonylpiperidine and using phenyl chloroformate instead of 4-chlorobutyl chloride, the desired compound was obtained in 26% yield.

b) [1-(*tert*-Butoxycarbonyl)piperidin-4-yl]methyl *N,N*-diethylcarbamate

Following a similar procedure to that described in section c of reference example 25, but starting from the compound obtained in the preceding section
15 instead of 1-*tert*-butoxycarbonyl-4-[2-(phenoxycarbonyloxy)ethyl]piperidine and using diethylamine instead of pyrrolidine, the desired compound was obtained in 66% yield.

c) Title compound

Following a similar procedure to that described in section c of reference
20 example 3, but using [1-(*tert*-butoxycarbonyl)piperidin-4-yl]methyl *N,N*-diethylcarbamate (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 9.74 (broad s, 1 H), 9.45 (broad s, 1 H), 3.99 (d, J = 5.3 Hz, 2 H), 3.52 (broad d, J = 11.4 Hz, 2 H), 3.27 (m, 4 H), 2.86 (broad d, J = 9.9 Hz, 2 H), 1.94 (m, 1 H), 1.90 (m, 2 H), 1.75 (m, 2 H), 1.12 (m, 6 H).
25

REFERENCE EXAMPLE 45

4-[[4-Methylpiperazin-1-yl]carbonyloxy]methyl]piperidine dihydrochloride

a) 1-(*tert*-Butoxycarbonyl)-4-[[4-methylpiperazin-1-yl]carbonyloxy]methyl]-piperidine

30 Following a similar procedure to that described in section c of reference example 25, but starting from 1-*tert*-butoxycarbonyl-4-(phenoxycarbonyloxymethyl)piperidine (obtained in section a of reference

example 44) and using 1-methylpiperazine instead of pyrrolidine, the desired compound was obtained in 79% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 4.12 (broad d, J = 11.9 Hz, 2 H), 3.95 (d, J = 6.3 Hz, 2 H), 3.50 (m, 4 H), 2.70 (broad t, J = 11.8 Hz, 2 H), 2.38 (m, 4 H), 2.30 (s, 3 H), 1.81 (m, 1 H), 1.68 (m, 2 H), 1.45 (s, 9 H), 1.17 (m, 2 H).

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in quantitative yield.

REFERENCE EXAMPLE 46

4-(4-Pyridyloxymethyl)piperidine dihydrochloride

a) 1-(tert-Butoxycarbonyl)-4-(4-pyridyloxymethyl)piperidine

To a suspension of 4-hydroxypyridine (1.3 g, 14 mmol), (1-*tert*-butoxycarbonylpiperidin-4-yl)methanol (3 g, 14 mmol) (obtained in section b of reference example 2) and triphenylphosphine (3.66 g, 14 mmol) in THF (40 mL), cooled to -20 °C, a solution of DEAD (2.2 mL, 14 mmol) in THF (12 mL) was added dropwise and under argon atmosphere, and the resulting mixture was stirred overnight at room temperature. THF was evaporated and the resulting residue was resuspended in H₂O and extracted 3 times with EtOAc. The combined organic extracts were dried over Na₂SO₄ and concentrated to dryness, to afford a crude product, which was purified by chromatography on silica gel using EtOAc/MeOH mixtures of increasing polarity as eluent. 1.15 g of the desired compound was obtained (28% yield).

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.66 (d, J = 7.5 Hz, 2 H), 7.57 (d, J = 7.5 Hz, 2 H), 4.90 (s, 3 H), 4.31 (d, J = 6.1 Hz, 2 H), 3.48 (m, 2 H), 3.08 (m, 2 H), 2.30 (m, 1 H), 2.10 (m, 2 H), 1.70 (m, 2 H).

REFERENCE EXAMPLE 47

N-(3,5-Dichlorophenylsulfonyl)-L-proline

To a solution of Na₂CO₃ (10.79 g, 101.85 mmol) in H₂O (50 mL), (L)-proline (3.9 g, 33.9 mmol) was added. The mixture was cooled to 0 °C and a suspension of 3,5-dichlorobenzenesulfonyl chloride (10.0 g, 40.7 mmol) in dioxane (20 mL) was slowly added. The resulting mixture was stirred at 0 °C for 30 min, H₂O (15 mL) was added and the mixture was stirred overnight at room temperature. Dioxane was evaporated, the aqueous phase was diluted with H₂O and extracted with EtOAc (x3). It was cooled to 0 °C and brought to pH 1.5 by the addition of 3 N HCl solution (50 mL). An insoluble material was obtained, which was collected by filtration and was washed with H₂O. The aqueous phase was extracted with EtOAc. The organic phase was dried over sodium sulfate and concentrated, and the product obtained was combined with the previous solid. 9.74 g of the title compound was obtained (89% yield).

¹H NMR (300 MHz, CDCl₃) δ (TMS): 9.84 (broad s, 1 H), 7.75 (broad s, 2 H), 7.55 (s, 1 H), 4.40 (m, 1 H), 3.50 (m, 1 H), 3.36 (m, 1 H), 1.9 - 2.20 (complex signal, 4 H).

REFERENCE EXAMPLE 48

1-Methyl *N*-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]-L-glutamate

a) *N*-[[*N*-(3,5-dichlorophenylsulfonyl)-L-prolyl]oxy]succinimide

To a solution of *N*-(3,5-dichlorophenylsulfonyl)-L-proline (obtained in reference example 47) (3.6 g, 11.1 mmol) and NHS (1.27 g, 11.1 mmol) in CHCl₃ (125 mL), cooled to 0 °C and under argon atmosphere, DCC (2.27 g, 11.1 mmol) was added and the resulting mixture was stirred overnight at room temperature. The solid obtained was filtered off and the solution was concentrated to dryness. A crude product was obtained which was directly used in the following step.

b) Title compound

N-[[*N*-(3,5-dichlorophenylsulfonyl)-L-prolyl]oxy]succinimide (prepared in the preceding section) (4.67 g, 11.1 mmol) was dissolved in CHCl₃ (60 mL). TEA (3.25 mL, 22.2 mmol) was added and then 1-methyl L-glutamate (1.81 g, 11.1 mmol) was slowly added portionwise. The solution was stirred overnight at room temperature, acidified with 0.5 N HCl (pH 4) and the product was extracted with CHCl₃. The crude product obtained was purified by chromatography on silica gel using EtOAc as eluent, to afford 3.1 g of the title compound of the example (60% yield).

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.75 (s, 2 H), 7.62 (s, 1 H), 7.35 (d, J = 7.6 Hz, 1 H), 4.62 (m, 1 H), 4.16 (m, 1 H), 3.79 (s, 3 H), 3.59 (m, 1 H), 3.23 (m, 1 H), 2.46 (m, 2 H), 2.23 (m, 2 H), 2.07 (m, 1 H), 1.75 - 1.85 (complex signal, 3 H).

REFERENCE EXAMPLE 49

5 **1-Methyl *N*-[1-tosyl-L-prolyl]-L-glutamate**

Following a similar procedure to that described in reference example 48 but using *N*-tosyl-L-proline instead of *N*-(3,5-dichlorophenylsulfonyl)-L-proline, the title compound of the example was obtained in 90% yield.

10 ¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.74 (d, J = 8.3 Hz, 2 H), 7.55 (d, J = 7.8 Hz, 1 H), 7.34 (d, J = 8.3 Hz, 2 H), 4.61 (m, 1 H), 4.12 (m, 1 H), 3.78 (s, 3 H), 3.52 (m, 1 H), 3.17 (m, 1 H), 2.44 (s, 3 H), 2.42 (m, 2 H), 2.01 (m, 2 H), 1.95 (m, 1 H), 1.78 (m, 1 H), 1.62 (m, 2 H).

REFERENCE EXAMPLE 50

1-Methyl *N*-*tert*-butoxycarbonyl-L-glutamate

15 To a suspension of 1-methyl L-glutamate (5.0 g, 30 mmol) in CH₂Cl₂ (250 mL) and TEA (8.64 mL, 60 mmol), cooled to 0 °C, a solution of di-*tert*-butyl dicarbonate (6.7 g, 30 mmol) in CH₂Cl₂ (40 mL) was added dropwise and under argon atmosphere. The mixture was stirred overnight at room temperature. The resulting mixture was brought to pH 3-4 by addition of 10% NaHSO₄ solution and
20 next it was extracted 3 times with CH₂Cl₂. The combined organic phases were dried over sodium sulfate and concentrated, to afford the title compound of the example in quantitative yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 5.30 (m, 1 H), 4.31 (m, 1 H), 3.74 (s, 3 H), 2.41 (m, 2 H), 2.14 (m, 1 H), 1.98 (m, 1 H), 1.45 (s, 9 H).

25 **REFERENCE EXAMPLE 51**

Methyl (2*S*)-2-amino-5-[4-(2-methylimidazo[4,5-*c*]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoate dihydrochloride

a) Methyl (2*S*)-2-(*tert*-butoxycarbonylamino)-5-[4-(2-methylimidazo[4,5-*c*]pyridin-1-yl-methyl)piperidin-1-yl]-5-oxopentanoate

30 A solution of the compound obtained in reference example 50 (3.8 g, 15 mmol), DCC (2.9 g, 14 mmol) and HOBT (1.9 g, 14 mmol) in DMF (50 mL) was stirred at room temperature and under argon atmosphere for 1 hour. Next, 2-methyl-1-(4-piperidylmethyl)imidazo[4,5-*c*]pyridine (obtained in reference example

8) (3.35 g, 15 mmol) was added, and the resulting mixture was stirred overnight at room temperature. The solid obtained was filtered off and the solution was concentrated to dryness. The residue obtained was partitioned between CHCl_3 and saturated NaHCO_3 solution. The phases were separated and the organic phase was dried over sodium sulfate and concentrated, to afford a crude product which was purified by chromatography on silica gel using a CHCl_3 :MeOH 5% mixture as eluent. 5.41 g of the desired compound was obtained (73% yield).

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in quantitative yield.

^1H NMR (300 MHz, DMSO-d_6) δ (TMS): 9.74 (broad s, 4 H), 9.32 (s, 1 H), 8.62 (d, $J = 6.5$ Hz, 1 H), 8.33 (d, $J = 6.5$ Hz, 1 H), 4.31 (d, $J = 7.5$ Hz, 2 H), 4.30 (m, 1 H), 4.00 (m, 1 H), 3.80 (m, 1 H), 3.70 (s, 3 H), 2.88 (m, 1 H), 2.75 (s, 3 H), 2.41 (m, 3 H), 1.98–2.06 (complex signal, 3 H), 1.15–1.52 (complex signal, 4 H).

REFERENCE EXAMPLE 52

Methyl (2S)-3-amino-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]aminopropionate hydrochloride

a) Methyl (2S)-3-tert-butoxycarbonylamino-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]aminopropionate

Following a similar procedure to that described in reference example 48 but using methyl (2S)-2-amino-3-tert-butoxycarbonylamino-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]aminopropionate hydrochloride instead of 1-methyl L-glutamate, the title compound of the example was obtained in 98% yield.

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using methyl (2S)-3-tert-butoxycarbonylamino-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]aminopropionate (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

^1H NMR (300 MHz, $\text{CDCl}_3 + \text{CD}_3\text{OD}$) δ (TMS): 7.79 (s, 2 H), 7.59 (s, 1 H), 4.71 (m, 1 H), 4.07 (m, 1 H), 3.76 (m, 1 H), 3.75 (s, 3 H), 3.67 (s, 4 H), 3.44 (m, 2 H), 3.16 (m, 1 H), 2.05 (m, 4 H).

REFERENCE EXAMPLE 53

Methyl (2S)-2-amino-3-[[4-(dimethylaminomethyl)piperidin-1-yl]carbonyloxy]propionate

a) *N*-*tert*-butoxycarbonyl-L-serine methyl ester

5 Following a similar procedure to that described in section a of reference example 3 but using L-serine methyl ester hydrochloride and di-*tert*-butyl dicarbonate as reagents, 6.19 g of the title compound was obtained (88% yield).

b) Methyl (2S)-2-(*tert*-butoxycarbonylamino)-3-[(1-imidazolyl)carbonyloxy]propionate

10 To a solution of 1,1'-carbonyldiimidazole (0.74 g, 4.56 mmol) in acetonitrile (15 mL), the compound obtained in the preceding section (1.0 g, 4.56 mmol) dissolved in 8 mL of acetonitrile was added dropwise and under argon atmosphere, and the resulting mixture was stirred overnight at room temperature. The solvent was removed and the residue obtained was treated with H₂O and
15 CHCl₃. The phases were separated, the organic phase was dried over sodium sulfate and concentrated to dryness. 1.10 g of the desired compound was obtained (77% yield).

c) Methyl (2S)-2-(*tert*-butoxycarbonylamino)-3-[[4-(dimethylaminomethyl)piperidin-1-yl]carbonyloxy]propionate

20 To a suspension of 4-(dimethylaminomethyl)piperidine dihydrochloride (obtained in reference example 21) (0.36 g, 1.67 mmol) and DIEA (1.2 mL, 6.9 mmol) in acetonitrile (10 mL), some drops of 2 N NaOH solution and some drops of H₂O were added until complete dissolution. Next, methyl (2S)-2-(*tert*-butoxycarbonylamino)-3-[(1-imidazolyl)carbonyloxy]propionate (obtained in the
25 preceding section) (7.3 mL, 1.67 mmol) was slowly added and the resulting mixture was stirred overnight at room temperature. Acetonitrile was evaporated and the residue obtained was treated with CHCl₃ and saturated NaHCO₃ solution. The phases were separated, the organic phase was dried over sodium sulfate and concentrated to dryness. The crude product obtained was purified on silica gel,
30 using CHCl₃/MeOH mixtures of increasing polarity as eluent. 77 mg of the desired compound was obtained (12% yield).

¹H NMR (300 MHz, CDCl₃) δ (TMS): 5.39 (d, J = 7.8 Hz, 1 H), 4.51 (m, 1 H), 4.27 (m, 2 H), 4.08 (m, 1 H), 3.96 (m, 1 H), 3.72 (s, 3 H), 2.71 (m, 2 H), 2.16 (s, 6 H),

2.07 (d, J = 7.1 Hz, 2 H), 1.70 (broad d, J = 13.1 Hz, 2 H), 1.62 (m, 1 H), 1.41 (s, 9 H), 1.10 (m, 2 H).

d) Title compound

Following a similar procedure to that described in section c of reference example 3, but using methyl (2S)-2-(*tert*-butoxycarbonylamino)-3-[[4-(dimethylaminomethyl)piperidin-1-yl]carbonyloxy]propionate (obtained in the preceding section) as starting product, the title compound of the example was obtained in quantitative yield.

REFERENCE EXAMPLE 54

10 Methyl (2S)-3-amino-2-[N-tosyl-L-prolyl]aminopropionate

a) Methyl (2S)-3-*tert*-butoxycarbonylamino-2-[N-tosyl-L-prolyl]aminopropionate

Following a similar procedure to that described in reference example 48 but using *N*-tosyl-L-proline instead of *N*-(3,5-dichlorophenylsulfonyl)-L-proline and methyl (2S)-2-amino-3-*tert*-butoxycarbonylamino-2-[N-tosyl-L-prolyl]aminopropionate hydrochloride instead of 1-methyl L-glutamate, the title compound of the example was obtained in 81% yield.

b) Title compound

The compound obtained in the preceding section and a 4 M dioxane/HCl_(g) mixture were mixed in a flask under argon atmosphere. The mixture was stirred overnight at room temperature and concentrated to dryness. The residue obtained was partitioned between aqueous NaHCO₃ solution and CHCl₃. The phases were separated and the organic phase was dried over sodium sulfate and concentrated to dryness, to afford the title compound of the example in quantitative yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.74 (d, J = 8.3 Hz, 2 H), 7.62 (d, J = 7.2 Hz, 1 H), 7.33 (d, J = 8.3 Hz, 2 H), 4.55 (m, 1 H), 4.13 (m, 1 H), 3.69 (s, 3 H), 3.52 (m, 1 H), 3.20 (m, 1 H), 3.10 (m, 2 H), 2.44 (s, 3 H), 2.17 (m, 1 H), 1.67 (m, 1 H), 1.60 (m, 2 H), 1.38 (s, 2 H).

REFERENCE EXAMPLE 55

30 1-(4-Piperidylmethyl)-2-propylimidazo[4,5-*c*]pyridine dihydrochloride

a) 1-[(1-*tert*-Butoxycarbonylpiperidin-4-yl)methyl]-2-propylimidazo[4,5-*c*]pyridine

A solution of 3-amino-4-[[1-*tert*-butoxycarbonylpiperidin-4-yl)methyl]amino]pyridine (obtained in section b of reference example 8) (3.6 g, 11.7 mmol) in butyric anhydride (15.5 mL) and butyric acid (16.5 mL) was heated under argon atmosphere at 100 °C for 4 h., and at 120 °C for 1 h more. The resulting mixture was poured over ice, brought to basic pH by the addition of 5% NaOH solution and stirred for 30 min. The resulting suspension was extracted 3 times with CH₂Cl₂. The combined organic phases were dried over sodium sulfate and concentrated to dryness, to afford a crude product which was purified by chromatography on silica gel, using a CHCl₃/MeOH (97:3) mixture as eluent. 1.28 g of the desired compound was obtained (32% yield).

¹H NMR (300 MHz, CDCl₃) δ (TMS): 9.03 (s, 1 H), 8.39 (d, J = 5.5 Hz, 1 H), 7.23 (d, J = 5.5 Hz, 1 H), 4.14 (m, 2 H), 3.98 (d, J = 8.2 Hz, 2 H), 2.84 (t, J = 7.5 Hz, 2 H), 2.61 (broad t, J = 12.2 Hz, 2 H), 1.95 (q, J = 7.5 Hz, 2 H), 1.66 (m, 3 H), 1.45 (s, 9 H), 1.27 (m, 2 H), 1.09 (t, J = 7.5 Hz, 3 H).

b) Title compound

Following a similar procedure to that described in section c of reference example 3, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.99 (s, 1 H), 8.48 (s, 1 H), 7.43 (s, 1 H), 4.36 (m, 5 H), 3.30 (m, 2 H), 3.00 (t, J = 7.5 Hz, 2 H), 2.90 (broad t, J = 12.5 Hz, 2 H), 2.25 (m, 1 H), 2.00 (q, J = 7.5 Hz, 2 H), 1.93 (m, 2 H), 1.67 (m, 2 H), 1.10 (q, J = 7.5 Hz, 3 H).

REFERENCE EXAMPLE 56

2-(4-Piperidyl)ethyl 4-phenylpiperazine-1-carboxylate dihydrochloride

a) 2-(1-*tert*-Butoxycarbonylpiperidin-4-yl)ethyl 4-phenylpiperazine-1-carboxylate

Following a similar procedure to that described in section b of reference example 37, but using 1-*tert*-butoxycarbonyl-4-[2-(phenoxy)ethoxy]piperidine (obtained in section b of reference example 25) and 1-phenylpiperazine as starting products, the desired compound was obtained in quantitative yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.28 (m, 2 H), 6.87 (m, 3 H), 4.14 (m, 4 H), 3.63 (m, 4 H), 3.14 (m, 4 H), 2.69 (broad t, J = 12.2 Hz, 2 H), 1.5 - 1.7 (m, 5 H), 1.48 (s, 9 H), 1.17 (m, 2 H).

b) Title compound

- 5 Following a similar procedure to that described in section c of reference example 3, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in quantitative yield.

REFERENCE EXAMPLE 57

10 **Methyl (4S)-3-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]-2-oxoimidazolidine-4-carboxylate**

a) 1-Methyl N-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]-L-aspartate

 Following a similar procedure to that described in reference example 48 but using 1-methyl L-aspartate instead of 1-methyl L-glutamate, the desired compound was obtained in 94% yield.

- 15 ¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.66 (s, 2 H), 7.51 (s, 1 H), 7.50 (m, 1 H), 4.75 (m, 1 H), 4.08 (m, 1 H), 3.70 (s, 3 H), 3.48 (m, 1 H), 3.11 (m, 1 H), 2.93 (qd, J = 8.7 Hz, J = 4.8 Hz, 2 H), 2.10 (m, 1 H), 1.72 (m, 3 H).

b) Title compound

- To a solution of the compound obtained in the preceding section (0.44 g, 0.97 mmol) and TEA (0.135 mL, 0.96 mmol) in benzene (10 mL), diphenylphosphoryl azide (0.221 mL, 1 mmol) was added under argon atmosphere, and the reaction mixture was stirred at room temperature for 30 min. and next at reflux overnight. The resulting mixture was partitioned three times between H₂O and EtOAc and the combined organic phases were dried over sodium sulfate and concentrated. The title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.77 (s, 2 H), 7.55 (s, 1 H), 7.35 (m, 1 H), 5.72 (m, 1 H), 4.95 (m, 1 H), 3.77 (s, 3 H), 3.55 (m, 2 H), 3.34 (m, 1 H), 3.01 (m, 1 H), 2.22 (m, 1 H), 2.12 (m, 1 H), 1.95 (m, 1 H), 1.86 (m, 1 H).

- 30 **REFERENCE EXAMPLE 58**

2-(4-Piperidyl)ethyl 4-(4-pyridyl)piperazine-1-carboxylate

a) 2-(1-tert-Butoxycarbonylpiperidin-4-yl)ethyl 4-(4-pyridyl)piperazine-1-carboxylate

Following a similar procedure to that described in section c of reference example 25, but using 1-*tert*-butoxycarbonyl-4-[2-(phenoxycarbonyloxy)ethyl]piperidine (obtained in section b of reference example 25) and 1-(4-pyridyl)piperazine as starting products, the desired compound was obtained in 89% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 8.21 (d, J = 4.8 Hz, 2 H), 6.64 (d, J = 4.8 Hz, 2 H), 4.14 (t, J = 6.3 Hz, 2 H), 4.04 (m, 4 H), 3.59 (m, 4 H), 3.37 (m, 4 H), 2.60 (broad t, J = 12.3 Hz, 2 H), 1.5-1.7 (m, 5 H), 1.43 (s, 9 H), 1.13 (m, 2 H).

b) Title compound

Following a similar procedure to that described in section b of reference example 7, but using 2-(1-*tert*-butoxycarbonylpiperidin-4-yl)ethyl 4-(4-pyridyl)piperazine-1-carboxylate (obtained in the preceding section) as starting product, the title compound of the example was obtained in 75% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 8.60 (d, J = 4.8 Hz, 2 H), 6.65 (d, J = 4.8 Hz, 2 H), 4.16 (t, J = 6.3 Hz, 2 H), 3.62 (m, 4 H), 3.33 (m, 4 H), 3.06 (m, 2 H), 2.60 (td, J = 12.3 Hz, J = 2.5 Hz, 2 H), 1.5-1.7 (m, 6 H), 1.13 (m, 2 H).

REFERENCE EXAMPLE 59

4-[2-[(4-Ethoxycarbonylpiperazin-1-yl)carbonyloxy]ethyl]piperidine

a) 1-(*tert*-Butoxycarbonyl)-4-[2-[(4-ethoxycarbonylpiperazin-1-yl)carbonyloxy]ethyl]piperidine

Following a similar procedure to that described in section b of reference example 37, but using 1-*tert*-butoxycarbonyl-4-[2-(phenoxycarbonyloxy)ethyl]piperidine (obtained in section b of reference example 25) instead of 1-(*tert*-butoxycarbonyl)-4-(phenoxycarbonylaminomethyl)piperidine and ethyl 1-piperazinecarboxylate instead of pyrrolidine, the desired compound was obtained in quantitative yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 4.13 (m, 6 H), 3.45 (s, 8 H), 2.67 (broad t, J = 12.3 Hz, 2 H), 1.5-1.7 (m, 5 H), 1.44 (s, 9 H), 1.25 (t, J = 4 Hz, 3 H), 1.15 (m, 2 H).

b) Title compound

Following a similar procedure to that described in section b of reference example 7, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in 98% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 4.17 (m, 4 H), 3.45 (s, 8 H), 3.04 (m, 2 H), 2.67 (broad t, J = 12.3 Hz, 2 H), 1.5-1.7 (m, 6 H), 1.25 (t, J = 4 Hz, 3 H), 1.15 (m, 2 H).

REFERENCE EXAMPLE 60

5 **2-(4-Piperidyl)ethyl 4-methylpiperidine-1-carboxylate**

a) 2-(1-*tert*-Butoxycarbonylpiperidin-4-yl)ethyl 4-methylpiperidine-1-carboxylate

Following a similar procedure to that described in section b of reference example 37, but using 1-*tert*-butoxycarbonyl-4-[2-(phenoxycarbonyloxy)ethyl]piperidine (obtained in section b of reference example 10 25) instead of 1-(*tert*-butoxycarbonyl)-4-(phenoxycarbonylaminomethyl)piperidine and 4-methylpiperidine instead of pyrrolidine, the desired compound was obtained in 98% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 4.11 (m, 6 H), 2.69 (broad q, J = 13.2 Hz, 4 15 H), 1.5-1.7 (m, 6 H), 1.45 (s, 9 H), 1.15 (m, 6 H), 0.93 (d, J = 6.6 Hz, 3 H).

b) Title compound

Following a similar procedure to that described in section b of reference example 7, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in 93% yield.

20 ¹H NMR (300 MHz, CDCl₃) δ (TMS): 4.11 (m, 4 H), 3.08 (m, 2 H), 2.72 (broad t, J = 12.3 Hz, 2 H), 2.57 (td, J = 12.3 Hz, J = 2.7 Hz, 2 H), 1.5-1.7 (m, 7 H), 1.15 (m, 6 H), 0.94 (d, J = 6.6 Hz, 3 H).

REFERENCE EXAMPLE 61

2-(4-Piperidyl)ethyl 4-methylhomopiperazine-1-carboxylate

25 **a) 2-(1-*tert*-Butoxycarbonylpiperidin-4-yl)ethyl 4-methylhomopiperazine-1-carboxylate**

Following a similar procedure to that described in section b of reference example 37, but using 1-*tert*-butoxycarbonyl-4-[2-(phenoxycarbonyloxy)ethyl]piperidine (obtained in section b of reference example 30 25) instead of 1-(*tert*-butoxycarbonyl)-4-(phenoxycarbonylaminomethyl)piperidine and 1-methylhomopiperazine instead of pyrrolidine, the desired compound was obtained in 87% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 4.12 (m, 4 H), 3.55 (m, 4 H), 2.67 (broad t, J = 12.3 Hz, 2 H), 2.57 (m, 4 H), 2.36 (s, 3 H), 1.84 (m, 2 H), 1.5-1.7 (m, 5 H), 1.45 (s, 9 H), 1.12 (m, 2 H).

b) Title compound

Following a similar procedure to that described in section b of reference example 7, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in 93% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 4.12 (t, J = 6.3 Hz, 2 H), 3.55 (m, 4 H), 3.05 (m, 2 H), 2.67 (m, 6 H), 2.35 (s, 3 H), 1.87 (m, 2 H), 1.5-1.7 (m, 6 H), 1.12 (m, 2 H).

REFERENCE EXAMPLE 62

4-[2-[(*cis*-2,6-Dimethylmorpholin-4-yl)carbonyloxy]ethyl]piperidine

a) 1-(*tert*-Butoxycarbonyl)-4-[2-[(*cis*-2,6-dimethylmorpholin-4-yl)carbonyloxy]ethyl]piperidine

Following a similar procedure to that described in section b of reference example 37, but using 1-(*tert*-butoxycarbonyl)-4-[2-(phenoxy carbonyloxy)ethyl]piperidine (obtained in section b of reference example 25) instead of 1-(*tert*-butoxycarbonyl)-4-(phenoxy carbonylaminomethyl)piperidine and *cis*-2,6-dimethylmorpholine instead of pyrrolidine, the desired compound was obtained in 86% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 3.8-4.2 (m, 6 H), 3.53 (m, 2 H), 2.68 (broad t, J = 12.3 Hz, 2 H), 2.51 (m, 2 H), 1.5-1.7 (m, 5 H), 1.45 (s, 9 H), 1.17 (d, J = 6 Hz, 6 H), 1.08 (m, 2 H).

b) Title compound

Following a similar procedure to that described in section b of reference example 7, but using the compound obtained in the preceding section as starting product, the title compound of the example was obtained in 88% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 4.13 (t, J = 6.9 Hz, 2 H), 3.91 (m, 2 H), 3.53 (m, 2 H), 3.05 (m, 2 H), 2.58 (m, 4 H), 1.7 (m, 2 H), 1.61 (m, 2 H), 1.48 (m, 2 H), 1.17 (d, J = 6 Hz, 6 H), 1.08 (m, 2 H).

EXAMPLE 1

Methyl (2*S*)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(2-oxooxazolidin-3-ylmethyl)piperidin-1-yl]pentanoate

To a solution of 1-methyl *N*-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]-L-glutamate (obtained in reference example 48) (500 mg, 1.05 mmol) in DMF (15 mL), EDC·HCl (250 mg, 1.3 mmol), HOBT (170 mg, 1.3 mmol) and NMM (0.7 mL, 6.4 mmol) were added under argon atmosphere, and the resulting mixture was stirred at room temperature for 30 min. Next, 3-[(4-piperidyl)methyl]oxazolidin-2-one hydrochloride (obtained in reference example 6) (230 mg, 1.05 mmol) was added, and the mixture was further stirred overnight. The solvent was evaporated and the residue obtained was partitioned between CHCl₃ and saturated NaHCO₃ solution. The phases were separated, the organic phase was dried over sodium sulfate and concentrated to dryness, to afford a crude product which was purified by chromatography on silica gel using CHCl₃/MeOH mixtures of increasing polarity as eluent. 300 mg of the title compound of the example was obtained (45% yield).
¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.76 (s, 2 H), 7.66 (m, 1 H), 7.59 (s, 1 H), 4.61 (m, 1 H), 4.49 (m, 1 H), 4.32 (m, 2 H), 4.13 (m, 1 H), 3.80 (m, 1 H), 3.76 (s, 3 H), 3.57 (m, 3 H), 3.25 (m, 1 H), 3.14 (m, 2 H), 3.00 (m, 1 H), 2.66 (m, 1 H), 2.43 (m, 2 H), 2.22 (m, 1 H), 2.16 (m, 2 H), 1.59-1.93 (complex signal, 6 H), 1.20 (m, 2 H).

Following a similar procedure to that described in example 1, but starting in each case from the corresponding acid and amine, the following compounds were obtained:

EXAMPLE 2: Methyl (2*S*)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-oxopyrrolidin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoate

Starting compounds: reference examples 48 and 3; 86% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.76 (s, 2 H), 7.69 (d, *J* = 7.0 Hz, 1 H), 7.59 (s, 1 H), 4.60 (m, 1 H), 4.47 (m, 1 H), 4.11 (m, 1 H), 3.81 (m, 1 H), 3.75 (s, 3 H), 3.58 (m, 1 H), 3.37 (m, 2 H), 3.21 (m, 2 H), 3.08 (m, 1 H), 2.99 (m, 1 H), 2.32-2.65 (complex signal, 5 H), 1.98-2.30 (complex signal, 5 H), 1.60-1.90 (complex signal, 6 H), 1.19 (m, 2 H).

EXAMPLE 3: Methyl (2*S*)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-oxoisindolin-2-ylmethyl)piperidin-1-yl]pentanoate

Starting compounds: reference examples 48 and 4; 97% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.82 (d, *J* = 7.2 Hz, 1 H), 7.75 (s, 2 H), 7.68 (m, 1 H), 7.57 (m, 1 H), 7.51 (m, 3 H), 4.53 (m, 1 H), 4.46 (m, 1 H), 4.39 (s, 2 H),

4.12 (m, 1 H), 3.79 (m, 1 H), 3.74 (s, 3 H), 3.54 (m, 2 H), 3.46 (m, 1 H), 3.23 (m, 1 H), 2.97 (m, 1 H), 2.60 (m, 1 H), 2.41 (m, 3 H), 1.69-2.30 (complex signal, 8 H), 1.24 (m, 2 H).

EXAMPLE 4: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-ethyl-5,7-dimethylimidazo[4,5-*b*]pyridin-3-ylmethyl)piperidin-1-yl]-5-oxopentanoate

Starting compounds: reference examples 48 and 9; 65% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.76 (s, 2 H), 7.69 (d, J = 6 Hz, 1 H), 7.59 (s, 1 H), 6.84 (s, 1 H), 4.63 (m, 1 H), 4.47 (m, 1 H), 4.07 (m, 3 H), 3.81 (m, 1 H), 3.74 (s, 3 H), 3.48 (m, 1 H), 3.22 (m, 1 H), 2.86 (m, 3 H), 2.59 (s, 3 H), 2.55 (s, 3 H), 2.46 (m, 3 H), 2.05-2.35 (complex signal, 4 H), 1.95 (m, 3 H), 1.62 (m, 2 H), 1.40 (q, J = 7.4 Hz, 3 H), 1.25 (m, 2 H).

EXAMPLE 5: Methyl (2S)-5-[4-(2-methylimidazo[4,5-*c*]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoate

Starting compounds: reference examples 49 and 8; 47% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 8.86 (s, 1 H), 8.21 (d, J = 5.5 Hz, 1 H), 7.66 (d, J = 7.8 Hz, 2 H), 7.57 (d, J = 7.3 Hz, 1 H), 7.28 (d, J = 7.8 Hz, 2 H), 7.19 (d, J = 5.5 Hz, 1 H), 4.50 (m, 2 H), 4.01 (m, 1 H), 3.95 (d, J = 7.7 Hz, 2 H), 3.82 (m, 1 H), 3.68 (s, 3 H), 3.44 (m, 1 H), 3.15 (m, 1 H), 2.60-2.90 (complex signal, 3 H), 2.57 (s, 3 H), 2.42 (m, 1 H), 2.36 (s, 3 H), 2.12 (m, 1 H), 2.03 (m, 3 H), 1.77 (m, 1 H), 1.50 (m, 4 H), 1.25 (m, 2 H).

EXAMPLE 6: Methyl (2S)-5-oxo-5-[4-[(2-oxopyrrolidin-1-yl)methyl]piperidin-1-yl]-2-[1-tosyl-L-prolylamino]pentanoate

Starting compounds: reference examples 49 and 3; 37% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.73 (d, J = 8.2 Hz, 2 H), 7.58 (t, J = 7.3 Hz, 1 H), 7.33 (d, J = 8.2 Hz, 2 H), 4.54 (m, 2 H), 4.05 (m, 1 H), 3.82 (m, 1 H), 3.75 (s, 3 H), 3.53 (m, 1 H), 3.37 (m, 2 H), 3.17 (m, 2 H), 3.09 (m, 1 H), 2.98 (m, 1 H), 2.59 (m, 1 H), 2.43 (s, 3 H), 2.36 (m, 3 H), 2.28 (m, 1 H), 2-2.2 (complex signal, 4 H), 1.85 (m, 3 H), 1.63 (m, 4 H), 1.18 (m, 2 H).

EXAMPLE 7: Methyl (2S)-5-oxo-5-[4-(2-phenylimidazol-1-ylmethyl)piperidin-1-yl]-2-[1-tosyl-L-prolylamino]pentanoate

Starting compounds: reference examples 49 and 7; 42% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.73 (d, J = 8.0 Hz, 2 H), 7.52 (m, 2 H), 7.50 (m, 1 H), 7.41 (m, 3 H), 7.34 (d, J = 8.0 Hz, 2 H), 7.11 (m, 1 H), 6.96 (m, 1 H), 4.53 (m, 2 H), 4.05 (m, 1 H), 3.89 (d, J = 7.3 Hz, 2 H), 3.82 (m, 1 H), 3.74 (s, 3 H), 3.47 (m, 1 H), 3.14 (m, 1 H), 2.92 (m, 1 H), 2.44 (s, 3 H), 2.42 (m, 3 H), 2.27 (m, 1 H), 2.09 (m, 2 H), 1.50-1.85 (complex signal, 6 H), 1.15 (m, 2 H).

EXAMPLE 8: Methyl (2S)-5-[4-[[1-(2-ethoxyethyl)benzimidazol-2-yl]methyl]piperazin-1-yl]-5-oxo-2-[[1-tosyl-L-prolyl]amino]pentanoate

Starting compounds: reference examples 49 and 10; 50% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.73 (d, J = 8.2 Hz, 2 H), 7.71 (m, 1 H), 7.54 (d, J = 7.5 Hz, 1 H), 7.33 (d, J = 8.2 Hz, 2 H), 7.31 (m, 1 H), 7.23 (m, 2 H), 4.50 (m, 3 H), 4.07 (m, 1 H), 3.88 (s, 2 H), 3.76 (s, 3 H), 3.74 (m, 2 H), 3.61 (m, 2 H), 3.56 (m, 1 H), 3.44 (m, 2 H), 3.37 (q, J = 7 Hz, 2 H), 3.15 (m, 1 H), 2.51 (m, 4 H), 2.47 (m, 2 H), 2.45 (s, 3 H), 2.30 (m, 1 H), 2.12 (m, 2 H), 1.85 (m, 1 H), 1.63 (m, 2 H), 1.10 (t, J = 7 Hz, 3 H).

EXAMPLE 9: Methyl (2S)-5-oxo-5-[4-(2-pyridylmethyl)piperazin-1-yl]-2-[[1-tosyl-L-prolyl]amino]pentanoate

Starting compounds: reference examples 49 and 11; 58% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 8.57 (m, 1 H), 7.74 (d, J = 8.2 Hz, 2 H), 7.65 (m, 1 H), 7.55 (d, J = 7.5 Hz, 1 H), 7.39 (m, 1 H), 7.35 (d, J = 8.2 Hz, 2 H), 7.17 (m, 1 H), 4.53 (m, 1 H), 4.08 (m, 1 H), 3.76 (s, 3 H), 3.66 (m, 2 H), 3.63 (s, 2 H), 3.53 (m, 1 H), 3.48 (m, 2 H), 3.18 (m, 1 H), 2.49 (m, 4 H), 2.46 (m, 2 H), 2.44 (s, 3 H), 2.25 (m, 1 H), 2.20 (m, 1 H), 2.10 (m, 2 H), 1.92 (m, 1 H), 1.65 (m, 1 H).

EXAMPLE 10: Methyl (2S)-5-oxo-5-[4-(1-oxoisindolin-2-ylmethyl)piperidin-1-yl]-2-[[1-tosyl-L-prolyl]amino]pentanoate

Starting compounds: reference examples 49 and 4; 56% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.83 (d, J = 7.9 Hz, 1 H), 7.74 (d, J = 8.2 Hz, 2 H), 7.51 (m, 4 H), 7.34 (d, J = 8.2 Hz, 2 H), 4.54 (m, 2 H), 4.39 (m, 2 H), 4.07 (m, 1 H), 3.82 (m, 1 H), 3.76 (s, 3 H), 3.53 (m, 2 H), 3.46 (m, 1 H), 3.16 (m, 1 H), 3.01 (m, 1 H), 2.63 (m, 1 H), 2.44 (s, 3 H), 2.39 (m, 3 H), 2.13 (m, 3 H), 1.65-1.95 (complex signal, 5 H), 1.25 (m, 2 H).

EXAMPLE 11: Methyl (2S)-5-oxo-5-[4-(2-thienylmethyl)piperazin-1-yl]-2-[[1-tosyl-L-prolyl]amino]pentanoate

Starting compounds: reference examples 49 and 12; 38% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.73 (d, J = 8.2 Hz, 2 H), 7.54 (d, J = 7.5 Hz, 1 H), 7.34 (d, J = 8.2 Hz, 2 H), 7.22 (m, 1 H), 6.93 (m, 2 H), 4.54 (m, 1 H), 4.07 (m, 1 H), 3.76 (s, 3 H), 3.71 (s, 2 H), 3.61 (m, 2 H), 3.52 (m, 1 H), 3.46 (m, 2 H), 3.17 (m, 1 H), 2.40 (m, 5 H), 2.29 (m, 1 H), 2.44 (s, 3 H), 2.13 (m, 2 H), 1.83 (m, 1 H), 1.62 (m, 3 H).

EXAMPLE 12: Methyl (2S)-5-[4-[(2,5-dioxopyrrolidin-1-yl)methyl]piperidin-1-yl]-5-oxo-2-[[1-tosyl-L-prolyl]amino]pentanoate

Starting compounds: reference examples 49 and 5; 33% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.75 (d, J = 8.2 Hz, 2 H), 7.58 (m, 1 H), 7.34 (d, J = 8.2 Hz, 2 H), 4.54 (m, 2 H), 4.07 (d, J = 7.9 Hz, 1 H), 3.84 (m, 1 H), 3.76 (s, 3 H), 3.54 (m, 1 H), 3.41 (m, 2 H), 3.17 (m, 1 H), 2.93 (m, 1 H), 2.71 (m, 4 H), 2.54 (m, 1 H), 2.44 (s, 3 H), 2.42 (m, 1 H), 2.32 (m, 1 H), 2.17 (m, 3 H), 2.10 (m, 2 H), 1.6-1.9 (complex signal, 4 H), 1.16 (m, 2 H).

EXAMPLE 13: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(3-methylbutanoylamino)methyl]piperidin-1-yl]-5-oxopentanoate

Starting compounds: reference examples 48 and 14; 68% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.76 (s, 2 H), 7.70 (m, 1 H), 7.60 (s, 1 H), 5.55 (m, 1 H), 4.65 (m, 1 H), 4.51 (m, 1 H), 4.12 (m, 1 H), 3.82 (m, 1 H), 3.76 (s, 3 H), 3.62 (m, 1 H), 3.18 (m, 3 H), 2.40 (m, 3 H), 1.7-2.30 (m, 10 H), 1.58 (m, 3 H), 1.15 (m, 2 H), 0.93 (d, J = 6.2 Hz, 6 H).

EXAMPLE 14: Methyl (2S)-5-[4-[(N'-tert-butylureido)methyl]piperidin-1-yl]-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxopentanoate

Starting compounds: reference examples 48 and 15; 48% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.77 (s, 2 H), 7.72 (m, 1 H), 7.61 (s, 1 H), 4.65 (m, 1 H), 4.55 (m, 1 H), 4.50 (m, 1 H), 4.13 (m, 2 H), 3.81 (m, 1 H), 3.76 (s, 3 H), 3.65 (m, 1 H), 3.18 (m, 4 H), 1.55-2.60 (m, 12 H), 1.31 (s, 9 H), 1.20 (m, 2 H).

EXAMPLE 15: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(isobutoxycarbonylamino)methyl]piperidin-1-yl]-5-oxopentanoate

Starting compounds: reference examples 48 and 16; 24% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.77 (s, 2 H), 7.71 (m, 1 H), 7.59 (s, 1 H), 4.75 (m, 1 H), 4.62 (m, 1 H), 4.49 (m, 1 H), 4.12 (m, 1 H), 3.82 (m, 3 H), 3.76 (s, 3 H), 3.59 (m, 1 H), 3.26 (m, 1 H), 3.02 (m, 3 H), 2.46 (m, 3 H), 2.14 (m, 3 H), 1.65-1.95 (broad m, 7 H), 1.16 (m, 2 H), 0.91 (d, J = 6.7 Hz, 6 H).

EXAMPLE 16: Methyl (2S)-5-oxo-2-[1-tosyl-L-prolyl]amino-5-[4-[[4-(trifluoromethyl)pyrimidin-2-yl]aminomethyl]piperidin-1-yl]pentanoate

Starting compounds: reference examples 49 and 26; 33% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 8.43 (m, 1 H), 7.73 (d, J = 8.0 Hz, 2 H), 7.56 (m, 1 H), 7.32 (d, J = 8.0 Hz, 2 H), 6.79 (m, 1 H), 5.64 (m, 1 H), 4.52 (m, 2 H), 4.06 (m, 1 H), 3.82 (m, 1 H), 3.74 (s, 3 H), 3.51 (m, 1 H), 3.35 (m, 2 H), 3.15 (m, 1 H), 2.98 (m, 1 H), 2.42 (s, 3 H), 1.9-2.6 (complex signal, 6 H), 1.76 (m, 4 H), 1.58 (m, 2 H), 1.21 (m, 2 H).

EXAMPLE 17

Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(isopropylsulfonylamino)methyl]piperidin-1-yl]-5-oxopentanoate

a) Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-(2,5-dioxopyrrolidinylloxy)-5-oxopentanoate

To a solution of 1-methyl N-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]-L-glutamate (obtained in reference example 48) (0.56 g, 1.2 mmol), and NHS (0.14 g, 1.2 mmol) in CHCl₃ (25 mL), cooled to 0 °C and under argon atmosphere, DCC (0.25 g, 1.2 mmol) was added, and the resulting mixture was stirred overnight at room temperature. The solid obtained was filtered off and the solution was concentrated to dryness. A crude product was obtained, which was directly used in the following step.

b) Title compound

In this second step, methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-(2,5-dioxopyrrolidinylloxy)-5-oxopentanoate (obtained in the preceding section) (0.67 g, 1.2 mmol) was dissolved in CHCl₃ (25 mL). TEA (0.7 mL, 5 mmol) was added, and then the amine obtained in reference example 17 (0.31 g, 1.2 mmol) was added slowly and portionwise. The solution was stirred overnight at room temperature. The product was partitioned between CHCl₃ and 0.2 M NaHCO₃. The crude product obtained was purified by chromatography on silica gel using a CHCl₃:MeOH 2% mixture as eluent. 0.78 g of the title compound of the example was obtained (97% yield).

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.77 (s, 2 H), 7.70 (m, 1 H), 7.59 (s, 1 H), 4.68 (m, 1 H), 4.51 (m, 1 H), 4.22 (m, 0.5 H), 4.10 (m, 1.5 H), 3.85 (m, 1 H), 3.76

(s, 3 H), 3.62 (m, 1 H), 3.18 (m, 2 H), 3.01 (m, 3 H), 2.48 (m, 3 H), 2.13 (m, 3 H), 1.92 (m, 1 H), 1.76 (m, 5 H), 1.35 (d, J = 6.8 Hz, 6 H), 1.16 (m, 2 H).

Following a similar procedure to that described in example 17, but using in each case a suitable acid and amine, in the first and second step, respectively, the following compounds were obtained:

EXAMPLE 18: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(N'-isopropylthioureido)methyl]piperidin-1-yl]-5-oxopentanoate

Compounds used: reference examples 48 and 18; 55% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.83 (s, 2 H), 7.76 (m, 1 H), 7.68 (s, 1 H), 5.85 (broad s, 0.5 H), 5.75 (broad s, 1.5 H), 4.74 (m, 1 H), 4.62 (m, 0.5 H), 4.50 (m, 0.5 H), 4.20 (m, 2 H), 3.95 (m, 1 H), 3.85 (s, 1.5 H), 3.83 (s, 1.5 H), 3.72 (m, 0.5 H), 3.62 (m, 0.5 H), 3.51 (m, 2 H), 3.31 (m, 1 H), 3.08 (m, 1 H), 2.55 (m, 3 H), 2.28 (m, 2 H), 2.05 (m, 3 H), 1.88 (m, 4 H), 1.30 (m, 8 H).

EXAMPLE 19: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)ethyl]piperidin-1-yl]-5-oxopentanoate

Compounds used: reference examples 48 and 28; 57% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.77 (s, 2 H), 7.71 (m, 1 H), 7.59 (s, 1 H), 6.83 (s, 1 H), 4.59 (m, 1 H), 4.48 (m, 1 H), 4.23 (m, 2 H), 4.12 (m, 1 H), 3.80 (m, 1 H), 3.76 (s, 3 H), 3.60 (m, 1 H), 3.22 (m, 1 H), 2.91 (m, 3 H), 2.59 (s, 3 H), 2.53 (s, 3 H), 2.45 (m, 3 H), 2.14 (m, 3 H), 1.7-1.95 (m, 8 H), 1.42 (t, J = 6.8 Hz, 3 H), 1.25 (m, 2 H).

EXAMPLE 20: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-[2-(pyrrolidin-1-ylcarbonyloxy)ethyl]piperidin-1-yl]pentanoate

Compounds used: reference examples 48 and 25; 76% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.77 (s, 2 H), 7.71 (m, 1 H), 7.59 (s, 1 H), 4.57 (m, 1 H), 4.48 (m, 1 H), 4.10 (m, 3 H), 3.80 (m, 1 H), 3.75 (s, 3 H), 3.59 (m, 1 H), 3.30 (m, 5 H), 2.98 (m, 1 H), 2.47 (m, 3 H), 2.15 (m, 3 H), 1.85 (m, 9 H), 1.72 (m, 3 H), 1.13 (m, 2 H).

EXAMPLE 21: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(4-methylpiperazin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoate

Compounds used: reference examples 48 and 27; 76% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.77 (s, 2 H), 7.73 (m, 1 H), 7.71 (s, 1 H), 4.61 (m, 1 H), 4.48 (m, 1 H), 4.14 (m, 1 H), 3.82 (m, 1 H), 3.75 (s, 3 H), 3.58 (m, 1 H), 3.24 (m, 1 H), 2.97 (m, 1 H), 2.42 (m, 11 H), 2.27 (s, 3 H), 2.16 (m, 5 H), 1.82 (m, 6 H), 1.09 (m, 2 H).

5 **EXAMPLE 22: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(4-morpholinyl)ethyl]piperidin-1-yl]-5-oxopentanoate**

Compounds used: reference examples 48 and 29; 88% yield.

10 ¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.83 (s, 2 H), 7.78 (m, 1 H), 7.66 (s, 1 H), 4.64 (m, 1 H), 4.52 (m, 1 H), 4.19 (m, 1 H), 3.87 (m, 1 H), 3.76 (s, 3 H), 3.67 (m, 4 H), 3.62 (m, 1 H), 3.30 (m, 1 H), 3.03 (m, 1 H), 2.50 (m, 8 H), 2.26 (m, 3 H), 1.8-2 (m, 6 H), 1.55 (m, 2 H), 1.20 (m, 3 H).

EXAMPLE 23: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[[dimethylaminoacetyl]amino]methyl]piperidin-1-yl]-5-oxopentanoate

Compounds used: reference examples 48 and 30; 10% yield.

15 ¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.76 (s, 2 H), 7.70 (m, 1 H), 7.60 (s, 1 H), 7.32 (m, 1 H), 4.66 (m, 1 H), 4.48 (m, 1 H), 4.13 (m, 1 H), 3.80 (m, 1 H), 3.76 (s, 3 H), 3.60 (m, 1 H), 3.20 (m, 3 H), 2.97 (m, 1 H), 2.95 (s, 2 H), 2.55 (m, 1 H), 2.43 (m, 2 H), 2.29 (s, 6 H), 2.20 (m, 2 H), 1.88 (m, 5 H), 1.60 (m, 2 H), 1.16 (m, 2 H).

20 **EXAMPLE 24: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(diethylamino)ethyl]piperidin-1-yl]-5-oxopentanoate**

Compounds used: reference examples 48 and 33; 59% yield.

25 ¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.76 (s, 2 H), 7.72 (d, J = 7.1 Hz, 1 H), 7.59 (s, 1 H), 4.55 (m, 1 H), 4.48 (m, 1 H), 4.14 (m, 1 H), 3.80 (m, 1 H), 3.75 (s, 3 H), 3.58 (m, 1 H), 3.25 (m, 1 H), 2.97 (m, 1 H), 2.49 (m, 10 H), 2.15 (m, 3 H), 1.74 (m, 4 H), 1.41 (m, 3 H), 1.10 (m, 2 H), 0.99 (m, 6 H).

EXAMPLE 25: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-[2-(1-pyrrolidinyl)ethyl]piperidin-1-yl]pentanoate

Compounds used: reference examples 48 and 34; 79% yield.

30 ¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.77 (s, 2 H), 7.74 (d, J = 7.1 Hz, 1 H), 7.58 (s, 1 H), 4.55 (m, 1 H), 4.48 (m, 1 H), 4.14 (m, 1 H), 3.79 (m, 1 H), 3.75 (s, 3 H), 3.58 (m, 1 H), 3.24 (s, 1 H), 2.97 (m, 1 H), 2.48 (m, 9 H), 2.16 (m, 4 H), 1.82 (m, 8 H), 1.44 (m, 3 H), 1.10 (m, 2 H).

EXAMPLE 26: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-[(4-methylpiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-yl]-5-oxopentanoate

Compounds used: reference examples 48 and 35.

5 Obtained as a crude product.

EXAMPLE 27: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-[(2-methoxyethyl)aminocarbonyloxy]ethyl]piperidin-1-yl]-5-oxopentanoate

Compounds used: reference examples 48 and 36; 47% yield.

10 ¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.77 (s, 2 H), 7.71 (m, 1 H), 7.59 (s, 1 H), 4.99 (m, 1 H), 4.58 (m, 1 H), 4.40 (m, 1 H), 4.10 (m, 3 H), 3.79 (m, 1 H), 3.75 (s, 3 H), 3.60 (m, 1 H), 3.47 (m, 2 H), 3.38 (s, 3 H), 3.18 (s, 1 H), 2.98 (m, 1 H), 2.48 (m, 3 H), 2.16 (m, 4 H), 1.90 (m, 1 H), 1.75 (m, 6 H), 1.54 (m, 2 H), 1.15 (m, 2 H).

EXAMPLE 28: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(4-morpholinylcarbonylaminomethyl)piperidin-1-yl]-5-oxopentanoate

15

Compounds used: reference examples 48 and 38; 72% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.76 (s, 2 H), 7.68 (m, 1 H), 7.60 (s, 1 H), 4.62 (m, 2 H), 4.49 (m, 1 H), 4.11 (m, 1 H), 3.80 (m, 1 H), 3.78 (s, 3 H), 3.68 (m, 4 H), 3.66 (m, 1 H), 3.34 (m, 4 H), 3.23 (m, 3 H), 3.00 (m, 1 H), 2.44 (m, 3 H), 2.15 (m, 3 H), 1.80 (m, 6 H), 1.16 (m, 2 H).

20

EXAMPLE 29: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-pyrrolidinylcarbonylaminomethyl)piperidin-1-yl]pentanoate

Compounds used: reference examples 48 and 37; 78% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.77 (s, 2 H), 7.71 (m, 1 H), 7.60 (s, 1 H), 4.63 (m, 1 H), 4.48 (m, 1 H), 4.29 (m, 1 H), 4.13 (m, 1 H), 3.80 (m, 1 H), 3.76 (s, 3 H), 3.61 (m, 1 H), 3.31 (m, 4 H), 3.29 (m, 1 H), 3.14 (m, 2 H), 2.99 (m, 1 H), 2.47 (m, 2 H), 2.15 (m, 2 H), 1.89 (m, 6 H), 1.78 (m, 4 H), 1.52 (m, 2 H), 1.12 (m, 2 H).

EXAMPLE 30: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-piperidylmethyl)piperidin-1-yl]pentanoate

30 Compounds used: reference examples 48 and 39; 65% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.78 (s, 2 H), 7.72 (m, 1 H), 7.59 (s, 1 H), 4.56 (m, 1 H), 4.46 (m, 1 H), 4.14 (m, 1 H), 3.81 (m, 1 H), 3.75 (s, 3 H), 3.58 (m, 1

H), 3.24 (m, 1 H), 2.97 (m, 1 H), 2.48 (m, 3 H), 2.20 (m, 4 H), 2.11 (m, 4 H), 1.82 (m, 7 H), 1.56 (m, 4 H), 1.42 (m, 2 H), 1.05 (m, 2 H).

EXAMPLE 31: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[[N-ethyl-N-(trifluoroacetyl)amino]methyl]piperidin-1-yl]-5-oxopentanoate

5 Compounds used: reference examples 48 and 40; 67% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.76 (s, 2 H), 7.68 (m, 1 H), 7.59 (s, 1 H), 4.70 (m, 1 H), 4.48 (m, 1 H), 4.12 (m, 1 H), 3.80 (m, 1 H), 3.75 (s, 3 H), 3.56 (m, 1 H), 3.44 (m, 2 H), 3.31 (m, 1 H), 3.23 (m, 2 H), 2.95 (m, 1 H) 2.48 (m, 3 H), 2.15 (m, 3 H), 1.89 (m, 4 H), 1.66 (m, 2 H), 1.16 (m, 5 H).

10 **EXAMPLE 32: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[[4-methylpiperazin-1-yl]carbonylamino]methyl]piperidin-1-yl]-5-oxopentanoate**

Compounds used: reference examples 48 and 41.

Obtained as a crude product.

15 **EXAMPLE 33: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(4-pyridylaminomethyl)piperidin-1-yl]pentanoate**

Compounds used: reference examples 48 and 42; 52% yield.

20 ¹H NMR (300 MHz, CDCl₃) δ (TMS): 8.17 (d, J = 5.8 Hz, 2 H), 7.76 (s, 2 H), 7.66 (m, 1 H), 7.60 (m, 1 H), 6.42 (d, J = 5.8 Hz, 2 H), 4.65 (m, 1 H), 4.45 (m, 1 H), 4.30 (m, 0.5 H), 4.25 (m, 0.5 H), 4.08 (m, 1 H), 3.87 (m, 1 H), 3.76 (s, 3 H), 3.57 (m, 1 H), 3.20 (m, 1 H), 3.05 (m, 3 H), 2.48 (m, 3 H), 2.20 (m, 3 H), 1.80 (m, 6 H), 1.22 (m, 2 H).

EXAMPLE 34: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(N-ethyl-N-isobutoxycarbonylamino)methyl]piperidin-1-yl]-5-

25 **oxopentanoate**

Compounds used: reference examples 48 and 43; 29% yield.

30 ¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.77 (s, 2 H), 7.72 (m, 1 H), 7.59 (s, 1 H), 4.61 (m, 1 H), 4.49 (m, 1 H), 4.13 (m, 1 H), 4.00 (m, 1 H), 3.83 (m, 2 H), 3.79 (s, 3 H), 3.59 (m, 1 H), 3.23 (m, 2 H), 3.08 (m, 1 H), 2.99 (m, 1 H), 2.46 (m, 2 H), 2.18 (m, 2 H), 1.92 (m, 4 H), 1.70 (m, 3 H), 1.35 (m, 2 H), 1.15 (m, 5 H), 0.93 (d, J = 6.5 Hz, 6 H).

Following a similar procedure to that described in section a of reference example 51, but starting in each case from a suitable acid and amine, and adding TEA to the reaction medium the following compounds were obtained:

EXAMPLE 35: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-methylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoate

Starting compounds: reference examples 47 and 51; 50% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 8.96 (s, 1 H), 8.33 (m, 1 H), 7.78 (s, 2 H 50%), 7.75 (s, 2 H 50%), 7.61 (s, 1 H), 7.58 (m, 1 H), 7.20 (m, 1 H), 4.71 (m, 1 H), 4.54 (m, 1 H), 4.11 (m, 1 H), 3.98 (m, 2 H), 3.81 (m, 1 H), 3.75 (s, 3 H 50%), 3.74 (s, 3 H 50%), 3.52 (m, 1 H), 3.22 (m, 1 H), 2.95 (m, 1 H), 2.62 (s, 3 H 50%), 2.58 (s, 3 H 50%), 2.44 (m, 2 H), 1.60-2.30 (complex signal, 6 H), 1.55 (m, 4 H), 1.25 (m, 2 H).

EXAMPLE 36: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-pyrrolylmethyl)piperidin-1-yl]pentanoate

Starting compounds: reference examples 48 and 19; 29% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.76 (s, 2 H), 7.67 (m, 1 H), 7.60 (s, 1 H), 6.59 (m, 2 H), 6.13 (m, 2 H), 4.66 (m, 1 H), 4.48 (m, 1 H), 4.12 (m, 1 H), 4.00 (m, 1 H), 3.75 (s, 3 H), 3.71 (m, 2 H), 3.55 (m, 1 H), 3.48 (m, 1 H), 3.23 (m, 1 H), 2.98 (m, 1 H), 2.45 (m, 2 H), 2.22 (m, 1 H), 2.18 (m, 2 H), 1.99 (m, 3 H), 1.57 (m, 3 H), 1.20 (m, 2 H).

EXAMPLE 37: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2,5-dimethylpyrrol-1-ylmethyl)piperidin-1-yl]-5-oxopentanoate

Starting compounds: reference examples 48 and 20.

Obtained as a crude product.

EXAMPLE 38: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(dimethylaminomethyl)piperidin-1-yl]-5-oxopentanoate

Starting compounds: reference examples 48 and 21; 54% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.78 (s, 2 H), 7.72 (d, J = 7.2 Hz, 1 H), 7.59 (s, 1 H), 4.58 (m, 1 H), 4.48 (m, 1 H), 4.15 (m, 1 H), 3.78 (m, 1 H), 3.75 (s, 3 H), 3.58 (m, 1 H), 3.26 (m, 1 H), 2.98 (m, 1 H), 2.55 (m, 1 H), 2.45 (m, 2 H), 2.16 (s, 6 H), 2.12 (m, 4 H), 1.92 (m, 3 H), 1.73 (m, 2 H), 1.65 (m, 2 H); 1.10 (m, 2 H).

EXAMPLE 39: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-oxopentanoate

Starting compounds: reference examples 48 and 22; 38% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.77 (s, 2 H), 7.64 (d, J = 7.2 Hz, 1 H), 7.59 (s, 1 H), 4.49 (m, 1 H), 4.15 (m, 1 H), 3.76 (s, 3 H), 3.60 (m, 3 H), 3.41 (m, 2 H), 3.26 (m, 1 H), 2.47 (m, 10 H), 2.30 (s, 6 H), 2.15 (m, 1 H), 2.05 (m, 2 H), 1.95 (m, 2 H), 1.80 (m, 1 H).

EXAMPLE 40: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-ethylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoate

Starting compounds: reference examples 48 and 23; 62% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 8.96 (s, 1 H), 8.28 (m, 1 H), 7.73 (s, 1 H), 7.71 (s, 1 H), 7.67 (d, J = 7.1 Hz, 1 H), 7.56 (s, 1 H), 7.19 (m, 1 H), 4.66 (broad d, J = 13 Hz, 1 H), 4.50 (m, 1 H), 4.08 (m, 1 H), 3.94 (m, 2 H), 3.80 (broad d, J = 13 Hz, 1 H), 3.72 (s, 1.5 H), 3.70 (s, 1.5 H), 3.56 (m, 1 H), 3.40 (m, 1 H), 3.15 (m, 1 H), 2.86 (m, 2 H), 2.40 (m, 3 H), 2.25 (m, 1 H), 2.00 (m, 4 H), 1.90 (m, 2 H), 1.57 (m, 2 H), 1.42 (q, J = 7.1 Hz, 3 H), 1.27 (m, 2 H).

EXAMPLE 41: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(2-oxo-2,3-dihydroimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]pentanoate

Starting compounds: reference examples 48 and 24; 33% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 8.39 (s, 1 H), 8.28 (d, J = 5 Hz, 1 H), 7.88 (m, 1 H), 7.77 (s, 2 H), 7.58 (s, 1 H), 7.30 (m, 1 H), 6.96 (m, 1 H), 4.65 (m, 1 H), 4.52 (m, 1 H), 4.16 (m, 1 H), 3.80 (m, 1 H), 3.75 (s, 3 H), 3.73 (m, 2 H), 3.57 (m, 1 H), 3.16 (m, 1 H), 2.97 (m, 1 H), 2.48 (m, 3 H), 2.26 (m, 1 H), 2.13 (m, 3 H), 1.92 (m, 2 H), 1.74 (m, 3 H), 1.30 (m, 2 H).

EXAMPLE 42: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-isopropylaminoimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoate

Starting compounds: reference examples 48 and 31; 43% yield.

Obtained as a crude product.

EXAMPLE 43: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(diethylaminomethyl)piperidin-1-yl]-5-oxopentanoate

Starting compounds: reference examples 48 and 32; 38% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.88 (m, 1 H); 7.67 (s, 2 H), 7.48 (s, 1 H), 4.40 (m, 2 H), 4.13 (m, 1 H), 3.68 (m, 1 H), 3.61 (s, 3 H), 3.44 (m, 1 H), 3.13 (m, 1

H), 2.74 (m, 5 H), 2.42 (m, 5 H), 2.10 (m, 1 H), 2.03 (m, 2 H), 1.68 (m, 6 H), 1.00 (m, 8 H).

EXAMPLE 44

Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-(2-methylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-ylcarbonyl]amino]propionate

To a solution of 2-methyl-1-(4-piperidylmethyl)imidazo[4,5-c]pyridine (obtained in reference example 8) (0.4 g, 1.74 mmol) and DIEA (0.37 mL, 2.12 mmol) in CHCl_3 (13 mL), triphosgene (0.182 g, 0.613 mmol) was slowly added under argon atmosphere, and the resulting mixture was stirred at room temperature for 30 min. Next, methyl (2S)-3-amino-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]aminopropionate hydrochloride (obtained in reference example 52) (0.8 g, 1.74 mmol) and DIEA (1.12 mL, 6.43 mmol) were added and the reaction mixture was stirred overnight at room temperature. It was cooled to 0 °C and treated with 0.2 M NaHCO_3 solution. The phases were separated, the organic phase was dried over sodium sulfate and concentrated to dryness. The crude product obtained was purified by chromatography on silica gel using $\text{CHCl}_3/\text{MeOH}$ mixtures of increasing polarity as eluent. 340 mg of the title compound of the example was obtained (29% yield).

^1H NMR (300 MHz, CDCl_3) δ (TMS): 9.00 (s, 1 H), 8.39 (d, $J = 5.6$ Hz, 1 H), 7.80 (s, 2 H), 7.74 (m, 1 H), 7.65 (m, 1 H), 7.25 (d, $J = 5.6$ Hz, 1 H), 5.20 (m, 1 H), 4.56 (m, 1 H), 4.12 (m, 1 H), 4.06 (m, 2 H), 3.80 (m, 2 H), 3.71 (s, 3 H), 3.66 (m, 2 H), 3.26 (s, 1 H), 2.75 (m, 2 H), 2.65 (s, 3 H), 2.07 (m, 1 H), 2.00 (m, 2 H), 1.81 (m, 3 H), 1.59 (m, 2 H), 1.28 (m, 2 H).

Following a similar procedure to that described in example 44, but using in each case suitable amines, the following compounds were obtained:

EXAMPLE 45: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-(dimethylaminomethyl)piperidin-1-ylcarbonyl]amino]propionate

Compounds used: reference examples 52 and 21; 15% yield.

^1H NMR (300 MHz, CDCl_3) δ (TMS): 7.92 (d, $J = 6.9$ Hz, 1 H), 7.75 (s, 2 H), 7.57 (s, 1 H), 5.18 (m, 1 H), 4.49 (m, 1 H), 4.13 (m, 1 H), 3.90 (m, 2 H), 3.74 (s, 3 H), 3.67 (m, 1 H), 3.60 (m, 2 H), 3.20 (m, 1 H), 2.97 (m, 2 H), 2.18 (s, 3 H), 2.12 (s, 3

H), 2.08 (m, 2 H), 1.93 (m, 4 H), 1.72 (broad d, J = 11.4 Hz, 2 H), 1.65 (m, 1 H), 1.07 (m, 2 H).

EXAMPLE 46: Methyl (2S)-3-[[4-(1-piperidylmethyl)piperidin-1-yl]carbonyl]amino]-2-[N-tosyl-L-prolyl]aminopropionate

5 Compounds used: reference examples 39 and 54; 48% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.73 (d, J = 8.3 Hz, 2 H), 7.67 (m, 1 H), 7.33 (d, J = 8.3 Hz, 2 H), 5.21 (m, 1 H), 4.54 (m, 1 H), 4.05 (m, 1 H), 3.91 (m, 2 H), 3.77 (s, 3 H), 3.75 (m, 1 H), 3.65 (m, 2 H), 3.15 (m, 1 H), 2.72 (m, 2 H), 2.43 (s, 3 H), 2.28 (m, 4 H), 2.09 (m, 3 H), 1.95 (m, 1 H), 1.73 (m, 2 H), 1.62 (m, 2 H), 1.58
10 (m, 4 H), 1.50 (m, 2 H), 1.38 (m, 3 H).

EXAMPLE 47

Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[4-(dimethylaminomethyl)piperidin-1-yl]carbonyloxy]propionate

To a solution of N-(3,5-dichlorophenylsulfonyl)-L-proline (obtained in
15 reference example 47) (67 mg, 0.2 mmol) in CHCl₃ (5 mL), EDC·HCl (40 mg, 0.2 mmol), NHS (23 mg, 0.2 mmol) and NMM (0.1 mL, 0.9 mmol) were added under argon atmosphere, and the resulting mixture was stirred at room temperature for 4 h. Next, methyl (2S)-2-amino-3-[4-(dimethylaminomethyl)piperidin-1-yl]carbonyloxy]propionate dihydrochloride (obtained in reference example 53) (72
20 mg, 0.2 mmol) dissolved in CHCl₃ (3 mL) and NMM (0.25 mL, 2.3 mmol) were added, and the mixture was further stirred overnight. It was treated with saturated NaHCO₃ solution and extracted 3 times with CHCl₃. The combined organic phases were dried over sodium sulfate and concentrated to dryness, to afford a crude product which was purified by chromatography on silica gel using a
25 CHCl₃/MeOH/NH₃ 60:2:0.1 mixture as eluent. 56 mg of the title compound of the example was obtained (47% yield).

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.75 (s, 2 H), 7.61 (m, 2 H), 4.73 (m, 1 H), 4.46 (m, 2 H), 4.12 (m, 2 H), 4.00 (m, 1 H), 3.79 (s, 3 H), 3.57 (m, 1 H), 3.21 (m, 1 H), 2.76 (m, 2 H), 2.27 (m, 2 H), 2.16 (s, 6 H), 2.08 (m, 2 H), 1.85 (m, 2 H), 1.75
30 (m, 2 H), 1.65 (m, 1 H), 1.04 (m, 2 H).

Following a similar procedure to that described in example 47, but starting in each case from the suitable acid and amine, the following compounds were obtained:

EXAMPLE 48: Methyl (2S)-5-[4-[2-[(4-methylpiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoate

Starting compounds: reference examples 49 and 35; 38% yield.

- 5 ^1H NMR (300 MHz, CDCl_3) δ (TMS): 7.75 (d, $J = 8.1$ Hz, 2 H), 7.59 (d, $J = 7.7$ Hz, 1 H), 7.34 (d, $J = 8.1$ Hz, 2 H), 4.55 (m, 2 H), 4.11 (m, 3 H), 3.80 (m, 1 H), 3.75 (s, 3 H), 3.55 (m, 1 H), 3.47 (m, 4 H), 3.25 (m, 1 H), 2.90 (m, 1 H), 2.49 (m, 1 H), 2.46 (s, 3 H), 2.40 (m, 4 H), 2.34 (m, 4 H), 2.10 (m, 2 H), 1.60 (m, 10 H), 1.10 (m, 2 H).

EXAMPLE 49: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-5-

- 10 **[4-[(diethylaminocarbonyloxy)methyl]piperidin-1-yl]-5-oxopentanoate**

Starting compounds: reference examples 48 and 44; 50% yield.

- ^1H NMR (300 MHz, CDCl_3) δ (TMS): 7.78 (s, 2 H), 7.73 (m, 1 H), 7.61 (s, 1 H), 4.66 (m, 1 H), 4.50 (m, 1 H), 4.14 (m, 1 H), 3.94 (m, 2 H), 3.90 (m, 1 H), 3.77 (s, 3 H), 3.60 (m, 1 H), 3.24 (m, 5 H), 3.02 (m, 1 H), 2.51 (m, 1 H), 2.47 (m, 2 H), 2.22 (m, 1 H), 2.17 (m, 2 H), 1.90 (m, 6 H), 1.20 (m, 2 H), 1.12 (m, 6 H).

EXAMPLE 50: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(4-methylpiperazin-1-yl)carbonyloxymethyl]piperidin-1-yl]-5-oxopentanoate

Starting compounds: reference examples 48 and 45; 75% yield.

- 20 ^1H NMR (300 MHz, CDCl_3) δ (TMS): 7.77 (s, 2 H), 7.67 (m, 1 H), 7.60 (s, 1 H), 4.63 (m, 1 H), 4.51 (m, 1 H), 4.13 (m, 1 H), 3.96 (m, 2 H), 3.81 (m, 1 H), 3.78 (s, 3 H), 3.60 (m, 1 H), 3.48 (m, 4 H), 3.24 (m, 1 H), 2.98 (m, 1 H), 2.48 (m, 1 H), 2.46 (m, 1 H), 2.42 (m, 2 H), 2.35 (m, 4 H), 2.30 (s, 3 H), 2.16 (m, 2 H), 1.92 (m, 2 H), 1.81 (m, 4 H), 1.21 (m, 2 H).

- 25 **EXAMPLE 51: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(4-pyridyloxymethyl)piperidin-1-yl]pentanoate**

Starting compounds: reference examples 48 and 46; 85% yield.

- 30 ^1H NMR (300 MHz, CDCl_3) δ (TMS): 8.41 (d, $J = 5.1$ Hz, 2 H), 7.76 (s, 2 H), 7.59 (s, 1 H), 7.46 (m, 1 H), 6.77 (d, $J = 5.1$ Hz, 2 H), 4.69 (m, 1 H), 4.51 (m, 1 H), 4.13 (m, 1 H), 3.86 (m, 3 H), 3.76 (s, 3 H), 3.58 (m, 1 H), 3.15 (m, 1 H), 3.05 (m, 1 H), 2.51 (m, 1 H), 2.49 (m, 2 H), 2.30 (m, 1 H), 2.18 (m, 2 H), 2.00 (m, 1 H), 1.90 (m, 5 H), 1.30 (m, 2 H).

EXAMPLE 52: Methyl (2S)-5-[4-(4-methylpiperazin-1-ylmethyl)piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoate

Starting compounds: reference examples 49 and 27; 33% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.75 (d, J = 8.3 Hz, 2 H), 7.60 (m, 1 H), 7.34 (d, J = 8.3 Hz, 2 H), 4.54 (m, 2 H), 4.09 (m, 1 H), 3.82 (m, 1 H), 3.79 (s, 3 H), 3.55 (m, 1 H), 3.19 (m, 1 H), 3.00 (m, 1 H), 2.48 (m, 12 H), 2.44 (s, 3 H), 2.27 (s, 3 H), 2.11 (m, 4 H), 1.82 (m, 2 H), 1.60 (m, 4 H), 1.25 (m, 2 H).

EXAMPLE 53: Methyl (2S)-5-[4-(dimethylaminomethyl)piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoate

Starting compounds: reference examples 49 and 21; 40% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.78 (d, J = 8.3 Hz, 2 H), 7.65 (m, 1 H), 7.38 (d, J = 8.3 Hz, 2 H), 4.62 (m, 2 H), 4.13 (m, 1 H), 3.87 (m, 1 H), 3.80 (s, 3 H), 3.58 (m, 1 H), 3.22 (m, 1 H), 3.01 (m, 1 H), 2.48 (m, 2 H), 2.44 (s, 3 H), 2.30 (m, 1 H), 2.22 (s, 6 H), 2.15 (m, 3 H), 2.11 (m, 2 H), 1.85 (m, 2 H), 1.65 (m, 4 H), 1.15 (m, 2 H).

EXAMPLE 54

(2S)-5-[4-[(1-Oxoisoindolin-2-yl)methyl]piperidin-1-yl]-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxopentanoic acid

To a solution of methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-oxoisoindolin-2-ylmethyl)piperidin-1-yl]pentanoate (obtained in example 3) (300 mg, 0.47 mmol) in THF (8 mL), LiOH.H₂O (45 mg, 1.07 mmol) dissolved in H₂O (8 mL) was added. The reaction mixture was stirred overnight at room temperature and THF was evaporated. The resulting residue was cooled to 0 °C and was acidified by adding 1 N HCl until reaching the maximal turbidity the solution. The solid obtained was collected by filtration and dried. The title compound of the example was obtained as a white solid (763 mg, 79% yield).

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.86 (s, 2 H), 7.76 (m, 2 H), 7.54 (m, 3 H), 4.84 (s, 2 H), 4.51 (s, 2 H), 4.47 (m, 2 H), 4.22 (m, 1 H), 3.98 (m, 1 H), 3.53 (m, 3 H), 3.29 (m, 1 H), 3.04 (m, 1 H), 2.61 (m, 3 H), 2.30 (m, 1 H), 1.90-2.10 (complex signal, 5 H), 1.69 (m, 3 H), 1.20 (m, 2 H).

MS: m/z 665 (MH⁺).

Following a similar procedure to that described in example 54, but starting in each case from a suitable ester, the following compounds were obtained:

EXAMPLE 55: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(3-methylbutanoylamino)methyl]piperidin-1-yl]-5-oxopentanoic acid

5 Starting compound: example 13; 61% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.88 (s, 2 H), 7.81 (s, 1 H), 4.84 (s, 3 H), 4.47 (m, 2 H), 4.23 (m, 1 H), 3.98 (m, 1 H), 3.55 (m, 1 H), 3.03 (m, 3 H), 2.57 (m, 3 H), 2.25 (m, 1 H), 1.90-2.10 (complex signal, 9 H), 1.72 (m, 3 H), 1.20 (m, 2 H), 0.91 (m, 6 H).

10 MS: m/z 633 (MH⁺).

EXAMPLE 56: (2S)-5-[4-[(N'-tert-Butylureido)methyl]piperidin-1-yl]-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxopentanoic acid

Starting compound: example 14; 69% yield.

15 ¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.88 (s, 2 H), 7.80 (s, 1 H), 4.85 (s, 4 H), 4.48 (m, 2 H), 4.23 (m, 1 H), 3.96 (m, 1 H), 3.54 (m, 1 H), 3.03 (m, 3 H), 2.60 (m, 3 H), 1.98 (m, 5 H), 1.59 (m, 5 H), 1.32 (s, 9 H), 1.21 (m, 2 H).

MS: m/z 648 (MH⁺).

EXAMPLE 57: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(isobutoxycarbonylamino)methyl]piperidin-1-yl]-5-oxopentanoic acid

20 Starting compound: example 15; 65% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.88 (s, 2 H), 7.80 (s, 1 H), 4.84 (s, 3 H), 4.48 (m, 2 H), 4.22 (m, 1 H), 3.96 (m, 1 H), 3.78 (m, 2 H), 3.54 (m, 1 H), 2.99 (m, 3 H), 2.57 (m, 3 H), 2.25 (m, 1 H), 1.0-1.98 (complex signal, 12 H), 0.92 (m, 6 H).

MS: m/z 646 (MH⁺).

25 **EXAMPLE 58: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(N'-isopropylthioureido)methyl]piperidin-1-yl]-5-oxopentanoic acid**

Starting compound: example 18; 63% yield.

30 ¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.88 (s, 2 H), 7.80 (s, 1 H), 4.85 (s, 4 H), 4.49 (m, 2 H), 4.23 (m, 2 H), 4.05 (m, 1 H), 3.53 (m, 1 H), 3.30 (m, 2 H), 3.01 (m, 1 H), 2.58 (m, 3 H), 2.26 (m, 1 H), 2.01 (m, 5 H), 1.71 (m, 4 H), 1.15 (m, 8 H).

MS: m/z 650 (MH⁺).

EXAMPLE 59: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(2-ethyl-5,7-dimethylimidazo[4,5-*b*]pyridin-3-yl)ethyl]piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 19; 59% yield.

5 MS: m/z 721 (MH^+).

EXAMPLE 60: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(isopropylsulfonylamino)methyl]piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 17; 59% yield.

10 1H NMR (300 MHz, CD_3OD) δ (TMS): 7.88 (s, 2 H), 7.81 (s, 1 H), 4.83 (s, 3 H), 4.49 (m, 2 H), 4.22 (m, 1 H), 3.99 (m, 1 H), 3.55 (m, 1 H), 3.18 (m, 1 H), 3.01 (m, 1 H), 2.93 (m, 2 H), 2.62 (m, 3 H), 2.32 (m, 1 H), 1.99 (m, 4 H), 1.77 (m, 5 H), 1.29 (m, 6 H), 1.05 (m, 2 H).

MS: m/z 655 (MH^+).

15 **EXAMPLE 61: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-[2-(pyrrolidin-1-ylcarbonyloxy)ethyl]piperidin-1-yl]pentanoic acid**

Starting compound: example 20; 60% yield.

20 1H NMR (300 MHz, CD_3OD) δ (TMS): 7.89 (s, 2 H), 7.81 (s, 1 H), 4.85 (s, 2 H), 4.50 (m, 2 H), 4.25 (m, 1 H), 4.11 (m, 2 H), 3.96 (m, 1 H), 3.54 (m, 1 H), 3.30 (m, 5 H), 3.01 (m, 1 H), 2.58 (m, 3 H), 2.27 (m, 1 H), 2.01 (m, 4 H), 1.87 (m, 4 H), 1.73 (m, 4 H), 1.55 (m, 2 H), 1.21 (m, 2 H).

MS: m/z 661 (MH^+).

EXAMPLE 62: (2S)-5-Oxo-5-[4-[(2-oxopyrrolidin-1-yl)methyl]piperidin-1-yl]-2-[1-tosyl-L-prolylamino]pentanoic acid

Starting compound: example 6; 85% yield.

25 1H NMR (300 MHz, CD_3OD) δ (TMS): 7.78 (d, $J = 8.1$ Hz, 2 H), 7.43 (d, $J = 8.1$ Hz, 2 H), 4.82 (s, 2 H), 4.44 (m, 2 H), 4.13 (m, 1 H), 3.98 (m, 1 H), 3.05-3.55 (complex signal, 7 H), 2.54 (m, 3 H), 2.44 (s, 3 H), 2.34 (m, 3 H), 1.75-2.1 (complex signal, 7 H), 1.65 (m, 3 H), 1.15 (m, 2 H).

MS: m/z 563 (MH^+).

30 **EXAMPLE 63: (2S)-5-Oxo-5-[4-(2-phenylimidazol-1-ylmethyl)piperidin-1-yl]-2-[1-tosyl-L-prolylamino]pentanoic acid**

Starting compound: example 7; 89% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.78 (d, J = 8.2 Hz, 2 H), 7.40-7.60 (complex signal, 6 H), 7.43 (d, J = 8.2 Hz, 2 H), 7.38 (m, 1 H), 4.82 (s, 2 H), 4.42 (m, 2 H), 3.9-4.1 (complex signal, 4 H), 3.46 (m, 1 H), 3.15 (m, 1 H), 2.93 (m, 1 H), 2.51 (m, 5 H), 2.26 (m, 1 H), 1.60-1.90 (complex signal, 9 H), 1.21 (m, 2 H).

5 MS: m/z 622 (MH⁺).

EXAMPLE 64: (2S)-5-Oxo-2-[1-tosyl-L-prolyl]amino-5-[4-[[4-(trifluoromethyl)pyrimidin-2-yl]aminomethyl]piperidin-1-yl]pentanoic acid

Starting compound: example 16; 45% yield.

10 ¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.86 (m, 1 H), 7.78 (d, J = 8.2 Hz, 2 H), 7.42 (d, J = 8.2 Hz, 2 H), 6.85 (m, 1 H), 4.83 (s, 3 H), 4.46 (m, 2 H), 4.13 (m, 1 H), 3.98 (m, 1 H), 3.66 (m, 1 H), 3.55 (m, 2 H), 3.23 (m, 1 H), 3.05 (m, 1 H), 2.61 (m, 1 H), 2.56 (m, 2 H), 2.44 (s, 3 H), 2.30 (m, 1 H), 1.7-2.05 (complex signal, 7 H), 1.58 (m, 1 H), 1.22 (m, 2 H).

MS: m/z 641 (MH⁺).

15 **EXAMPLE 65: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid**

Starting compound: example 4; 79% yield.

20 ¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.85 (s, 2 H), 7.76 (s, 1 H), 6.96 (s, 1 H), 4.78 (s, 2 H), 4.47 (m, 2 H), 4.19 (m, 3 H), 3.95 (m, 1 H), 3.66 (m, 1 H), 3.55 (m, 2 H), 2.96 (m, 2 H), 2.56 (s, 3 H), 2.55 (s, 3 H), 2.53 (m, 3 H), 2.28 (m, 2 H), 2.00 (m, 4 H), 1.69 (m, 2 H), 1.57 (m, 1 H), 1.21-1.42 (complex signal, 5 H).

MS: m/z 707 (MH⁺).

25 **EXAMPLE 66: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-[(2-methoxyethyl)aminocarbonyloxy]ethyl]piperidin-1-yl]-5-oxopentanoic acid**

Starting compound: example 27; 62% yield.

MS: m/z 665 (MH⁺).

30 **EXAMPLE 67: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(4-morpholinylcarbonylaminomethyl)piperidin-1-yl]-5-oxopentanoic acid**

Starting compound: example 28; 64% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.88 (s, 2 H), 7.81 (s, 1 H), 4.83 (s, 3 H), 4.49 (m, 2 H), 4.25 (m, 1 H), 4.00 (m, 1 H), 3.63 (m, 4 H), 3.51 (m, 1 H), 3.30 (m,

4 H), 3.04 (m, 4 H), 2.60 (m, 3 H), 2.25 (m, 1 H), 1.99 (m, 4 H), 1.70 (m, 4 H), 1.10 (m, 2 H).

MS: m/z 662 (MH⁺).

EXAMPLE 68: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-pyrrolidinylcarbonylaminomethyl)piperidin-1-yl]pentanoic acid

Starting compound: example 29; 30% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.88 (s, 2 H), 7.81 (s, 1 H), 4.83 (s, 3 H), 4.55 (m, 2 H), 4.27 (m, 1 H), 4.00 (m, 1 H), 3.53 (m, 1 H), 3.30 (m, 4 H), 3.01 (m, 4 H), 2.60 (m, 2 H), 2.25 (m, 1 H), 2.00 (m, 10 H), 1.88 (m, 3 H), 1.12 (m, 2 H).

MS: m/z 646 (MH⁺).

EXAMPLE 69: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolyl]amino-5-[4-[(diethylaminocarbonyloxy)methyl]piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 49; 72% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.89 (s, 2 H), 7.80 (s, 1 H), 4.83 (s, 2 H), 4.54 (m, 1H), 4.48 (m, 1H), 4.22 (m, 1H), 4.01 (m, 1H), 3.92 (m, 2H), 3.54 (m, 1H), 3.30 (m, 5H), 3.00 (m, 1H), 2.59 (m, 3H), 2.22 (m, 1H), 2.00 (m, 6H), 1.75 (m, 2H), 1.25 (m, 2H), 1.09 (m, 6H).

MS: m/z 646 (MH⁺).

EXAMPLE 70

(2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(2-oxooxazolidin-3-ylmethyl)piperidin-1-yl]pentanoic acid

To a solution of methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(2-oxooxazolidin-3-ylmethyl)piperidin-1-yl]pentanoate (obtained in example 1) (300 mg, 0.47 mmol) in THF (8 mL), LiOH.H₂O (45 mg, 1.07 mmol) dissolved in H₂O (8 mL) was added. The reaction mixture was stirred overnight at room temperature and THF was evaporated. The resulting residue was cooled to 0 °C and brought to pH = 2 by the addition of 1 N HCl. It was concentrated to dryness and the crude product obtained was purified by chromatography on silica gel using CHCl₃/MeOH 5-30 % mixtures as eluent. The title compound of the example was obtained as a white solid (155 mg, 53% yield).

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.78 (s, 2 H), 7.79 (s, 1 H), 4.78 (s, 2 H), 4.55 (m, 1 H), 4.45 (m, 1 H), 4.33 (m, 2 H), 4.24 (m, 1 H), 4.01 (m, 1 H), 3.45-3.70

(m, 5 H), 3.11 (m, 2 H), 2.60 (m, 2 H), 2.28 (m, 1 H), 1.1-2.2 (complex signal, 11 H).

MS: m/z 619 (MH⁺).

Following a similar procedure to that described in example 70, but starting in each case from a suitable ester, the following compounds were obtained:

EXAMPLE 71: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-oxopyrrolidin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 2; 19% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.87 (s, 2 H), 7.79 (s, 1 H), 4.78 (s, 2 H), 4.46 (m, 2 H), 4.25 (m, 1 H), 3.94 (m, 1 H), 3.40-3.60 (complex signal, 3 H), 3.30 (m, 2 H), 3.14 (m, 1 H), 3.04 (m, 1 H), 2.59 (m, 3 H), 2.36 (m, 3 H), 2.00-2.10 (complex signal, 7 H), 1.66 (m, 3 H), 1.21 (m, 2 H).

MS: m/z 617 (MH⁺).

EXAMPLE 72: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-methylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 35; 17% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.81 (s, 1 H), 8.28 (d, J = 5.7 Hz, 1 H), 7.85 (s, 2 H), 7.78 (s, 1 H), 7.66 (m, 1 H), 4.57 (m, 1 H), 4.87 (s, 2 H), 4.45 (m, 1 H), 4.18 (m, 2 H), 3.98 (m, 1 H), 3.52 (m, 1 H), 3.27 (m, 1 H), 2.97 (m, 1 H), 2.66 (s, 3 H), 2.51 (m, 2 H), 2.35 (m, 1 H), 2.25 (m, 1 H), 1.98 (m, 4 H), 1.2-1.85 (complex signal, 7 H).

MS: m/z 665 (MH⁺).

EXAMPLE 73: (2S)-5-[4-(2-Methylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoic acid

Starting compound: example 5; 23% yield.

¹H NMR (300 MHz, CD₃OD + CDCl₃) δ (TMS): 9.04 (s, 1 H), 8.45 (m, 1 H), 8.09 (m, 1 H), 7.73 (d, J = 7.9 Hz, 2 H), 7.37 (d, J = 7.9 Hz, 2 H), 4.63 (m, 1 H), 4.52 (m, 1 H), 4.44 (s, 2 H), 4.28 (m, 1 H), 4.07 (m, 1 H), 3.95 (m, 1 H), 3.57 (m, 1 H), 3.15 (m, 1 H), 2.95 (m, 1 H), 2.77 (m, 3 H), 2.40-2.65 (complex signal, 3 H), 2.44 (s, 3 H), 1.9-2.30 (complex signal, 5 H), 1.20-1.80 (complex signal, 7 H).

MS: m/z 611 (MH⁺).

EXAMPLE 74: (2S)-5-[4-[[1-(2-Ethoxyethyl)benzimidazol-2-yl]methyl]piperazin-1-yl]-5-oxo-2-[1-tosyl-L-prolyl]amino]pentanoic acid

Starting compound: example 8; 10% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.76 (d, J = 8.3 Hz, 2 H), 7.57 (m, 2 H), 7.39 (d, J = 8.3 Hz, 2 H), 7.30 (m, 2 H), 4.83 (s, 2 H), 4.59 (m, 2 H), 4.45 (m, 1 H), 4.12 (m, 1 H), 3.91 (s, 2 H), 3.79 (m, 2 H), 3.2-3.6 (complex signal, 8 H), 2.53 (m, 4 H),
5 2.41 (s, 3 H), 2.25 (m, 2 H), 1.93 (m, 2 H), 1.80 (m, 2 H), 1.56 (m, 2 H), 1.04 (t, J = 7 Hz, 3 H).

MS: m/z 669 (MH⁺).

EXAMPLE 75: (2S)-5-Oxo-5-[4-(2-pyridylmethyl)piperazin-1-yl]-2-[[1-tosyl-L-prolyl]amino]pentanoic acid

10 Starting compound: example 9; 47% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.50 (m, 1 H), 7.82 (m, 1 H), 7.78 (d, J = 8.3 Hz, 2 H), 7.52 (m, 1 H), 7.42 (d, J = 8.3 Hz, 2 H), 7.33 (m, 1 H), 4.83 (s, 2 H), 4.41 (m, 1 H), 4.11 (m, 1 H), 3.81 (s, 2 H), 3.70 (m, 4 H), 3.55 (m, 1 H), 3.20 (m, 1 H),
15 2.65 (m, 4 H), 2.55 (m, 2 H), 2.44 (s, 3 H), 2.30 (m, 1 H), 1.92 (m, 4 H), 1.56 (m, 1 H).

MS: m/z 558 (MH⁺).

EXAMPLE 76: (2S)-5-Oxo-5-[4-(1-oxoisindolin-2-ylmethyl)piperidin-1-yl]-2-[[1-tosyl-L-prolyl]amino]pentanoic acid

Starting compound: example 10; 48% yield.

20 ¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.77 (d, J = 8.2 Hz, 2 H), 7.73 (m, 1 H), 7.55 (m, 3 H), 7.41 (d, J = 8.2 Hz, 2 H), 4.84 (s, 2 H), 4.51 (m, 3 H), 4.45 (m, 1 H), 4.35 (m, 1 H), 3.99 (m, 1 H), 3.66 (m, 1 H), 3.53 (m, 2 H), 3.23 (m, 1 H), 3.02 (m, 1 H),
2.52-2.64 (complex signal, 3 H), 2.43 (s, 3 H), 2.25 (m, 1 H) 1.15-2.00 (complex signal, 10 H).

25 MS: m/z 611 (MH⁺).

EXAMPLE 77: (2S)-5-Oxo-5-[4-(2-thienylmethyl)piperazin-1-yl]-2-[[1-tosyl-L-prolyl]amino]pentanoic acid

Starting compound: example 11; 63% yield.

30 ¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.79 (d, J = 8.2 Hz, 2 H), 7.43 (d, J = 8.2 Hz, 2 H), 7.29 (m, 1 H), 6.93 (m, 2 H), 4.84 (s, 2 H), 4.56 (m, 1 H), 4.29 (m, 1 H), 4.18 (m, 1 H), 4.11 (m, 1 H), 3.74 (s, 2 H), 3.23-3.65 (complex signal, 3 H), 3.07 (m, 1 H), 2.44 (s, 3 H), 2.41 (m, 6 H), 2.21 (m, 1 H), 1.90 (m, 3 H), 1.60 (m, 2 H).

MS: m/z 563 (MH⁺).

EXAMPLE 78: (2S)-5-[4-[(3-Carboxypropionylamino)methyl]piperidin-1-yl]-5-oxo-2-[[1-tosyl-L-prolyl]amino]pentanoic acid

Starting compound: example 12; 39% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.79 (d, J = 8.2 Hz, 2 H), 7.44 (d, J = 8.2 Hz, 2 H), 4.89 (s, 4 H), 4.52 (m, 2 H), 4.12 (m, 1 H), 4.00 (m, 1 H), 3.67 (m, 1 H), 3.54 (m, 2 H), 3.25 (m, 2 H), 3.05 (m, 2 H), 2.60 (m, 4 H), 2.45 (s, 3 H), 2.25 (m, 2 H), 2.17 (m, 1 H), 1.2-2.00 (complex signal, 6 H), 1.55 (m, 1 H), 1.20 (m, 2 H).

MS: m/z 595 (MH⁺).

EXAMPLE 79: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(4-methylpiperazin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 21; 56% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.88 (s, 2 H), 7.80 (s, 1 H), 4.86 (s, 2 H), 4.47 (m, 1 H), 4.24 (m, 2 H), 3.97 (m, 1 H), 3.66 (m, 1 H), 3.01 (m, 1 H), 2.66 (m, 11 H), 2.56 (m, 2 H), 2.27 (s, 3 H), 1.98 (m, 5 H), 1.68 (m, 5 H), 1.09 (m, 2 H).

MS: m/z 632 (MH⁺).

EXAMPLE 80: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(4-morpholinyl)ethyl]piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 22; 76% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.89 (s, 2 H), 7.80 (s, 1 H), 4.83 (s, 2 H), 4.50 (m, 1 H), 4.32 (m, 1 H), 4.26 (m, 1 H), 3.99 (m, 1 H), 3.73 (m, 4 H), 3.45 (m, 1 H), 3.31 (m, 1 H), 3.01 (m, 1 H), 2.70 (m, 4 H), 2.61 (m, 2 H), 2.48 (m, 2 H), 2.25 (m, 1 H), 2.01 (m, 4 H), 1.70 (m, 3 H), 1.55 (m, 3 H), 1.27 (m, 3 H).

MS: m/z 633 (MH⁺).

EXAMPLE 81: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-pyrrolylmethyl)piperidin-1-yl]pentanoic acid

Starting compound: example 36; 57% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.98 (m, 1 H), 7.76 (s, 2 H), 7.59 (s, 1 H), 6.62 (m, 2 H), 6.14 (m, 2 H), 4.70 (m, 1 H), 4.30 (m, 1 H), 4.12 (m, 1 H), 3.80 (m, 1 H), 3.75 (m, 2 H), 3.62 (m, 1 H), 3.30 (m, 1 H), 3.05 (m, 1 H), 2.63 (m, 3 H), 2.25 (m, 1 H), 1.92 (m, 4 H), 1.70 (m, 4 H), 1.25 (m, 2 H).

EXAMPLE 82: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2,5-dimethylpyrrol-1-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 37; 6% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.83 (m, 1 H), 7.76 (s, 2 H), 7.59 (s, 1 H), 5.76 (d, J = 1.2 Hz, 2 H), 4.69 (broad d, J = 12.8 Hz, 1 H), 4.42 (m, 1 H), 4.16 (m, 1 H), 3.88 (m, 1 H), 3.60 (m, 3 H), 3.26 (m, 1 H), 2.98 (m, 2 H), 2.53 (m, 2 H), 2.25 (m, 1 H), 2.16 (s, 6 H), 1.99 (m, 3 H), 1.80 (m, 4 H), 1.62 (m, 2 H), 1.22 (m, 2 H).

5 MS: m/z 627 (MH⁺).

EXAMPLE 83: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(dimethylaminomethyl)piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 38; 81% yield.

10 ¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.89 (s, 2 H), 7.81 (s, 1 H), 4.85 (s, 2 H), 4.54 (m, 1 H), 4.30 (m, 1 H), 4.24 (m, 1 H), 4.02 (m, 1 H), 3.55 (m, 1 H), 3.35 (m, 1 H), 3.10 (m, 1 H), 2.93 (m, 3 H), 2.83 (s, 6 H), 2.50 (m, 3 H), 2.22 (m, 1 H), 2.05 (m, 4 H), 1.79 (m, 3 H), 1.10 (m, 2 H).

MS: m/z 577 (MH⁺).

15 **EXAMPLE 84: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-oxopentanoic acid**

Starting compound: example 39; 25% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.90 (s, 2 H), 7.81 (s, 1 H), 4.85 (s, 2 H), 4.28 (m, 2 H), 3.58 (m, 5 H), 3.43 (m, 4 H), 2.5-3 (m, 7 H), 2.58 (s, 6 H), 2.25 (m, 1 H), 2.01 (m, 5 H).

20 MS: m/z 592 (MH⁺).

EXAMPLE 85: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-ethylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 40; 55% yield.

25 ¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.99 (s, 1 H), 8.40 (m, 1 H), 7.96 (m, 1 H), 7.85 (s, 2 H), 7.79 (s, 1 H), 4.94 (s, 2 H), 4.57 (m, 1 H), 4.47 (m, 1 H), 4.42 (m, 1 H), 4.12 (m, 2 H), 3.99 (m, 1 H), 3.56 (m, 1 H), 3.30 (m, 1 H), 3.02 (m, 3 H), 2.56 (m, 3 H), 2.25 (m, 2 H), 1.99 (m, 4 H). 1.65-1.15 (complex signal, 8 H).

MS: m/z 677 (MH⁺).

30 **EXAMPLE 86: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(2-oxo-2,3-dihydroimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]pentanoic acid**

Starting compound: example 41; 59% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.27 (s, 1 H), 8.22 (d, J = 5.5 Hz, 1 H), 7.94 (s, 2 H), 7.84 (s, 1 H), 7.30 (m, 1 H), 4.91 (s, 3 H), 4.60 (m, 1 H), 4.38 (m, 1 H), 4.30 (m, 1 H), 4.07 (m, 1 H), 3.86 (m, 2 H), 3.62 (m, 1 H), 3.37 (m, 1 H), 3.08 (m, 1 H), 2.63 (m, 3 H), 2.29 (m, 1 H), 2.06 (m, 4 H), 1.73 (m, 3 H), 1.3-1.5 (m, 3 H).

5 MS: m/z 667 (MH⁺).

EXAMPLE 87: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-isopropylaminoimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 42; 36% yield.

10 ¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.41 (s, 1 H), 8.07 (m, 1 H), 7.86 (s, 2 H), 7.78 (s, 1 H), 7.36 (m, 1 H), 4.86 (s, 3 H), 4.53 (m, 1 H), 4.29 (m, 1 H), 4.23 (m, 2 H), 4.20 (m, 1 H), 3.97 (m, 2 H), 3.54 (m, 1 H), 3.32 (m, 1 H), 2.98 (m, 1 H), 2.49 (m, 3 H), 2.25 (m, 1 H), 1.99 (m, 6 H), 1.58 (m, 2 H), 1.30 (m, 8 H).

MS: m/z 708 (MH⁺).

15 **EXAMPLE 88: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(diethylaminomethyl)piperidin-1-yl]-5-oxopentanoic acid**

Starting compound: example 43; 66% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.80 (m, 1 H), 7.76 (s, 2 H), 7.62 (s, 1 H), 4.58 (m, 1 H), 4.27 (m, 1 H), 4.12 (m, 1 H), 3.90 (m, 1 H), 3.62 (m, 1 H), 3.37 (m, 20 1 H), 3.18 (m, 5 H), 2.79 (m, 2 H), 2.65 (m, 1 H), 2.45 (m, 2 H), 2.16 (m, 7 H), 1.80 (m, 2 H), 1.18 (m, 8 H).

MS: m/z 605 (MH⁺).

EXAMPLE 89: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-(2-methylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-ylcarbonyl]amino]propionic acid

Starting compound: example 44; 42% yield.

¹H NMR (300 MHz, CD₃OD+ CDCl₃) δ (TMS): 8.80 (s, 1 H), 8.25 (d, J = 5.6 Hz, 1 H), 7.76 (s, 2 H), 7.61 (s, 1 H), 7.33 (d, J = 5.6 Hz, 1 H), 4.16 (s, 3 H), 4.01 (m, 1 H), 3.73 (m, 5 H), 3.65 (m, 2 H), 3.12 (m, 1 H), 2.60 (m, 2 H), 2.59 (s, 3 H), 1.84 (m, 4 H), 1.58 (m, 1 H), 1.44 (m, 1 H), 1.15 (m, 2 H), 0.95 (m, 2 H).

30 MS: m/z 666 (MH⁺).

EXAMPLE 90: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[[[(dimethylaminoacetyl)amino]methyl]piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 23; 51% yield.

¹H NMR (300 MHz, TFA + DMSO-d₆) δ (TMS): 9.61 (broad s, 1 H), 8.45 (s, 1 H), 8.35 (d, J = 7.6 Hz, 1 H), 7.96 (s, 1 H), 7.85 (s, 2 H), 4.35 (broad d, J = 13.2 Hz, 2 H), 4.25 (m, 2 H), 3.86 (m, 2 H), 3.77 (m, 2 H), 3.35 (m, 1 H), 3.22 (m, 1 H), 2.98 (m, 3 H), 2.76 (s, 6 H), 2.35 (m, 2 H), 2.02 (m, 1 H), 1.82 (m, 4 H), 1.62 (m, 3 H), 1.12 (m, 2 H).

MS: m/z 634 (MH⁺).

EXAMPLE 91: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(diethylamino)ethyl]piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 24; 61% yield.

¹H NMR (300 MHz, DMSO-d₆) δ (TMS): 8.12 (d, J = 7.3 Hz, 1 H), 8.00 (s, 1 H), 7.88 (s, 2 H), 4.31 (m, 2 H), 4.07 (m, 1 H), 3.76 (broad d, J = 13 Hz, 1 H), 3.38 (m, 1 H), 3.20 (m, 1 H), 2.99 (m, 1 H), 2.62 (m, 6 H), 2.48 (m, 2 H), 2.28 (m, 2 H), 1.98 (m, 1 H), 1.79 (m, 3 H), 1.60 (m, 3 H), 1.40 (m, 1 H), 1.34 (m, 2 H), 1.01 (m, 2 H), 0.99 (t, J = 7.1 Hz, 6 H).

MS: m/z 619 (MH⁺).

EXAMPLE 92: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-[2-(1-pyrrolidinyl)ethyl]piperidin-1-yl]pentanoic acid

Starting compound: example 25; 64% yield.

MS: m/z 617 (MH⁺).

EXAMPLE 93: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-[(4-methylpiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 26; 34% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.89 (s, 2 H), 7.80 (s, 1 H), 4.84 (s, 2 H), 4.55 (m, 1 H), 4.33 (m, 1 H), 4.23 (m, 1 H), 4.15 (m, 2 H), 3.91 (m, 1 H), 3.53 (m, 4 H), 3.31 (m, 1 H), 3.02 (m, 1 H), 2.61 (m, 4 H), 2.55 (m, 2 H), 2.45 (s, 3 H), 2.25 (m, 1 H), 2.00 (m, 4 H), 1.70 (m, 8 H), 1.28 (m, 2 H).

MS: m/z 690 (MH⁺).

EXAMPLE 94: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-piperidylmethyl)piperidin-1-yl]pentanoic acid

Starting compound: example 30; 56% yield.

MS: m/z 617 (MH⁺).

EXAMPLE 95: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-(dimethylaminomethyl)piperidin-1-yl]carbonyl]amino]propionic acid

Starting compound: example 45; 51% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.90 (s, 2 H), 7.81 (s, 1 H), 4.91 (s, 3 H),
5 4.57 (m, 1 H), 4.40 (m, 1 H), 4.20 (m, 1 H), 4.02 (m, 2 H) 3.67 (m, 1 H), 3.50 (m, 2
H), 3.30 (m, 1 H), 2.94 (m, 1 H), 2.81 (m, 2 H), 2.79 (s, 6 H), 2.05 (m, 4 H), 1.70
(m, 3 H), 1.22 (m, 2 H).

MS: m/z 578 (MH⁺).

**EXAMPLE 96: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-
10 [(ethylamino)methyl]piperidin-1-yl]-5-oxopentanoic acid**

Starting compound: example 31; 37% yield.

MS: m/z 577 (MH⁺).

**EXAMPLE 97: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[[4-
15 methylpiperazin-1-yl]carbonylamino]methyl]piperidin-1-yl]-5-oxopentanoic
acid**

Starting compound: example 32; 26% yield.

MS: m/z 675 (MH⁺).

**EXAMPLE 98: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolyl]amino-3-[4-
20 (dimethylaminomethyl)piperidin-1-yl]carbonyloxy]propionic acid**

Starting compound: example 47; 11% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.88 (s, 2 H), 7.81 (s, 1 H), 4.83 (s, 2 H),
4.58 (m, 2 H), 4.35 (m, 1 H), 4.28 (m, 1 H), 4.12 (m, 2 H), 3.53 (m, 1 H), 3.27 (m,
1 H), 2.80 (m, 2 H), 2.70 (m, 2 H), 2.68 (s, 6 H), 1.90 (m, 4 H), 1.70 (m, 3 H), 1.21
(m, 2 H).

25 MS: m/z 577 (MH⁺).

EXAMPLE 99

**(2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(4-
pyridylaminomethyl)piperidin-1-yl]pentanoic acid**

To a solution of methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-
30 prolylamino]-5-oxo-5-[4-(4-pyridylaminomethyl)piperidin-1-yl]pentanoate (obtained
in example 33) (200 mg, 0.31 mmol) in THF (1 mL), LiOH.H₂O (26 mg, 0.62
mmol) dissolved in H₂O (2.6 mL) was added. The reaction mixture was stirred
overnight at room temperature and THF was evaporated. The resulting residue

was brought to neutral pH by the addition of 1 N HCl and the mixture was concentrated to a volume of 1 mL by evaporation of the solvent. Next, it was chromatographed using a Supelco Supelclean LC-18 column, using first H₂O and then MeOH as eluents. The fraction eluted with MeOH was concentrated to dryness, to give 86 mg of the title compound of the example (44% yield).

¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.00 (d, J = 6.5 Hz, 2 H), 7.87 (s, 2 H), 7.79 (s, 1 H), 6.82 (d, J = 6.5 Hz, 2 H), 4.85 (s, 3 H), 4.53 (m, 1 H), 4.30 (m, 1 H), 4.24 (m, 1 H), 4.00 (m, 1 H), 3.52 (m, 1 H), 3.22 (m, 3 H), 3.04 (m, 1 H), 2.60 (m, 3 H) 2.25 (m, 1 H) 2.01 (m, 8 H), 1.28 (m, 2 H).

MS: m/z 626 (MH⁺).

Following a similar procedure to that described in example 99, but starting in each case from a suitable ester, the following compounds were obtained:

EXAMPLE 100: (2S)-5-[4-[2-[(4-Methylpiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoic acid

Starting compound: example 48; 16% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.80 (d, J = 7.8 Hz, 2 H), 7.44 (d, J = 7.8 Hz, 2 H), 4.87 (s, 2 H), 4.47 (m, 1 H), 4.26 (m, 1 H), 4.15 (m, 3 H), 3.98 (m, 1 H), 3.47 (m, 4 H), 3.31 (m, 1 H), 3.02 (m, 1 H), 2.61 (m, 4 H), 2.55 (m, 2 H), 2.45 (s, 3 H), 2.29 (s, 3 H), 2.25 (m, 1 H), 2.00 (m, 4 H), 1.70 (m, 8 H), 1.28 (m, 2 H).

MS: m/z 634 (MH⁺).

EXAMPLE 101: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(4-methylpiperazin-1-yl)carbonyloxymethyl]piperidin-1-yl]-5-oxopentanoic acid

Starting compound: example 50; 20% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.90 (s, 2 H), 7.80 (s, 1 H), 4.85 (s, 2 H), 4.50 (m, 1 H), 4.28 (m, 2 H), 4.00 (m, 1 H), 3.92 (m, 2 H), 3.58 (m, 1 H), 3.52 (m, 4 H), 3.30 (m, 1 H), 3.00 (m, 1 H), 2.60 (m, 3 H), 2.36 (m, 4 H), 2.28 (s, 3 H), 2.25 (m, 1 H), 1.98 (m, 5 H), 1.72 (m, 3 H), 1.24 (m, 2 H).

MS: m/z 673 (MH⁺).

EXAMPLE 102: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(4-pyridyloxymethyl)piperidin-1-yl]pentanoic acid

Starting compound: example 51; 11% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.32 (m, 2 H), 7.88 (s, 2 H), 7.75 (s, 1 H), 6.98 (m, 2 H), 4.87 (s, 2 H), 4.58 (m, 1 H), 4.39 (m, 1 H), 4.22 (m, 1 H), 4.04 (m, 1 H), 3.93 (d, J = 6 Hz, 2 H), 3.51 (m, 1 H), 3.29 (m, 1 H), 3.08 (m, 1 H), 2.65 (m, 1 H), 2.58 (m, 2 H), 2.27 (m, 1 H), 1.98 (m, 5 H), 1.85 (m, 2 H), 1.67 (m, 1 H), 1.31 (m, 2 H).

MS: m/z 625 (MH⁺).

EXAMPLE 103: (2S)-5-[4-(4-Methylpiperazin-1-ylmethyl)piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoic acid

Starting compound: example 52; 42% yield.

MS: m/z 575 (MH⁺).

EXAMPLE 104: (2S)-5-[4-(Dimethylaminomethyl)piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoic acid

Starting compound: example 53; 47% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.85 (d, J = 8 Hz, 2 H), 7.49 (d, J = 8 Hz, 2 H), 4.92 (s, 2 H), 4.57 (m, 1 H), 4.32 (m, 1 H), 4.15 (m, 1 H), 4.05 (m, 1 H), 3.55 (m, 1 H), 3.26 (m, 1 H), 3.12 (m, 1 H), 2.79 (d, J = 7 Hz, 2 H), 2.71 (s, 6 H), 2.59 (m, 1 H), 2.52 (m, 2 H), 2.50 (s, 3 H), 2.45 (m, 1 H), 2.20 (m, 1 H), 2.00 (m, 2 H), 1.90 (m, 4 H), 1.66 (m, 1 H), 1.20 (m, 2 H).

MS: m/z 521 (MH⁺).

EXAMPLE 105: (2S)-3-[[4-(1-Piperidylmethyl)piperidin-1-ylcarbonyl]amino]-2-[N-tosyl-L-prolyl]aminopropionic acid

Starting compound: example 46; 41% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.8 (d, J = 8 Hz, 2 H), 7.43 (d, J = 8 Hz, 2 H), 4.89 (s, 3 H), 4.31 (m, 1 H), 4.11 (m, 1 H), 4.03 (m, 2 H), 3.69 (m, 1 H), 3.48 (m, 2 H), 3.24 (m, 1 H), 2.82 (m, 4 H), 2.66 (m, 2 H), 2.44 (s, 3 H), 2.00 (m, 2 H), 1.87 (m, 8 H), 1.71 (m, 4 H), 1.24 (m, 3 H).

MS: m/z 564 (MH⁺).

EXAMPLE 106

(2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(N-ethyl-N-isobutoxycarbonylamino)methyl]piperidin-1-yl]-5-oxopentanoic acid

To a solution of methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(N-ethyl-N-isobutoxycarbonylamino)methyl]piperidin-1-yl]-5-oxopentanoate (obtained in example 34) (159 mg, 0.23 mmol) in THF (1.5 mL),

LiOH.H₂O (19 mg, 0.45 mmol) dissolved in H₂O (1.9 mL) was added. The reaction mixture was stirred overnight at room temperature and THF was evaporated. The resulting residue was cooled to 0 °C and acidified by adding 1 N HCl until reaching the maximal turbidity. The solid obtained was collected by filtration, it was dried and purified using a Supelco Supelclean LC-18 column, sequentially using H₂O/MeOH 5%, 0.2 M NaHCO₃, 2 M NaOH, 1 N HCl, H₂O and MeOH as eluents. The fraction eluted with MeOH was concentrated to dryness, to give 45 mg of the title compound of the example (29% yield).

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.88 (s, 2 H), 7.80 (s, 1 H), 4.85 (s, 2 H), 4.49 (m, 2 H), 4.26 (m, 1 H), 4.01 (m, 1 H), 3.81 (m, 2 H), 3.52 (m, 1 H), 3.27 (m, 2 H), 3.12 (m, 1 H), 3.01 (m, 1 H), 2.60 (m, 3 H), 2.25 (m, 1 H), 2.00 (m, 5 H), 1.65 (m, 4 H), 1.32 (m, 2 H), 1.18 (m, 5 H), 0.92 (m, 6 H).
MS: m/z 677 (MH⁺).

EXAMPLE 107

Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(4-methylpiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionate

A solution of the compounds obtained in reference examples 57 (0.65 g, 1.44 mmol) and 35 (0.88 g, 3.4 mmol) and DIEA (0.88 mL, 5 mmol) in DMF (4 mL) was irradiated with a multimode microwaves at 140 °C for 1.5 min and at 150 °C for 40 min at a potency of 450 W. The resulting mixture was concentrated to dryness and partitioned three times between EtOAc and saturated NaHCO₃ solution. The combined organic phases were dried over sodium sulfate and concentrated, to afford a crude product which was purified by chromatography on silica gel, using a CH₂Cl₂/MeOH (9:1) mixture as eluent. 0.42 g of the title compound of the example was obtained (42% yield).

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.85 (m, 1 H), 7.72 (s, 2 H), 7.59 (s, 1 H), 5.07 (m, 1 H), 4.51 (m, 1 H), 4.44 (m, 1 H), 4.14 (m, 2 H), 3.95 (m, 1 H), 3.81 (s, 3 H), 3.70 (m, 1 H), 3.63 (m, 2 H), 3.47 (m, 4 H), 3.26 (m, 1 H), 3.08 (m, 1 H), 2.75 (m, 1 H), 2.63 (m, 1 H), 2.38 (m, 4 H), 2.32 (s, 3 H), 2.12 (m, 1 H), 1.5 - 2.0 (m, 8 H), 1.12 (m, 2 H).

Following a similar procedure to that described in example 107, but using a suitable amine in each case, the following compounds were obtained:

EXAMPLE 108: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(4-methylpiperidin-1-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionate

Compounds used: reference examples 57 and 60; 51% yield.

- 5 ^1H NMR (300 MHz, CD_3OD) δ (TMS): 7.87 (s, 2 H), 7.78 (m, 1 H), 4.80 (s, 2 H), 4.43 (m, 1 H), 4.12 (m, 1 H), 3.9-4.10 (m, 6 H), 3.71 (s, 3 H), 3.51 (m, 1 H), 3.49 (m, 2 H), 3.26 (m, 1 H), 2.74 (m, 4 H), 1.95 (m, 4 H), 1.45-1.75 (m, 8 H), 1.20 (m, 4 H), 0.95 (d, $J = 6.5$ Hz, 3 H).

EXAMPLE 109: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[[4-(ethoxycarbonyl)piperazin-1-yl]carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionate

Compounds used: reference examples 57 and 59; 28% yield.

- 10 ^1H NMR (300 MHz, CDCl_3) δ (TMS): 7.82 (m, 1 H), 7.78 (s, 2 H), 7.70 (s, 1 H), 5.10 (m, 1 H), 4.55 (m, 1 H), 4.15 (m, 5 H), 3.99 (m, 2 H), 3.72 (s, 3 H), 3.68 (m, 1 H), 3.65 (m, 2 H), 3.48 (s, 8 H), 3.18 (m, 1 H), 2.70 (m, 2 H), 2.17 (m, 1 H), 1.5-2.0 (m, 8 H), 1.25 (m, 5 H).

EXAMPLE 110: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[[4-(4-pyridyl)piperazin-1-yl]carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionate

- 20 Compounds used: reference examples 57 and 58; 33% yield.

^1H NMR (300 MHz, CDCl_3) δ (TMS): 8.30 (d, $J = 5$ Hz, 2 H), 7.85 (m, 1 H), 7.77 (s, 2 H), 7.60 (s, 1 H), 6.66 (d, $J = 5$ Hz, 2 H), 5.17 (m, 1 H), 4.49 (m, 1 H), 4.13 (m, 3 H), 4.01 (m, 2 H), 3.75 (s, 3 H), 3.70 (m, 1 H), 3.61 (m, 6 H), 3.38 (m, 4 H), 3.22 (m, 1 H), 2.75 (m, 2 H), 2.10 (m, 1 H), 1.5-2.0 (m, 8 H), 1.20 (m, 2 H).

EXAMPLE 111: Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(cis-2,6-dimethylmorpholin-4-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionate

Compounds used: reference examples 57 and 62; 23% yield.

- 30 ^1H NMR (300 MHz, CD_3OD) δ (TMS): 7.87 (s, 1 H), 7.80 (s, 2 H), 4.86 (s, 2 H), 4.43 (m, 1 H), 4.11 (m, 3 H), 3.97 (m, 2 H), 3.85 (m, 2 H), 3.71 (s, 3 H), 3.63 (m, 2 H), 3.51 (m, 5 H), 3.27 (m, 1 H), 2.74 (m, 2 H), 2.49 (m, 2 H), 1.95 (m, 3 H), 1.67 (m, 2 H), 1.56 (m, 2 H), 1.10 (d, $J = 6$ Hz, 6 H), 1.20 (m, 2 H).

EXAMPLE 112: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(4-methylhomopiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionic acid

Compounds used: reference examples 57 and 61; 10% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.88 (s, 2 H), 7.79 (s, 1 H), 4.88 (s, 3 H), 4.30 (m, 1 H), 4.11 (m, 3 H), 4.01 (m, 2 H), 3.60 (m, 5 H), 3.55 (m, 2 H), 3.20 (m, 1 H), 2.88 (m, 4 H), 2.73 (m, 2 H), 2.50 (s, 3 H), 1.8-2.0 (m, 5 H), 1.5-1.7 (m, 6 H), 1.20 (m, 2 H).

MS: m/z 705 (MH⁺).

EXAMPLE 113

Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-(2-ethylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-ylcarbonyl]amino]propionate

Following a similar procedure to that described in example 44, but using the compounds obtained in reference examples 23 and 52 as starting amines, the title compound of the example was obtained in 7% yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 9.03 (s, 1 H), 8.37 (d, J = 5.4 Hz, 1 H), 7.80 (s, 2 H), 7.63 (s, 1 H), 7.27 (m, 2 H), 5.24 (m, 1 H), 4.54 (m, 1 H), 4.12 (m, 1 H), 4.08 (m, 1 H), 4.01 (d, J = 7.2 Hz, 2 H), 3.81 (m, 1 H), 3.71 (double s, 3 H), 3.67 (m, 2 H), 3.25 (m, 2 H), 2.91 (q, J = 7.5 Hz, 2 H), 2.72 (m, 2 H), 2.21 (m, 1 H), 2.02 (m, 2 H), 1.5 - 1.9 (m, 4 H), 1.54 (t, J = 7.5 Hz, 3 H), 1.28 (m, 2 H).

EXAMPLE 114

Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-[2-(4-phenylpiperazin-1-ylcarbonyloxy)ethyl]piperidin-1-yl]pentanoate

To a solution of the acid obtained in reference example 48 (0.72 g, 1.5 mmol) in DMF (10 mL), the amine obtained in reference example 56 (0.6 g, 1.5 mmol), HBTU (584 mg, 1.5 mmol) and DIEA (1.07 mL, 6 mmol) were added under argon atmosphere, and the reaction mixture was stirred overnight at room temperature. DMF was evaporated and the crude product obtained was partitioned three times between EtOAc and saturated NaHCO₃ solution. The combined organic phases were dried over sodium sulfate and concentrated, to afford a crude product which was purified by chromatography on silica gel, using

EtOAc as eluent. The title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.77 (s, 2 H), 7.71 (m, 1 H), 7.58 (s, 1 H), 7.28 (m, 2 H), 6.90 (m, 3 H), 4.55 (m, 1 H), 4.47 (m, 1 H), 4.15 (m, 4 H), 3.80 (m, 1 H), 3.76 (s, 3 H), 3.57 (m, 5 H), 3.25 (m, 1 H), 3.16 (m, 4 H), 3.00 (m, 1 H), 2.55 (m, 2 H), 2.16 (m, 2 H). 1.7 - 1.9 (m, 4 H), 1.5 - 1.6 (m, 5 H), 1.15 (m, 2 H).

EXAMPLE 115

Methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(2-propylimidazo[4,5-c]pyridin-1-yl)methyl]piperidin-1-yl]pentanoate

Following a similar procedure to that described in example 114, but using the amine obtained in reference example 55 instead of the amine obtained in reference example 56, the title compound of the example was obtained in quantitative yield.

¹H NMR (300 MHz, CDCl₃) δ (TMS): 9.00 (s, 1 H), 8.35 (d, J = 4.2 Hz, 1 H), 7.77 (m, 2 H), 7.60 (m, 2 H), 7.23 (m, 1 H), 4.72 (m, 1 H), 4.54 (m, 1 H), 4.14 (m, 1 H), 4.00 (m, 2 H), 3.97 (m, 1 H), 3.76 (s, 1.5 H), 3.74 (s, 1.5 H), 3.66 (m, 1 H), 3.08 (m, 1 H), 2.85 (m, 2 H), 2.2 - 2.6 (m, 6 H), 2.12 (m, 2 H), 1.90 (m, 3 H), 1.75 (m, 2 H), 1.61 (m, 2 H), 1.3 (m, 2 H), 1.05 (m, 3 H).

EXAMPLE 116

(2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(4-methylpiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-yl]carbonyl]amino]propionic acid

Following a similar procedure to that described in example 99, but starting from the compound obtained in example 107 instead of the compound obtained in example 33, the title compound of the example was obtained in 61% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.88 (s, 2 H), 7.78 (s, 1 H), 4.84 (s, 3 H), 4.34 (m, 1 H), 4.16 (m, 3 H), 3.95 (m, 2 H), 3.45 - 3.70 (m, 7 H), 3.26 (m, 1 H), 3.08 (m, 1 H), 2.65 - 2.85 (m, 6 H), 2.62 (s, 3 H), 1.5-2.0 (m, 8 H), 1.12 (m, 2 H).
MS: m/z 691 (MH⁺).

Following a similar procedure to that described in example 54, but starting in each case from a suitable ester, the following compounds were obtained:

EXAMPLE 117: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-[2-(4-phenylpiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-yl]pentanoic acid

Starting compound: example 114; 54% yield.

5 MS: m/z 752 (MH⁺).

EXAMPLE 118: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(4-methylpiperidin-1-yl)carbonyloxy]ethyl]piperidin-1-yl]carbonyl]amino]propionic acid

Starting compound: example 108; 59% yield.

10 ¹H NMR (300 MHz, CD₃OD) δ (TMS): 7.88 (s, 2 H), 7.78 (s, 1 H), 4.80 (s, 3 H), 4.44 (m, 1 H), 4.15 (m, 1 H), 3.9-4.00 (m, 6H), 3.66 (m, 1 H), 3.55 (m, 2 H), 3.30 (m, 1 H), 2.77 (m, 4 H), 2.00 (m, 4 H), 1.5-1.75 (m, 8 H), 1.20 (m, 4 H), 0.92 (d, J = 6.6 Hz, 3 H).

MS: m/z 690 (MH⁺).

15 Following a similar procedure to that described in example 70, but starting in each case from a suitable ester, the following compounds were obtained:

EXAMPLE 119: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(2-propylimidazo[4,5-c]pyridin-1-yl)methyl]piperidin-1-yl]pentanoic acid

Starting compound: example 115; 34% yield.

20 ¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.82 (s, 1 H), 8.40 (s, 1 H), 8.28 (d, J = 4.8 Hz, 1 H), 7.87 (s, 1 H), 7.85 (s, 1 H), 7.68 (m, 1 H), 4.90 (s, 2 H), 4.56 (m, 1 H), 4.37 (m, 1 H), 4.17 (m, 3 H), 3.99 (m, 1 H), 3.52 (m, 1 H), 3.28 (m, 1 H), 2.92 (m, 3 H), 2.54 (m, 3 H), 2.23 (m, 2 H), 1.8 - 2.05 (m, 6 H), 1.45 - 1.75 (m, 3 H), 1.2 - 1.4 (m, 2 H), 1.03 (m, 3 H).

25 MS: m/z 693 (MH⁺).

EXAMPLE 120: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[[4-(ethoxycarbonyl)piperazin-1-yl]carbonyloxy]ethyl]piperidin-1-yl]carbonyl]amino]propionic acid

Starting compound: example 109; 27% yield.

30 ¹H NMR (300 MHz, CDCl₃) δ (TMS): 7.78 (s, 2 H), 7.83 (s, 1 H), 4.86 (s, 3 H), 4.37 (m, 1 H), 4.15 (m, 5 H), 4.00 (m, 2 H), 3.69 (m, 1 H), 3.55 (m, 2 H), 3.41 (s, 8 H), 3.26 (m, 1 H), 2.72 (m, 2 H), 2.05 (m, 3 H), 1.5-1.8 (m, 6 H), 1.23 (t, J = 7.2 Hz, 3 H), 1.20 (m, 2 H).

MS: m/z 749 (MH⁺).

EXAMPLE 121: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[[4-(4-pyridyl)piperazin-1-yl]carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionic acid

5 Starting compound: example 110; 69% yield.

¹H NMR (300 MHz, CD₃OD) δ (TMS): 8.11 (d, J = 7.2 Hz, 2 H), 7.87 (s, 2 H), 7.76 (s, 1 H), 7.01 (d, J = 7.2 Hz, 2 H), 4.86 (s, 3 H), 4.35 (m, 1 H), 4.15 (m, 3 H), 4.00 (m, 2 H), 3.65 (m, 1 H), 3.61 (m, 4 H), 3.55 (m, 2 H), 3.20-3.30 (m, 5 H), 2.73 (m, 2 H), 1.8-2.0 (m, 3 H), 1.5-1.7 (m, 6 H), 1.20 (m, 2 H).

10 MS: m/z 754 (MH⁺).

EXAMPLE 122: (2S)-2-[1-(3,5-Dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(cis-2,6-dimethylmorpholin-4-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionic acid

Starting compound: example 111; 8% yield.

15 MS: m/z 754 (MH⁺).

EXAMPLE 123


Lithium (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-(2-ethylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-ylcarbonyl]amino]propionate

20 To a solution of the compound obtained in example 113 (23 mg, 0.03 mmol) in THF (0.3 mL) and H₂O (0.15 mL), LiOH.H₂O (1.4 mg, 0.03 mmol) was added, and the resulting mixture was stirred overnight at room temperature. The resulting solution was concentrated to dryness, affording the title compound of the example in quantitative yield.

25 MS: m/z 680.4 (MH⁺).

CLAIMS

1.- A compound of general formula I:



5 wherein:

R^1 represents $-\text{SO}_2\text{R}^2$, $-\text{COR}^2$ or $-\text{CH}_2\text{R}^3$;

R^2 represents C_{1-8} alkyl, C_{2-8} alkenyl or C_{2-8} alkynyl, which can be optionally substituted with one or more groups R^a , or R^2 represents Cy, CyC_{1-4} alkyl, CyC_{2-4} alkenyl or CyC_{2-4} alkynyl, where the groups Cy can be optionally substituted with one or more groups R^b ;

R^3 represents hydrogen, C_{1-8} alkyl, C_{2-8} alkenyl or C_{2-8} alkynyl, where the groups C_{1-8} alkyl, C_{2-8} alkenyl and C_{2-8} alkynyl can be optionally substituted with one or more groups R^c , or R^3 represents Cy or CyC_{1-4} alkyl, where the groups Cy can be optionally substituted with one or more groups selected from R^c and R^d ;

15 each R^4 independently represents hydrogen, C_{1-8} alkyl, Cy or CyC_{1-4} alkyl, where the C_{1-8} alkyl group can be optionally substituted with one or more groups R^c and where the groups Cy can be optionally substituted with one or more groups selected from R^c and R^d ;

20 W represents $-\text{CR}^4\text{R}^4-$ when R^1 is $-\text{SO}_2\text{R}^2$ or $-\text{COR}^2$, or W represents $-\text{CO}-$ when R^1 is $-\text{CH}_2\text{R}^3$;

Z represents $-\text{CO}-$ or $-\text{CS}-$;

E represents $-\text{COOR}^6$, $-\text{CONR}^7\text{R}^8$ or 5-tetrazolyl;

X represents $-\text{CH}_2-$, $-\text{NR}^5-$ or $-\text{O}-$;

each R^5 independently represents hydrogen or C_{1-4} alkyl;

25 R^6 represents hydrogen, C_{1-8} alkyl, C_{3-7} cycloalkyl or aryl, where the C_{1-8} alkyl group can be optionally substituted with a group selected from C_{3-7} cycloalkyl, aryl, $-\text{OR}^9$, $-\text{OCOR}^d$, $-\text{OCOOR}^d$, $-\text{COOR}^9$ and $-\text{NHCOR}^9$ and the aryl

groups can be optionally substituted with one or more groups R^b ;

R^7 represents hydrogen, C_{1-8} alkyl, C_{3-7} cycloalkyl, aryl or $-SO_2R^d$, where the C_{1-8} alkyl group can be optionally substituted with a group selected from C_{3-7} cycloalkyl, aryl, $-SO_2R^d$, $-COOR^g$ and $-COR^d$;

5 R^8 represents hydrogen or C_{1-8} alkyl;

or R^7 and R^8 together with the nitrogen atom to which they are bound can form a cycle Het^1 ;

A represents C_{3-7} cycloalkyl or Het^1 , which can be optionally substituted with one or more groups selected from oxo, C_{1-8} alkyl and C_{1-8} haloalkyl;

10 L represents $-(CR^gR^g)_n-$;

each R^g independently represents hydrogen or C_{1-4} alkyl;

B represents:

i) C_{3-7} cycloalkyl, Het^1 or Het^2 , which can be optionally substituted with one or more groups selected from oxo, R^b and Cy optionally substituted with one or more groups R^b ; or

15 ii) a group selected from $-COR^e$, $-NR^fR^f$, $-OR^f$, $-SR^f$, $-S(O)_pR^e$, $-CONR^fR^f$, $-NR^fCOR^f$, $-NR^fCONR^fR^f$, $-NR^fCSNR^fR^f$, $-NR^fCOOR^e$, $-OCOR^e$, $-OCONR^fR^f$, $-NR^fSO_2R^e$ and $-SO_2NR^fR^f$;

m represents 0 or 1;

20 n represents 1, 2, 3 or 4;

p represents 1 or 2;

each R^a independently represents halogen, $-COR^d$, $-OR^g$, $-NR^gR^g$, $-COOR^g$, $-OCOR^d$, $-CONR^gR^g$, $-NR^gCOR^g$, $-OCONR^gR^g$ or $-NR^gCOOR^d$;

each R^b independently represents a group R^a , $-NO_2$, $-SR^g$, $-S(O)_pR^d$ or C_{1-8} alkyl optionally substituted with one or more groups R^c ;

25 each R^c independently represents halogen, $-OR^h$ or $-NR^hR^h$;

each R^d independently represents C_{1-8} alkyl, C_{3-7} cycloalkyl or aryl, which can be optionally substituted with one or more groups R^c ;

each R^e independently represents C_{1-8} alkyl, C_{2-8} alkenyl or C_{2-8} alkynyl,

30 which can be optionally substituted with one or more groups R^a , or R^e represents Cy or CyC_{1-4} alkyl, where the groups Cy can be optionally substituted with one or more groups selected from oxo, Cy^* and R^b , and where the groups Cy^* can be optionally substituted with one or more groups selected from oxo and R^b ;

each R^f independently represents hydrogen or any of the meanings

described for R^e;

or two groups R^f placed on the same nitrogen atom can be attached to each other to form together with said nitrogen atom a cycle Het¹ which can be optionally substituted with one or more groups selected from oxo, Cy and R^b,
5 where the groups Cy can be optionally substituted with one or more groups selected from oxo and R^b;

each R^g independently represents hydrogen or any of the meanings described for R^d;

10 or two groups R^g placed on the same nitrogen atom can be attached to each other to form together with said nitrogen atom a cycle Het¹ which can be optionally substituted with one or more groups selected from oxo, Cy and R^b, where the groups Cy can be optionally substituted with one or more groups selected from oxo and R^b;

15 each R^h independently represents hydrogen, C₁₋₈ alkyl, C₃₋₇ cycloalkyl or aryl, where the groups C₁₋₈ alkyl, C₃₋₇ cycloalkyl and aryl can be optionally substituted with one or more halogen atoms;

Cy and Cy* independently represent aryl, C₃₋₇ cycloalkyl, Het¹ or Het²;

aryl in the above definitions represents phenyl or naphthyl;

20 Het¹ in the above definitions represents a saturated or insaturated non-aromatic 5- to 7-membered monocyclic ring containing from one to four heteroatoms selected from N, O and S, which can be optionally fused to a phenyl, naphthyl or Het² ring, and which is chemically stable and obtainable through chemical synthesis; and

25 Het² in the above definitions represents an aromatic 5- to 7-membered monocyclic or 9- to 11-membered bicyclic ring, which contains from one to four heteroatoms selected from N, O and S, and which is chemically stable and obtainable through chemical synthesis;
and the salts, solvates and prodrugs thereof.

2.- A compound according to claim 1 wherein R¹ represents -SO₂R².

30 3.- A compound according to claim 1 or 2 wherein R² represents aryl optionally substituted with one or more groups R^b.

4.- A compound according to any of claims 1 to 3 wherein all the groups R⁴ represent hydrogen.

5.- A compound according to any of claims 1 to 4 wherein R⁵ represents

hydrogen.

6.- A compound according to any of claims 1 to 5 wherein W represents $-CR^4R^4-$.

7.- A compound according to claim 6 wherein W represents $-CH_2-$.

8.- A compound according to any of claims 1 to 7 wherein Z represents $-CO-$.

5 9.- A compound according to any of claims 1 to 8 wherein E represents $-COOR^6$.

10.- A compound according to claim 9 wherein E represents $-COOH$.

11.- A compound according to any of claims 1 to 10 wherein m represents 1.

12.- A compound according to any of claims 1 to 11 wherein X represents $-NH-$.

13.- A compound according to any of claims 1 to 11 wherein X represents $-CH_2-$.

10 14.- A compound according to any of claims 1 to 11 wherein X represents $-O-$.

15.- A compound according to any of claims 1 to 14 wherein A represents piperidine or piperazine.

16.- A compound according to any of claims 1 to 15 wherein L represents $-(CH_2)_n-$.

15 17.- A compound according to claim 16 wherein L represents methylene or ethylene.

18.- A compound according to any of claims 1 to 17 wherein B represents Het^1 or Het^2 optionally substituted with one or more groups selected from oxo, R^b and Cy optionally substituted with one or more groups R^b .

20 19.- A compound according to claim 18 wherein B represents imidazopyridine optionally substituted with one or more groups selected from oxo, R^b and Cy optionally substituted with one or more groups R^b .

20.- A compound according to any of claims 1 to 17 wherein B represents $-NR^fR^f$, $-OR^f$, $-NR^fCOR^f$, $-NR^fCONR^fR^f$, $-NR^fCSNR^fR^f$, $-NR^fCOOR^e$ or $-OCONR^fR^f$.

25 21.- A compound according to claim 20 wherein B represents $-OCONR^fR^f$.

22.- A compound according to claim 21 wherein both groups R^f are attached to each other to form together with the nitrogen atom a cycle Het^1 , which can be optionally substituted with one or more groups selected from oxo, Cy and R^b , wherein the groups Cy can be optionally substituted with one or more groups selected from oxo and R^b .

30

23.- A compound according to claim 1 selected from:

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(2-oxooxazolidin-3-ylmethyl)piperidin-1-yl]pentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-oxopyrrolidin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-oxoisindolin-2-ylmethyl)piperidin-1-yl]pentanoate;

5 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-ethyl-5,7-dimethylimidazo[4,5-*b*]pyridin-3-ylmethyl)piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-5-[4-(2-methylimidazo[4,5-*c*]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoate;

10 methyl (2S)-5-oxo-5-[4-[(2-oxopyrrolidin-1-yl)methyl]piperidin-1-yl]-2-[1-tosyl-L-prolylamino]pentanoate;

methyl (2S)-5-oxo-5-[4-(2-phenylimidazol-1-ylmethyl)piperidin-1-yl]-2-[1-tosyl-L-prolylamino]pentanoate;

methyl (2S)-5-[4-[[1-(2-ethoxyethyl)benzimidazol-2-yl]methyl]piperazin-1-yl]-5-oxo-2-[[1-tosyl-L-prolyl]amino]pentanoate;

15 methyl (2S)-5-oxo-5-[4-(2-pyridylmethyl)piperazin-1-yl]-2-[[1-tosyl-L-prolyl]amino]pentanoate;

methyl (2S)-5-oxo-5-[4-(1-oxoisindolin-2-ylmethyl)piperidin-1-yl]-2-[[1-tosyl-L-prolyl]amino]pentanoate;

20 methyl (2S)-5-oxo-5-[4-(2-thienylmethyl)piperazin-1-yl]-2-[[1-tosyl-L-prolyl]amino]pentanoate;

methyl (2S)-5-[4-[(2,5-dioxopyrrolidin-1-yl)methyl]piperidin-1-yl]-5-oxo-2-[[1-tosyl-L-prolyl]amino]pentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(3-methylbutanoylamino)methyl]piperidin-1-yl]-5-oxopentanoate;

25 methyl (2S)-5-[4-[(*N'*-*tert*-butylureido)methyl]piperidin-1-yl]-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(isobutoxycarbonylamino)methyl]piperidin-1-yl]-5-oxopentanoate;

30 methyl (2S)-5-oxo-2-[1-tosyl-L-prolyl]amino-5-[4-[[4-(trifluoromethyl)pyrimidin-2-yl]aminomethyl]piperidin-1-yl]pentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(isopropylsulfonylamino)methyl]piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(*N'*-isopropylthioureido)methyl]piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)ethyl]piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-[2-(pyrrolidin-1-ylcarbonyloxy)ethyl]piperidin-1-yl]pentanoate;

5 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(4-methylpiperazin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(4-morpholinyl)ethyl]piperidin-1-yl]-5-oxopentanoate;

10 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[[[(dimethylaminoacetyl)amino]methyl]piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(diethylamino)ethyl]piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-[2-(1-pyrrolidinyl)ethyl]piperidin-1-yl]pentanoate;

15 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-[(4-methylpiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-[(2-methoxyethyl)aminocarbonyloxy]ethyl]piperidin-1-yl]-5-oxopentanoate;

20 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(4-morpholinylcarbonylaminomethyl)piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-pyrrolidinylcarbonylaminomethyl)piperidin-1-yl]pentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-piperidylmethyl)piperidin-1-yl]pentanoate;

25 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[[N-ethyl-N-(trifluoroacetyl)amino]methyl]piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[[4-methylpiperazin-1-yl)carbonylamino]methyl]piperidin-1-yl]-5-oxopentanoate;

30 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(4-pyridylaminomethyl)piperidin-1-yl]pentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(N-ethyl-N-isobutoxycarbonylamino)methyl]piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-methylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-pyrrolylmethyl)piperidin-1-yl]pentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2,5-dimethylpyrrol-1-ylmethyl)piperidin-1-yl]-5-oxopentanoate;

5 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(dimethylaminomethyl)piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-oxopentanoate;

10 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-ethylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(2-oxo-2,3-dihydroimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]pentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-isopropylaminoimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoate;

15 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(diethylaminomethyl)piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-(2-methylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-ylcarbonyl]amino]propionate;

20 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-(dimethylaminomethyl)piperidin-1-ylcarbonyl]amino]propionate;

methyl (2S)-3-[[4-(1-piperidylmethyl)piperidin-1-ylcarbonyl]amino]-2-[N-tosyl-L-prolyl]aminopropionate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[4-(dimethylaminomethyl)piperidin-1-ylcarbonyloxy]propionate;

25 methyl (2S)-5-[4-[2-[(4-methylpiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-5-[4-[(diethylaminocarbonyloxy)methyl]piperidin-1-yl]-5-oxopentanoate;

30 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(4-methylpiperazin-1-yl)carbonyloxymethyl]piperidin-1-yl]-5-oxopentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(4-pyridyloxymethyl)piperidin-1-yl]pentanoate;

methyl (2S)-5-[4-(4-methylpiperazin-1-ylmethyl)piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoate;

methyl (2S)-5-[4-(dimethylaminomethyl)piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoate;

(2S)-5-[4-[(1-oxoisindolin-2-yl)methyl]piperidin-1-yl]-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxopentanoic acid;

5 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(3-methylbutanoylamino)methyl]piperidin-1-yl]-5-oxopentanoic acid;

(2S)-5-[4-[(*N'*-*tert*-butylureido)methyl]piperidin-1-yl]-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxopentanoic acid;

10 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(isobutoxycarbonylamino)methyl]piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(*N'*-isopropylthioureido)methyl]piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(2-ethyl-5,7-dimethylimidazo[4,5-*b*]pyridin-3-yl)ethyl]piperidin-1-yl]-5-oxopentanoic acid;

15 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(isopropylsulfonylamino)methyl]piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-[2-(pyrrolidin-1-ylcarbonyloxy)ethyl]piperidin-1-yl]pentanoic acid;

20 (2S)-5-oxo-5-[4-[(2-oxopyrrolidin-1-yl)methyl]piperidin-1-yl]-2-[1-tosyl-L-prolylamino]pentanoic acid;

(2S)-5-oxo-5-[4-(2-phenylimidazol-1-ylmethyl)piperidin-1-yl]-2-[1-tosyl-L-prolylamino]pentanoic acid;

(2S)-5-oxo-2-[1-tosyl-L-prolyl]amino-5-[4-[[4-(trifluoromethyl)pyrimidin-2-yl]aminomethyl]piperidin-1-yl]pentanoic acid;

25 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-ethyl-5,7-dimethylimidazo[4,5-*b*]pyridin-3-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-[(2-methoxyethyl)aminocarbonyloxy]ethyl]piperidin-1-yl]-5-oxopentanoic acid;

30 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(4-morpholinylcarbonylamino)methyl]piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-pyrrolidinylcarbonylamino)methyl]piperidin-1-yl]pentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-5-[4-[(diethylaminocarbonyloxy)methyl]piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(2-oxooxazolidin-3-ylmethyl)piperidin-1-yl]pentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-oxopyrrolidin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid;

5 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-methylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid;

(2S)-5-[4-(2-methylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoic acid;

10 (2S)-5-[4-[[1-(2-ethoxyethyl)benzimidazol-2-yl]methyl]piperazin-1-yl]-5-oxo-2-[[1-tosyl-L-prolyl]amino]pentanoic acid;

(2S)-5-oxo-5-[4-(2-pyridylmethyl)piperazin-1-yl]-2-[[1-tosyl-L-prolyl]amino]pentanoic acid;

(2S)-5-oxo-5-[4-(1-oxoisindolin-2-ylmethyl)piperidin-1-yl]-2-[[1-tosyl-L-prolyl]amino]pentanoic acid;

15 (2S)-5-oxo-5-[4-(2-thienylmethyl)piperazin-1-yl]-2-[[1-tosyl-L-prolyl]amino]pentanoic acid;

(2S)-5-[4-[(3-carboxypropionylamino)methyl]piperidin-1-yl]-5-oxo-2-[[1-tosyl-L-prolyl]amino]pentanoic acid;

20 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(4-methylpiperazin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(4-morpholinyl)ethyl]piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(1-pyrrolylmethyl)piperidin-1-yl]pentanoic acid;

25 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2,5-dimethylpyrrol-1-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(dimethylaminomethyl)piperidin-1-yl]-5-oxopentanoic acid;

30 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-(2-ethylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(2-oxo-2,3-dihydroimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]pentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proylamino]-5-[4-(2-isopropylaminoimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]-5-oxopentanoic acid;

5 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proylamino]-5-[4-(diethylaminomethyl)piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proyl]amino-3-[[4-(2-methylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-ylcarbonyl]amino]propionic acid;

10 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proylamino]-5-[4-[[[(dimethylaminoacetyl)amino]methyl]piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proylamino]-5-[4-[2-(diethylamino)ethyl]piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proylamino]-5-oxo-5-[4-[2-(1-pyrrolidiny)ethyl]piperidin-1-yl]pentanoic acid;

15 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proylamino]-5-[4-[2-[(4-methylpiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proylamino]-5-oxo-5-[4-(1-piperidylmethyl)piperidin-1-yl]pentanoic acid;

20 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proyl]amino-3-[[4-(dimethylaminomethyl)piperidin-1-ylcarbonyl]amino]propionic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proylamino]-5-[4-[(ethylamino)methyl]piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proylamino]-5-[4-[[4-(4-methylpiperazin-1-yl)carbonylamino]methyl]piperidin-1-yl]-5-oxopentanoic acid;

25 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proyl]amino-3-[4-(dimethylaminomethyl)piperidin-1-ylcarbonyloxy]propionic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proylamino]-5-oxo-5-[4-(4-pyridylaminomethyl)piperidin-1-yl]pentanoic acid;

30 (2S)-5-[4-[2-[(4-methylpiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-yl]-5-oxo-2-[1-tosyl-L-proylamino]pentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proylamino]-5-[4-[(4-methylpiperazin-1-yl)carbonyloxymethyl]piperidin-1-yl]-5-oxopentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-proylamino]-5-oxo-5-[4-(4-pyridyloxymethyl)piperidin-1-yl]pentanoic acid;

(2S)-5-[4-(4-methylpiperazin-1-ylmethyl)piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoic acid;

(2S)-5-[4-(dimethylaminomethyl)piperidin-1-yl]-5-oxo-2-[1-tosyl-L-prolylamino]pentanoic acid;

5 (2S)-3-[[4-(1-piperidylmethyl)piperidin-1-ylcarbonyl]amino]-2-[N-tosyl-L-prolyl]aminopropionic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-[4-[(N-ethyl-N-isobutoxycarbonylamino)methyl]piperidin-1-yl]-5-oxopentanoic acid;

10 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(4-methylpiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(4-methylpiperidin-1-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionate;

15 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(4-(ethoxycarbonyl)piperazin-1-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(4-(4-pyridyl)piperazin-1-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionate;

20 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(cis-2,6-dimethylmorpholin-4-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionate;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(4-methylhomopiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionic acid;

25 methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-(2-ethylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-ylcarbonyl]amino]propionate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-[2-(4-phenylpiperazin-1-ylcarbonyloxy)ethyl]piperidin-1-yl]pentanoate;

methyl (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(2-propylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]pentanoate;

30 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(4-methylpiperazin-1-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-[2-(4-phenylpiperazin-1-ylcarbonyloxy)ethyl]piperidin-1-yl]pentanoic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(4-methylpiperidin-1-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionic acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolylamino]-5-oxo-5-[4-(2-propylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-yl]pentanoic acid;

5 (2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[[4-(ethoxycarbonyl)piperazin-1-yl]carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionic acid;


(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[[4-(4-pyridyl)piperazin-1-yl]carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionic
10 acid;

(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-[2-[(cis-2,6-dimethylmorpholin-4-yl)carbonyloxy]ethyl]piperidin-1-ylcarbonyl]amino]propionic acid;


(2S)-2-[1-(3,5-dichlorophenylsulfonyl)-L-prolyl]amino-3-[[4-(2-ethylimidazo[4,5-c]pyridin-1-ylmethyl)piperidin-1-ylcarbonyl]amino]propionic acid;
15 or a salt, solvate or prodrug thereof.

24.- A process for preparing a compound of formula I according to claim 1, which comprises:

(a) when in a compound of formula I X represents -NR⁵-, reacting an amine of
20 formula II with an acid of formula III




II




III

wherein R¹, R⁴, R⁵, W, Z, E, A, L, B and m have the meaning described in claim 1;
or

(b) when in a compound of formula I X represents -O-, reacting an alcohol of
25 formula IV with an acid of formula III




IV



III

wherein R^1 , R^4 , R^5 , W , Z , E , A , L , B and m have the meaning described in claim 1;
or

- (c) when in a compound of formula I X represents $-\text{CH}_2-$ and cycle A is bound to the carbonyl group through a nitrogen atom, reacting an acid of formula V with an amine of formula VI




V




VI

wherein R^1 , R^4 , R^5 , W , Z , E , A , L , B and m have the meaning described in claim 1;
or

- (d) when in a compound of formula I X represents $-\text{NR}^5-$ and cycle A is bound to the carbonyl group through a nitrogen atom, reacting an amine of formula II previously activated with an activating agent suitable for the preparation of ureas with an amine of formula VI





II




VI

- wherein R^1 , R^4 , R^5 , W , Z , E , A , L , B and m have the meaning described in claim 1,
or reacting an amine of formula VI previously activated with an activating agent suitable for the preparation of ureas with an amine of formula II, or alternatively reacting a compound of formula V' previously activated with an azide suitable for a Curtius rearrangement with an amine of formula VI

**V'****VI**

wherein R^1 , R^4 , R^5 , W , Z , E , A , L , B and m have the meaning described in claim 1;
or



- (e) when in a compound of formula I X represents $-O-$ and cycle A is bound to the
5 carbonyl group through a nitrogen atom, reacting an alcohol of formula IV
previously activated with an activating agent suitable for the preparation of
carbamates with an amine of formula VI

**IV****VI**

wherein R^1 , R^4 , R^5 , W , Z , E , A , L , B and m have the meaning described in claim 1;

10 or


- (f) when in a compound of formula I Z represents $-CO-$, reacting an acid of
formula VII with an amine of formula XVII

**VII****XVII**

wherein R^1 , R^4 , R^5 , W , E , X , A , L , B and m have the meaning described above; or


- 15 (g) when in a compound of formula I W represents $-CR^4R^4-$ and R^1 represents
 $-SO_2R^2$, reacting a compound of formula XVIII with a sulfonyl chloride of formula
IX

140

**XVIII****IX**


wherein R^2 , R^4 , R^5 , Z, E, X, A, L, B and m have the meaning described in claim 1;
or

- (h) when in a compound of formula I W represents $-\text{CR}^4\text{R}^4-$ and R^1 represents
5 $-\text{COR}^2$, reacting a compound of formula XVIII with an acid of formula X

**XVIII****X**

wherein R^2 , R^4 , R^5 , Z, E, X, A, L, B and m have the meaning described in claim 1;
or


- (i) when in a compound of formula I W represents $-\text{CO}-$ and R^1 represents
10 $-\text{CH}_2\text{R}^3$, reacting a compound of formula XIX with a compound of formula XI

**XIX****XI**

wherein R^2 , R^4 , R^5 , Z, E, X, A, L, B and m have the meaning described in claim 1
and D represents a good leaving group; or

- (j) when in a compound of formula I cycle A is bound to the -L-B moiety through a
15 ring nitrogen atom, alkylating the secondary amine of a compound of formula XX

with a compound of formula XIV



wherein R^1 , R^4 , R^5 , W, Z, E, X, A, L, B and m have the meaning described in claim 1 and D represents a good leaving group; or

5 (k) transforming, in one or a plurality of steps, a compound of formula I into another compound of formula I; and

(l) if desired, after the above steps, reacting a compound of formula I with an acid or a base to give the corresponding addition salt.

25.- A pharmaceutical composition which comprises an effective amount of a
10 compound of formula I according to any of claims 1 to 23 or a pharmaceutically acceptable salt, solvate or prodrug thereof and one or more pharmaceutically acceptable excipients.

26.- Use of a compound of formula I according to any of claims 1 to 23 or a
15 pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament for the treatment or prevention of diseases mediated by integrins α_4 .

27.- Use according to claim 26 wherein the disease mediated by integrins α_4 is selected from inflammatory diseases, immune diseases, autoimmune diseases, degenerative disorders, tumor metastasis and ischemia-reperfusion disorders.

20 28.- Use of a compound of formula I according to any of claims 1 to 23 or a pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament for the treatment or prevention of inflammatory, immune and/or autoimmune diseases.

29.- Use according to claim 28 wherein the inflammatory, immune and/or
25 autoimmune disease is selected from diseases with an allergic component, inflammatory diseases with an autoimmune component, inflammatory bowel disease, inflammatory processes having an alloimmune origin caused by

transplants or rejections, inflammatory processes that develop as a consequence of blood vessel revascularization treatments, encephalomyelitis, hepatitis, bronchitis, vasculitis and atherosclerosis.

30.- Use according to claim 29 wherein the disease with an allergic component is selected from asthma, allergic rhinitis, allergic dermatitis and allergic conjunctivitis.

31.- Use according to claim 29 wherein the inflammatory disease with an autoimmune component is selected from rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, psoriasis and diabetes.

32.- Use according to claim 29 wherein the inflammatory bowel disease is selected from Crohn's disease and ulcerative colitis.

33.- Use of a compound of formula I according to any of claims 1 to 23 or a pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament for the treatment or prevention of degenerative disorders.

34.- Use according to claim 33 wherein the degenerative disorder is selected from Alzheimer's disease and arthrosis.

35.- Use of a compound of formula I according to any of claims 1 to 23 or a pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament for the treatment or prevention of tumor metastasis.

36.- Use of a compound of formula I according to any of claims 1 to 23 or a pharmaceutically acceptable salt, solvate or prodrug thereof for the manufacture of a medicament for the treatment or prevention of ischemia-reperfusion disorders.

37.- Use according to claim 36 wherein the ischemia-reperfusion disorder is selected from acute coronary diseases and stroke.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/03635

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K5/078 A61K31/4025 A61P25/28 A61P29/00 A61P35/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 12186 A (BIOGEN INC ;CORNEBISE MARK (US); LEE WEN CHERNG (US); PETTER RUSSE) 22 February 2001 (2001-02-22) page 43, line 9 - line 18 page 70, line 17 - line 24 examples 6697,6715,7515,7517 -----	1,25
A	WO 01 54690 A (LIN KOCHUNG ;ZHENG ZHONGLI (US); BIOGEN INC (US); CUERVO JULIO H () 2 August 2001 (2001-08-02) examples 2,3 claim 1 -----	1,25
A	WO 98 53814 A (HAGMANN WILLIAM K ;MUMFORD RICHARD A (US); KEVIN NANCY J (US); MAC) 3 December 1998 (1998-12-03) claims 1,5,19 -----	1,25



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the International search

23 July 2003

Date of mailing of the International search report

31/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seitner, I

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-23 (all partially)

The scope of claims 1-23, in as far as the expression "prodrug" is concerned, is so unclear (Article 6 PCT) that a meaningful International Search is impossible with regard to this expression.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/03635

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-23 (all partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/03635

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0112186	A	22-02-2001	AU 7058600 A	13-03-2001
			BG 106510 A	31-10-2002
			BR 0013248 A	23-07-2002
			CA 2380817 A1	22-02-2001
			CN 1377268 T	30-10-2002
			CZ 20020518 A3	15-05-2002
			EE 200200070 A	15-04-2003
			EP 1265606 A1	18-12-2002
			HU 0202469 A2	28-11-2002
			JP 2003506491 T	18-02-2003
			NO 20020725 A	08-04-2002
			SK 2152002 A3	02-07-2002
			WO 0112186 A1	22-02-2001
WO 0154690	A	02-08-2001	AU 3306901 A	07-08-2001
			EP 1253923 A1	06-11-2002
			WO 0154690 A1	02-08-2001
			US 2003114514 A1	19-06-2003
WO 9853814	A	03-12-1998	EP 1001764 A1	24-05-2000
			JP 2002512625 T	23-04-2002
			WO 9853814 A1	03-12-1998